Datasets:
bio-datasets
/
bigbio-ner-merged

Dataset card Data Studio Files
xet
Community
answer
stringlengths
1
16.1k
id
stringlengths
7
56
instruction
stringlengths
106
72.6k
ner_tags
list
text
stringlengths
5
72.4k
tokens
list
types
list
stearic acid is a compound, MCP-1 is a protein
DS.d517_task1
Sentence: The stimulatory effects of stearic, palmitic and palmitoleic acids on resistin secretion and the stimulatory effect of stearic acid on MCP-1 secretion are mediated via TLR-4. Instructions: please typing these entity words according to sentence: stearic acid, MCP-1 Options: compound, protein
[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-compound", "I-compound", "O", "B-protein", "O", "O", "O", "O", "O", "O" ]
The stimulatory effects of stearic, palmitic and palmitoleic acids on resistin secretion and the stimulatory effect of stearic acid on MCP-1 secretion are mediated via TLR-4.
[ "The", "stimulatory", "effects", "of", "stearic", ",", "palmitic", "and", "palmitoleic", "acids", "on", "resistin", "secretion", "and", "the", "stimulatory", "effect", "of", "stearic", "acid", "on", "MCP-1", "secretion", "are", "mediated", "via", "TLR-4", "." ]
[ "compound", "protein" ]
stearic acid, MCP-1
DS.d517_task2
Sentence: The stimulatory effects of stearic, palmitic and palmitoleic acids on resistin secretion and the stimulatory effect of stearic acid on MCP-1 secretion are mediated via TLR-4. Instructions: please extract entity words from the input sentence
[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-compound", "I-compound", "O", "B-protein", "O", "O", "O", "O", "O", "O" ]
The stimulatory effects of stearic, palmitic and palmitoleic acids on resistin secretion and the stimulatory effect of stearic acid on MCP-1 secretion are mediated via TLR-4.
[ "The", "stimulatory", "effects", "of", "stearic", ",", "palmitic", "and", "palmitoleic", "acids", "on", "resistin", "secretion", "and", "the", "stimulatory", "effect", "of", "stearic", "acid", "on", "MCP-1", "secretion", "are", "mediated", "via", "TLR-4", "." ]
[ "compound", "protein" ]
Males is a Person, females is a Person, above the age of 18 is a Value, laparoscopic or robotic is a Scope, colorectal resections is a Procedure
NCT02958566_inc_task0
Sentence: Males or females above the age of 18 Patients undergoing laparoscopic or robotic colorectal resections Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: Scope, Person, Procedure, Value
[ "B-Person", "O", "B-Person", "B-Value", "I-Value", "I-Value", "I-Value", "I-Value", "O", "O", "O", "B-Scope", "I-Scope", "I-Scope", "B-Procedure", "I-Procedure", "O" ]
Males or females above the age of 18 Patients undergoing laparoscopic or robotic colorectal resections
[ "Males", "or", "females", "above", "the", "age", "of", "18", "\n", "Patients", "undergoing", "laparoscopic", "or", "robotic", "colorectal", "resections", "\n" ]
[ "Scope", "Procedure", "Value", "Qualifier", "Person" ]
Males is a Person, females is a Person, above the age of 18 is a Value, laparoscopic or robotic is a Scope, colorectal resections is a Procedure
NCT02958566_inc_task1
Sentence: Males or females above the age of 18 Patients undergoing laparoscopic or robotic colorectal resections Instructions: please typing these entity words according to sentence: Males, females, above the age of 18, laparoscopic or robotic, colorectal resections Options: Scope, Person, Procedure, Value
[ "B-Person", "O", "B-Person", "B-Value", "I-Value", "I-Value", "I-Value", "I-Value", "O", "O", "O", "B-Scope", "I-Scope", "I-Scope", "B-Procedure", "I-Procedure", "O" ]
Males or females above the age of 18 Patients undergoing laparoscopic or robotic colorectal resections
[ "Males", "or", "females", "above", "the", "age", "of", "18", "\n", "Patients", "undergoing", "laparoscopic", "or", "robotic", "colorectal", "resections", "\n" ]
[ "Scope", "Procedure", "Value", "Qualifier", "Person" ]
Males, females, above the age of 18, laparoscopic or robotic, colorectal resections
NCT02958566_inc_task2
Sentence: Males or females above the age of 18 Patients undergoing laparoscopic or robotic colorectal resections Instructions: please extract entity words from the input sentence
[ "B-Person", "O", "B-Person", "B-Value", "I-Value", "I-Value", "I-Value", "I-Value", "O", "O", "O", "B-Scope", "I-Scope", "I-Scope", "B-Procedure", "I-Procedure", "O" ]
Males or females above the age of 18 Patients undergoing laparoscopic or robotic colorectal resections
[ "Males", "or", "females", "above", "the", "age", "of", "18", "\n", "Patients", "undergoing", "laparoscopic", "or", "robotic", "colorectal", "resections", "\n" ]
[ "Scope", "Procedure", "Value", "Qualifier", "Person" ]
apixaban is a CHEMICAL, factor Xa is a GENE-N
23386703_task0
Sentence: Investigating the enteroenteric recirculation of apixaban, a factor Xa inhibitor: administration of activated charcoal to bile duct-cannulated rats and dogs receiving an intravenous dose and use of drug transporter knockout rats. Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: GENE-N, CHEMICAL
[ "O", "O", "O", "O", "O", "B-CHEMICAL", "O", "O", "B-GENE-N", "I-GENE-N", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]
Investigating the enteroenteric recirculation of apixaban, a factor Xa inhibitor: administration of activated charcoal to bile duct-cannulated rats and dogs receiving an intravenous dose and use of drug transporter knockout rats.
[ "Investigating", "the", "enteroenteric", "recirculation", "of", "apixaban", ",", "a", "factor", "Xa", "inhibitor", ":", "administration", "of", "activated", "charcoal", "to", "bile", "duct", "-", "cannulated", "rats", "and", "dogs", "receiving", "an", "intravenous", "dose", "and", "use", "of", "drug", "transporter", "knockout", "rats", "." ]
[ "GENE-Y", "CHEMICAL", "GENE-N" ]
apixaban is a CHEMICAL, factor Xa is a GENE-N
23386703_task1
Sentence: Investigating the enteroenteric recirculation of apixaban, a factor Xa inhibitor: administration of activated charcoal to bile duct-cannulated rats and dogs receiving an intravenous dose and use of drug transporter knockout rats. Instructions: please typing these entity words according to sentence: apixaban, factor Xa Options: GENE-N, CHEMICAL
[ "O", "O", "O", "O", "O", "B-CHEMICAL", "O", "O", "B-GENE-N", "I-GENE-N", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]
Investigating the enteroenteric recirculation of apixaban, a factor Xa inhibitor: administration of activated charcoal to bile duct-cannulated rats and dogs receiving an intravenous dose and use of drug transporter knockout rats.
[ "Investigating", "the", "enteroenteric", "recirculation", "of", "apixaban", ",", "a", "factor", "Xa", "inhibitor", ":", "administration", "of", "activated", "charcoal", "to", "bile", "duct", "-", "cannulated", "rats", "and", "dogs", "receiving", "an", "intravenous", "dose", "and", "use", "of", "drug", "transporter", "knockout", "rats", "." ]
[ "GENE-Y", "CHEMICAL", "GENE-N" ]
apixaban, factor Xa
23386703_task2
Sentence: Investigating the enteroenteric recirculation of apixaban, a factor Xa inhibitor: administration of activated charcoal to bile duct-cannulated rats and dogs receiving an intravenous dose and use of drug transporter knockout rats. Instructions: please extract entity words from the input sentence
[ "O", "O", "O", "O", "O", "B-CHEMICAL", "O", "O", "B-GENE-N", "I-GENE-N", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]
Investigating the enteroenteric recirculation of apixaban, a factor Xa inhibitor: administration of activated charcoal to bile duct-cannulated rats and dogs receiving an intravenous dose and use of drug transporter knockout rats.
[ "Investigating", "the", "enteroenteric", "recirculation", "of", "apixaban", ",", "a", "factor", "Xa", "inhibitor", ":", "administration", "of", "activated", "charcoal", "to", "bile", "duct", "-", "cannulated", "rats", "and", "dogs", "receiving", "an", "intravenous", "dose", "and", "use", "of", "drug", "transporter", "knockout", "rats", "." ]
[ "GENE-Y", "CHEMICAL", "GENE-N" ]
Ateminsuffizienz is an umlsterm, Belastung is an umlsterm, Lebenstage is an umlsterm, Fallbericht is an umlsterm, Patient is an umlsterm, Neugeborenes is an umlsterm, respiratorische Insuffizienz is an umlsterm, Atemnotsyndrom is an umlsterm, Diagnosestellung is an umlsterm, Therapie is an umlsterm, kardiale Dekompensation is an umlsterm, Pneumonektomie is an umlsterm, Histologie is an umlsterm, radiologische is an umlsterm, Diagnose is an umlsterm, Patient is an umlsterm, Sauerstoff is an umlsterm, Pneumonie is an umlsterm, Literaturprognose is an umlsterm, Risiko is an umlsterm, kardialen Dekompensation is an umlsterm, Risiko is an umlsterm
MonatsschriftKinderheilkunde.81460129.ger.abstr_task0
Sentence: Folgen der seltenen beidseitigen pulmonalen CCAM sind hochgradige Ateminsuffizienz und rechtskardiale Belastung mit Dekompensation typischerweise innerhalb weniger Lebenstage . Fallbericht : Unser Patient fiel als Neugeborenes durch respiratorische Insuffizienz auf . Eine beidseitige CCAM wurde initial als Atemnotsyndrom verkannt . Auch nach zuegiger Diagnosestellung drohte unter konservativer Therapie die respiratorische und kardiale Dekompensation , weshalb wir uns zur einseitigen Pneumonektomie mit Einlage eines Ballonplatzhalters entschlossen . Die Histologie bestaetigte unsere radiologische Diagnose . Im weiteren Verlauf zeigte sich zunaechst eine Stabilisierung ; der Patient war zeitweilig ohne Atemhilfe oder supplementaeren Sauerstoff . Mit 1 Jahr kam es zum Sekundenherztod im Rahmen einer schweren Pneumonie . Entgegen der kurzfristig infausten Literaturprognose berichten wir von einem zunaechst guten Behandlungserfolg . Diskussion : In Analogie zur bronchopulmunalen Dysplasie ist ein bis zum 3. Lebensjahr wesentlich erhoehtes Risiko der kardialen Dekompensation anzunehmen . Die Operation kann dieses Risiko nur mindern , nicht ausschliessen . In Anbetracht des - wenngleich temporaeren Operationserfolgs - halten wir therapeutischen Nihilismus bei beidseitiger CCAM fuer unangebracht . Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: umlsterm
[ "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]
Folgen der seltenen beidseitigen pulmonalen CCAM sind hochgradige Ateminsuffizienz und rechtskardiale Belastung mit Dekompensation typischerweise innerhalb weniger Lebenstage . Fallbericht : Unser Patient fiel als Neugeborenes durch respiratorische Insuffizienz auf . Eine beidseitige CCAM wurde initial als Atemnotsyndrom verkannt . Auch nach zuegiger Diagnosestellung drohte unter konservativer Therapie die respiratorische und kardiale Dekompensation , weshalb wir uns zur einseitigen Pneumonektomie mit Einlage eines Ballonplatzhalters entschlossen . Die Histologie bestaetigte unsere radiologische Diagnose . Im weiteren Verlauf zeigte sich zunaechst eine Stabilisierung ; der Patient war zeitweilig ohne Atemhilfe oder supplementaeren Sauerstoff . Mit 1 Jahr kam es zum Sekundenherztod im Rahmen einer schweren Pneumonie . Entgegen der kurzfristig infausten Literaturprognose berichten wir von einem zunaechst guten Behandlungserfolg . Diskussion : In Analogie zur bronchopulmunalen Dysplasie ist ein bis zum 3. Lebensjahr wesentlich erhoehtes Risiko der kardialen Dekompensation anzunehmen . Die Operation kann dieses Risiko nur mindern , nicht ausschliessen . In Anbetracht des - wenngleich temporaeren Operationserfolgs - halten wir therapeutischen Nihilismus bei beidseitiger CCAM fuer unangebracht .
[ "Folgen", "der", "seltenen", "beidseitigen", "pulmonalen", "CCAM", "sind", "hochgradige", "Ateminsuffizienz", "und", "rechtskardiale", "Belastung", "mit", "Dekompensation", "typischerweise", "innerhalb", "weniger", "Lebenstage", ".", "Fallbericht", ":", "Unser", "Patient", "fiel", "als", "Neugeborenes", "durch", "respiratorische", "Insuffizienz", "auf", ".", "Eine", "beidseitige", "CCAM", "wurde", "initial", "als", "Atemnotsyndrom", "verkannt", ".", "Auch", "nach", "zuegiger", "Diagnosestellung", "drohte", "unter", "konservativer", "Therapie", "die", "respiratorische", "und", "kardiale", "Dekompensation", ",", "weshalb", "wir", "uns", "zur", "einseitigen", "Pneumonektomie", "mit", "Einlage", "eines", "Ballonplatzhalters", "entschlossen", ".", "Die", "Histologie", "bestaetigte", "unsere", "radiologische", "Diagnose", ".", "Im", "weiteren", "Verlauf", "zeigte", "sich", "zunaechst", "eine", "Stabilisierung", ";", "der", "Patient", "war", "zeitweilig", "ohne", "Atemhilfe", "oder", "supplementaeren", "Sauerstoff", ".", "Mit", "1", "Jahr", "kam", "es", "zum", "Sekundenherztod", "im", "Rahmen", "einer", "schweren", "Pneumonie", ".", "Entgegen", "der", "kurzfristig", "infausten", "Literaturprognose", "berichten", "wir", "von", "einem", "zunaechst", "guten", "Behandlungserfolg", ".", "Diskussion", ":", "In", "Analogie", "zur", "bronchopulmunalen", "Dysplasie", "ist", "ein", "bis", "zum", "3", ".", "Lebensjahr", "wesentlich", "erhoehtes", "Risiko", "der", "kardialen", "Dekompensation", "anzunehmen", ".", "Die", "Operation", "kann", "dieses", "Risiko", "nur", "mindern", ",", "nicht", "ausschliessen", ".", "In", "Anbetracht", "des", "-", "wenngleich", "temporaeren", "Operationserfolgs", "-", "halten", "wir", "therapeutischen", "Nihilismus", "bei", "beidseitiger", "CCAM", "fuer", "unangebracht", "." ]
[ "umlsterm" ]
Ateminsuffizienz is an umlsterm, Belastung is an umlsterm, Lebenstage is an umlsterm, Fallbericht is an umlsterm, Patient is an umlsterm, Neugeborenes is an umlsterm, respiratorische Insuffizienz is an umlsterm, Atemnotsyndrom is an umlsterm, Diagnosestellung is an umlsterm, Therapie is an umlsterm, kardiale Dekompensation is an umlsterm, Pneumonektomie is an umlsterm, Histologie is an umlsterm, radiologische is an umlsterm, Diagnose is an umlsterm, Patient is an umlsterm, Sauerstoff is an umlsterm, Pneumonie is an umlsterm, Literaturprognose is an umlsterm, Risiko is an umlsterm, kardialen Dekompensation is an umlsterm, Risiko is an umlsterm
MonatsschriftKinderheilkunde.81460129.ger.abstr_task1
Sentence: Folgen der seltenen beidseitigen pulmonalen CCAM sind hochgradige Ateminsuffizienz und rechtskardiale Belastung mit Dekompensation typischerweise innerhalb weniger Lebenstage . Fallbericht : Unser Patient fiel als Neugeborenes durch respiratorische Insuffizienz auf . Eine beidseitige CCAM wurde initial als Atemnotsyndrom verkannt . Auch nach zuegiger Diagnosestellung drohte unter konservativer Therapie die respiratorische und kardiale Dekompensation , weshalb wir uns zur einseitigen Pneumonektomie mit Einlage eines Ballonplatzhalters entschlossen . Die Histologie bestaetigte unsere radiologische Diagnose . Im weiteren Verlauf zeigte sich zunaechst eine Stabilisierung ; der Patient war zeitweilig ohne Atemhilfe oder supplementaeren Sauerstoff . Mit 1 Jahr kam es zum Sekundenherztod im Rahmen einer schweren Pneumonie . Entgegen der kurzfristig infausten Literaturprognose berichten wir von einem zunaechst guten Behandlungserfolg . Diskussion : In Analogie zur bronchopulmunalen Dysplasie ist ein bis zum 3. Lebensjahr wesentlich erhoehtes Risiko der kardialen Dekompensation anzunehmen . Die Operation kann dieses Risiko nur mindern , nicht ausschliessen . In Anbetracht des - wenngleich temporaeren Operationserfolgs - halten wir therapeutischen Nihilismus bei beidseitiger CCAM fuer unangebracht . Instructions: please typing these entity words according to sentence: Ateminsuffizienz, Belastung, Lebenstage, Fallbericht, Patient, Neugeborenes, respiratorische Insuffizienz, Atemnotsyndrom, Diagnosestellung, Therapie, kardiale Dekompensation, Pneumonektomie, Histologie, radiologische, Diagnose, Patient, Sauerstoff, Pneumonie, Literaturprognose, Risiko, kardialen Dekompensation, Risiko Options: umlsterm
[ "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]
Folgen der seltenen beidseitigen pulmonalen CCAM sind hochgradige Ateminsuffizienz und rechtskardiale Belastung mit Dekompensation typischerweise innerhalb weniger Lebenstage . Fallbericht : Unser Patient fiel als Neugeborenes durch respiratorische Insuffizienz auf . Eine beidseitige CCAM wurde initial als Atemnotsyndrom verkannt . Auch nach zuegiger Diagnosestellung drohte unter konservativer Therapie die respiratorische und kardiale Dekompensation , weshalb wir uns zur einseitigen Pneumonektomie mit Einlage eines Ballonplatzhalters entschlossen . Die Histologie bestaetigte unsere radiologische Diagnose . Im weiteren Verlauf zeigte sich zunaechst eine Stabilisierung ; der Patient war zeitweilig ohne Atemhilfe oder supplementaeren Sauerstoff . Mit 1 Jahr kam es zum Sekundenherztod im Rahmen einer schweren Pneumonie . Entgegen der kurzfristig infausten Literaturprognose berichten wir von einem zunaechst guten Behandlungserfolg . Diskussion : In Analogie zur bronchopulmunalen Dysplasie ist ein bis zum 3. Lebensjahr wesentlich erhoehtes Risiko der kardialen Dekompensation anzunehmen . Die Operation kann dieses Risiko nur mindern , nicht ausschliessen . In Anbetracht des - wenngleich temporaeren Operationserfolgs - halten wir therapeutischen Nihilismus bei beidseitiger CCAM fuer unangebracht .
[ "Folgen", "der", "seltenen", "beidseitigen", "pulmonalen", "CCAM", "sind", "hochgradige", "Ateminsuffizienz", "und", "rechtskardiale", "Belastung", "mit", "Dekompensation", "typischerweise", "innerhalb", "weniger", "Lebenstage", ".", "Fallbericht", ":", "Unser", "Patient", "fiel", "als", "Neugeborenes", "durch", "respiratorische", "Insuffizienz", "auf", ".", "Eine", "beidseitige", "CCAM", "wurde", "initial", "als", "Atemnotsyndrom", "verkannt", ".", "Auch", "nach", "zuegiger", "Diagnosestellung", "drohte", "unter", "konservativer", "Therapie", "die", "respiratorische", "und", "kardiale", "Dekompensation", ",", "weshalb", "wir", "uns", "zur", "einseitigen", "Pneumonektomie", "mit", "Einlage", "eines", "Ballonplatzhalters", "entschlossen", ".", "Die", "Histologie", "bestaetigte", "unsere", "radiologische", "Diagnose", ".", "Im", "weiteren", "Verlauf", "zeigte", "sich", "zunaechst", "eine", "Stabilisierung", ";", "der", "Patient", "war", "zeitweilig", "ohne", "Atemhilfe", "oder", "supplementaeren", "Sauerstoff", ".", "Mit", "1", "Jahr", "kam", "es", "zum", "Sekundenherztod", "im", "Rahmen", "einer", "schweren", "Pneumonie", ".", "Entgegen", "der", "kurzfristig", "infausten", "Literaturprognose", "berichten", "wir", "von", "einem", "zunaechst", "guten", "Behandlungserfolg", ".", "Diskussion", ":", "In", "Analogie", "zur", "bronchopulmunalen", "Dysplasie", "ist", "ein", "bis", "zum", "3", ".", "Lebensjahr", "wesentlich", "erhoehtes", "Risiko", "der", "kardialen", "Dekompensation", "anzunehmen", ".", "Die", "Operation", "kann", "dieses", "Risiko", "nur", "mindern", ",", "nicht", "ausschliessen", ".", "In", "Anbetracht", "des", "-", "wenngleich", "temporaeren", "Operationserfolgs", "-", "halten", "wir", "therapeutischen", "Nihilismus", "bei", "beidseitiger", "CCAM", "fuer", "unangebracht", "." ]
[ "umlsterm" ]
Ateminsuffizienz, Belastung, Lebenstage, Fallbericht, Patient, Neugeborenes, respiratorische Insuffizienz, Atemnotsyndrom, Diagnosestellung, Therapie, kardiale Dekompensation, Pneumonektomie, Histologie, radiologische, Diagnose, Patient, Sauerstoff, Pneumonie, Literaturprognose, Risiko, kardialen Dekompensation, Risiko
MonatsschriftKinderheilkunde.81460129.ger.abstr_task2
Sentence: Folgen der seltenen beidseitigen pulmonalen CCAM sind hochgradige Ateminsuffizienz und rechtskardiale Belastung mit Dekompensation typischerweise innerhalb weniger Lebenstage . Fallbericht : Unser Patient fiel als Neugeborenes durch respiratorische Insuffizienz auf . Eine beidseitige CCAM wurde initial als Atemnotsyndrom verkannt . Auch nach zuegiger Diagnosestellung drohte unter konservativer Therapie die respiratorische und kardiale Dekompensation , weshalb wir uns zur einseitigen Pneumonektomie mit Einlage eines Ballonplatzhalters entschlossen . Die Histologie bestaetigte unsere radiologische Diagnose . Im weiteren Verlauf zeigte sich zunaechst eine Stabilisierung ; der Patient war zeitweilig ohne Atemhilfe oder supplementaeren Sauerstoff . Mit 1 Jahr kam es zum Sekundenherztod im Rahmen einer schweren Pneumonie . Entgegen der kurzfristig infausten Literaturprognose berichten wir von einem zunaechst guten Behandlungserfolg . Diskussion : In Analogie zur bronchopulmunalen Dysplasie ist ein bis zum 3. Lebensjahr wesentlich erhoehtes Risiko der kardialen Dekompensation anzunehmen . Die Operation kann dieses Risiko nur mindern , nicht ausschliessen . In Anbetracht des - wenngleich temporaeren Operationserfolgs - halten wir therapeutischen Nihilismus bei beidseitiger CCAM fuer unangebracht . Instructions: please extract entity words from the input sentence
[ "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]
Folgen der seltenen beidseitigen pulmonalen CCAM sind hochgradige Ateminsuffizienz und rechtskardiale Belastung mit Dekompensation typischerweise innerhalb weniger Lebenstage . Fallbericht : Unser Patient fiel als Neugeborenes durch respiratorische Insuffizienz auf . Eine beidseitige CCAM wurde initial als Atemnotsyndrom verkannt . Auch nach zuegiger Diagnosestellung drohte unter konservativer Therapie die respiratorische und kardiale Dekompensation , weshalb wir uns zur einseitigen Pneumonektomie mit Einlage eines Ballonplatzhalters entschlossen . Die Histologie bestaetigte unsere radiologische Diagnose . Im weiteren Verlauf zeigte sich zunaechst eine Stabilisierung ; der Patient war zeitweilig ohne Atemhilfe oder supplementaeren Sauerstoff . Mit 1 Jahr kam es zum Sekundenherztod im Rahmen einer schweren Pneumonie . Entgegen der kurzfristig infausten Literaturprognose berichten wir von einem zunaechst guten Behandlungserfolg . Diskussion : In Analogie zur bronchopulmunalen Dysplasie ist ein bis zum 3. Lebensjahr wesentlich erhoehtes Risiko der kardialen Dekompensation anzunehmen . Die Operation kann dieses Risiko nur mindern , nicht ausschliessen . In Anbetracht des - wenngleich temporaeren Operationserfolgs - halten wir therapeutischen Nihilismus bei beidseitiger CCAM fuer unangebracht .
[ "Folgen", "der", "seltenen", "beidseitigen", "pulmonalen", "CCAM", "sind", "hochgradige", "Ateminsuffizienz", "und", "rechtskardiale", "Belastung", "mit", "Dekompensation", "typischerweise", "innerhalb", "weniger", "Lebenstage", ".", "Fallbericht", ":", "Unser", "Patient", "fiel", "als", "Neugeborenes", "durch", "respiratorische", "Insuffizienz", "auf", ".", "Eine", "beidseitige", "CCAM", "wurde", "initial", "als", "Atemnotsyndrom", "verkannt", ".", "Auch", "nach", "zuegiger", "Diagnosestellung", "drohte", "unter", "konservativer", "Therapie", "die", "respiratorische", "und", "kardiale", "Dekompensation", ",", "weshalb", "wir", "uns", "zur", "einseitigen", "Pneumonektomie", "mit", "Einlage", "eines", "Ballonplatzhalters", "entschlossen", ".", "Die", "Histologie", "bestaetigte", "unsere", "radiologische", "Diagnose", ".", "Im", "weiteren", "Verlauf", "zeigte", "sich", "zunaechst", "eine", "Stabilisierung", ";", "der", "Patient", "war", "zeitweilig", "ohne", "Atemhilfe", "oder", "supplementaeren", "Sauerstoff", ".", "Mit", "1", "Jahr", "kam", "es", "zum", "Sekundenherztod", "im", "Rahmen", "einer", "schweren", "Pneumonie", ".", "Entgegen", "der", "kurzfristig", "infausten", "Literaturprognose", "berichten", "wir", "von", "einem", "zunaechst", "guten", "Behandlungserfolg", ".", "Diskussion", ":", "In", "Analogie", "zur", "bronchopulmunalen", "Dysplasie", "ist", "ein", "bis", "zum", "3", ".", "Lebensjahr", "wesentlich", "erhoehtes", "Risiko", "der", "kardialen", "Dekompensation", "anzunehmen", ".", "Die", "Operation", "kann", "dieses", "Risiko", "nur", "mindern", ",", "nicht", "ausschliessen", ".", "In", "Anbetracht", "des", "-", "wenngleich", "temporaeren", "Operationserfolgs", "-", "halten", "wir", "therapeutischen", "Nihilismus", "bei", "beidseitiger", "CCAM", "fuer", "unangebracht", "." ]
[ "umlsterm" ]
C2orf71 is a Gene, C2orf71 is a Gene, C2orf71 is a Gene, C2orf71 is a Gene, EYS is a Gene, C2orf71 is a Gene, C2orf71 is a Gene
613_task0
Sentence: Novel C2orf71 mutations account for ∼1% of cases in a large French arRP cohort. Autosomal-recessive retinitis pigmentosa (arRP) is a genetically heterogeneous group of disorders to which a novel gene, C2orf71, was recently associated. The purpose of our study was to establish the prevalence and nature of C2orf71 mutations in a clinically well-characterized cohort of 345 sporadic and arRP French cases. Direct sequencing of C2orf71 was performed in 209 subjects for whom mutations had previously been excluded by microarray technology and direct sequencing of EYS. Putative pathogenicity of the identified variants was evaluated through co-segregation analysis, screening of more than 188 control chromosomes and prediction programs. We identified two patients compound heterozygous for mutations predicted to lead to a premature stop codon, 3 of which are novel. In addition, 3 patients carried a single variant of likely pathogenicity. Furthermore a large number of novel putative non-disease causing variants were identified, highlighting the extremely polymorphic nature of C2orf71. To our knowledge, our study provides the first large scale screening of C2orf71 in a French arRP cohort through direct sequencing and suggests that it would account for approximately 1% of arRP cases. Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: Gene
[ "O", "B-Gene", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Gene", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Gene", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Gene", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Gene", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Gene", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Gene", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]
Novel C2orf71 mutations account for ∼1% of cases in a large French arRP cohort. Autosomal-recessive retinitis pigmentosa (arRP) is a genetically heterogeneous group of disorders to which a novel gene, C2orf71, was recently associated. The purpose of our study was to establish the prevalence and nature of C2orf71 mutations in a clinically well-characterized cohort of 345 sporadic and arRP French cases. Direct sequencing of C2orf71 was performed in 209 subjects for whom mutations had previously been excluded by microarray technology and direct sequencing of EYS. Putative pathogenicity of the identified variants was evaluated through co-segregation analysis, screening of more than 188 control chromosomes and prediction programs. We identified two patients compound heterozygous for mutations predicted to lead to a premature stop codon, 3 of which are novel. In addition, 3 patients carried a single variant of likely pathogenicity. Furthermore a large number of novel putative non-disease causing variants were identified, highlighting the extremely polymorphic nature of C2orf71. To our knowledge, our study provides the first large scale screening of C2orf71 in a French arRP cohort through direct sequencing and suggests that it would account for approximately 1% of arRP cases.
[ "Novel", "C2orf71", "mutations", "account", "for", "∼1", "%", "of", "cases", "in", "a", "large", "French", "arRP", "cohort", ".", "Autosomal", "-", "recessive", "retinitis", "pigmentosa", "(", "arRP", ")", "is", "a", "genetically", "heterogeneous", "group", "of", "disorders", "to", "which", "a", "novel", "gene", ",", "C2orf71", ",", "was", "recently", "associated", ".", "The", "purpose", "of", "our", "study", "was", "to", "establish", "the", "prevalence", "and", "nature", "of", "C2orf71", "mutations", "in", "a", "clinically", "well", "-", "characterized", "cohort", "of", "345", "sporadic", "and", "arRP", "French", "cases", ".", "Direct", "sequencing", "of", "C2orf71", "was", "performed", "in", "209", "subjects", "for", "whom", "mutations", "had", "previously", "been", "excluded", "by", "microarray", "technology", "and", "direct", "sequencing", "of", "EYS", ".", "Putative", "pathogenicity", "of", "the", "identified", "variants", "was", "evaluated", "through", "co", "-", "segregation", "analysis", ",", "screening", "of", "more", "than", "188", "control", "chromosomes", "and", "prediction", "programs", ".", "We", "identified", "two", "patients", "compound", "heterozygous", "for", "mutations", "predicted", "to", "lead", "to", "a", "premature", "stop", "codon", ",", "3", "of", "which", "are", "novel", ".", "In", "addition", ",", "3", "patients", "carried", "a", "single", "variant", "of", "likely", "pathogenicity", ".", "Furthermore", "a", "large", "number", "of", "novel", "putative", "non", "-", "disease", "causing", "variants", "were", "identified", ",", "highlighting", "the", "extremely", "polymorphic", "nature", "of", "C2orf71", ".", "To", "our", "knowledge", ",", "our", "study", "provides", "the", "first", "large", "scale", "screening", "of", "C2orf71", "in", "a", "French", "arRP", "cohort", "through", "direct", "sequencing", "and", "suggests", "that", "it", "would", "account", "for", "approximately", "1", "%", "of", "arRP", "cases", ".", "\n" ]
[ "Gene" ]
C2orf71 is a Gene, C2orf71 is a Gene, C2orf71 is a Gene, C2orf71 is a Gene, EYS is a Gene, C2orf71 is a Gene, C2orf71 is a Gene
613_task1
Sentence: Novel C2orf71 mutations account for ∼1% of cases in a large French arRP cohort. Autosomal-recessive retinitis pigmentosa (arRP) is a genetically heterogeneous group of disorders to which a novel gene, C2orf71, was recently associated. The purpose of our study was to establish the prevalence and nature of C2orf71 mutations in a clinically well-characterized cohort of 345 sporadic and arRP French cases. Direct sequencing of C2orf71 was performed in 209 subjects for whom mutations had previously been excluded by microarray technology and direct sequencing of EYS. Putative pathogenicity of the identified variants was evaluated through co-segregation analysis, screening of more than 188 control chromosomes and prediction programs. We identified two patients compound heterozygous for mutations predicted to lead to a premature stop codon, 3 of which are novel. In addition, 3 patients carried a single variant of likely pathogenicity. Furthermore a large number of novel putative non-disease causing variants were identified, highlighting the extremely polymorphic nature of C2orf71. To our knowledge, our study provides the first large scale screening of C2orf71 in a French arRP cohort through direct sequencing and suggests that it would account for approximately 1% of arRP cases. Instructions: please typing these entity words according to sentence: C2orf71, C2orf71, C2orf71, C2orf71, EYS, C2orf71, C2orf71 Options: Gene
[ "O", "B-Gene", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Gene", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Gene", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Gene", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Gene", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Gene", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Gene", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]
Novel C2orf71 mutations account for ∼1% of cases in a large French arRP cohort. Autosomal-recessive retinitis pigmentosa (arRP) is a genetically heterogeneous group of disorders to which a novel gene, C2orf71, was recently associated. The purpose of our study was to establish the prevalence and nature of C2orf71 mutations in a clinically well-characterized cohort of 345 sporadic and arRP French cases. Direct sequencing of C2orf71 was performed in 209 subjects for whom mutations had previously been excluded by microarray technology and direct sequencing of EYS. Putative pathogenicity of the identified variants was evaluated through co-segregation analysis, screening of more than 188 control chromosomes and prediction programs. We identified two patients compound heterozygous for mutations predicted to lead to a premature stop codon, 3 of which are novel. In addition, 3 patients carried a single variant of likely pathogenicity. Furthermore a large number of novel putative non-disease causing variants were identified, highlighting the extremely polymorphic nature of C2orf71. To our knowledge, our study provides the first large scale screening of C2orf71 in a French arRP cohort through direct sequencing and suggests that it would account for approximately 1% of arRP cases.
[ "Novel", "C2orf71", "mutations", "account", "for", "∼1", "%", "of", "cases", "in", "a", "large", "French", "arRP", "cohort", ".", "Autosomal", "-", "recessive", "retinitis", "pigmentosa", "(", "arRP", ")", "is", "a", "genetically", "heterogeneous", "group", "of", "disorders", "to", "which", "a", "novel", "gene", ",", "C2orf71", ",", "was", "recently", "associated", ".", "The", "purpose", "of", "our", "study", "was", "to", "establish", "the", "prevalence", "and", "nature", "of", "C2orf71", "mutations", "in", "a", "clinically", "well", "-", "characterized", "cohort", "of", "345", "sporadic", "and", "arRP", "French", "cases", ".", "Direct", "sequencing", "of", "C2orf71", "was", "performed", "in", "209", "subjects", "for", "whom", "mutations", "had", "previously", "been", "excluded", "by", "microarray", "technology", "and", "direct", "sequencing", "of", "EYS", ".", "Putative", "pathogenicity", "of", "the", "identified", "variants", "was", "evaluated", "through", "co", "-", "segregation", "analysis", ",", "screening", "of", "more", "than", "188", "control", "chromosomes", "and", "prediction", "programs", ".", "We", "identified", "two", "patients", "compound", "heterozygous", "for", "mutations", "predicted", "to", "lead", "to", "a", "premature", "stop", "codon", ",", "3", "of", "which", "are", "novel", ".", "In", "addition", ",", "3", "patients", "carried", "a", "single", "variant", "of", "likely", "pathogenicity", ".", "Furthermore", "a", "large", "number", "of", "novel", "putative", "non", "-", "disease", "causing", "variants", "were", "identified", ",", "highlighting", "the", "extremely", "polymorphic", "nature", "of", "C2orf71", ".", "To", "our", "knowledge", ",", "our", "study", "provides", "the", "first", "large", "scale", "screening", "of", "C2orf71", "in", "a", "French", "arRP", "cohort", "through", "direct", "sequencing", "and", "suggests", "that", "it", "would", "account", "for", "approximately", "1", "%", "of", "arRP", "cases", ".", "\n" ]
[ "Gene" ]
C2orf71, C2orf71, C2orf71, C2orf71, EYS, C2orf71, C2orf71
613_task2
Sentence: Novel C2orf71 mutations account for ∼1% of cases in a large French arRP cohort. Autosomal-recessive retinitis pigmentosa (arRP) is a genetically heterogeneous group of disorders to which a novel gene, C2orf71, was recently associated. The purpose of our study was to establish the prevalence and nature of C2orf71 mutations in a clinically well-characterized cohort of 345 sporadic and arRP French cases. Direct sequencing of C2orf71 was performed in 209 subjects for whom mutations had previously been excluded by microarray technology and direct sequencing of EYS. Putative pathogenicity of the identified variants was evaluated through co-segregation analysis, screening of more than 188 control chromosomes and prediction programs. We identified two patients compound heterozygous for mutations predicted to lead to a premature stop codon, 3 of which are novel. In addition, 3 patients carried a single variant of likely pathogenicity. Furthermore a large number of novel putative non-disease causing variants were identified, highlighting the extremely polymorphic nature of C2orf71. To our knowledge, our study provides the first large scale screening of C2orf71 in a French arRP cohort through direct sequencing and suggests that it would account for approximately 1% of arRP cases. Instructions: please extract entity words from the input sentence
[ "O", "B-Gene", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Gene", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Gene", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Gene", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Gene", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Gene", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Gene", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]
Novel C2orf71 mutations account for ∼1% of cases in a large French arRP cohort. Autosomal-recessive retinitis pigmentosa (arRP) is a genetically heterogeneous group of disorders to which a novel gene, C2orf71, was recently associated. The purpose of our study was to establish the prevalence and nature of C2orf71 mutations in a clinically well-characterized cohort of 345 sporadic and arRP French cases. Direct sequencing of C2orf71 was performed in 209 subjects for whom mutations had previously been excluded by microarray technology and direct sequencing of EYS. Putative pathogenicity of the identified variants was evaluated through co-segregation analysis, screening of more than 188 control chromosomes and prediction programs. We identified two patients compound heterozygous for mutations predicted to lead to a premature stop codon, 3 of which are novel. In addition, 3 patients carried a single variant of likely pathogenicity. Furthermore a large number of novel putative non-disease causing variants were identified, highlighting the extremely polymorphic nature of C2orf71. To our knowledge, our study provides the first large scale screening of C2orf71 in a French arRP cohort through direct sequencing and suggests that it would account for approximately 1% of arRP cases.
[ "Novel", "C2orf71", "mutations", "account", "for", "∼1", "%", "of", "cases", "in", "a", "large", "French", "arRP", "cohort", ".", "Autosomal", "-", "recessive", "retinitis", "pigmentosa", "(", "arRP", ")", "is", "a", "genetically", "heterogeneous", "group", "of", "disorders", "to", "which", "a", "novel", "gene", ",", "C2orf71", ",", "was", "recently", "associated", ".", "The", "purpose", "of", "our", "study", "was", "to", "establish", "the", "prevalence", "and", "nature", "of", "C2orf71", "mutations", "in", "a", "clinically", "well", "-", "characterized", "cohort", "of", "345", "sporadic", "and", "arRP", "French", "cases", ".", "Direct", "sequencing", "of", "C2orf71", "was", "performed", "in", "209", "subjects", "for", "whom", "mutations", "had", "previously", "been", "excluded", "by", "microarray", "technology", "and", "direct", "sequencing", "of", "EYS", ".", "Putative", "pathogenicity", "of", "the", "identified", "variants", "was", "evaluated", "through", "co", "-", "segregation", "analysis", ",", "screening", "of", "more", "than", "188", "control", "chromosomes", "and", "prediction", "programs", ".", "We", "identified", "two", "patients", "compound", "heterozygous", "for", "mutations", "predicted", "to", "lead", "to", "a", "premature", "stop", "codon", ",", "3", "of", "which", "are", "novel", ".", "In", "addition", ",", "3", "patients", "carried", "a", "single", "variant", "of", "likely", "pathogenicity", ".", "Furthermore", "a", "large", "number", "of", "novel", "putative", "non", "-", "disease", "causing", "variants", "were", "identified", ",", "highlighting", "the", "extremely", "polymorphic", "nature", "of", "C2orf71", ".", "To", "our", "knowledge", ",", "our", "study", "provides", "the", "first", "large", "scale", "screening", "of", "C2orf71", "in", "a", "French", "arRP", "cohort", "through", "direct", "sequencing", "and", "suggests", "that", "it", "would", "account", "for", "approximately", "1", "%", "of", "arRP", "cases", ".", "\n" ]
[ "Gene" ]
Klassifikationen is an umlsterm, Lymphome is an umlsterm, Klassifikation is an umlsterm, kutanes T - Zell - Lymphom is an umlsterm, kutanes T - Zell - Lymphom is an umlsterm, ATLL is an umlsterm
DerHautarzt.60470096.ger.abstr_task0
Sentence: Neben den klassischen kutanen T-Zell-Lymphomen ( C-CTCL ) , wie der Mykosis fungoides und dem Sézary-Syndrom , kommen ungewoehnliche Varianten kutaner T-Zell-Lymphome vor , die als seltene " kutane T-Zell-Lymphome " bezeichnet werden koennen . Die Einordnung dieser seltenen kutanen T-Zell-Lymphome ist problematisch und umstritten . Neuere Klassifikationen der Lymphome allgemein wie die Revised European-American Lymphoma ( R.E.A.L. ) Classification stellen wohldefinierte klinisch-morphologische Entitaeten in den Vordergrund . In Anlehnung an den Grundgedanken dieser Klassifikation ist auch groessere Klarheit bei den seltenen kuktanen T-Zell-Lymphomen zu erzielen . In dieser Uebersicht wird der Versuch gemacht , die seltenen kutanen T-Zell-Lymphome aufzulisten und zu charakterisieren . Wir stellen dabei die folgende Einteilung vor , wobei insbesondere alle pleomorphen , immunoblastischen und grosszellig-anaplastischen CD30- kutanen T-Zell-Lymphome entsprechend ihrem Verlauf als progressive T-Zell-Lymphome zusammengefasst werden : 1 Klinische Sonderformen und Varianten ) der Mykosis fungoides 2 ) progressive kutane T-Zell-Lymphome ( P-CTCL ) einschliesslich der transformierten klassischen kutanen T-Zell-Lymphome ( TC-CTCL ) und der primaer-progressiven kutanen T-Zell-Lymphome ( PP-CTCL ) ; 3 angiozentrisches und angioimmunoblastisches kutanes T-Zell-Lymphom ; ) 4 ) grosszellig-anaplastisches , CD30+ kutanes T-Zell-Lymphom ; 5 HTLV-I-assoziierte adulte T-Zell-Leukaemie/Lymphom ( ) ATLL ) ; 6 kutane Manifestationen primaer extrakutaner ) T-Zell-Neoplasien 7 ) ; andere schwer klassifizierbare kutane T-Zell-Lymphome . , Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: umlsterm
[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "I-umlsterm", "I-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "I-umlsterm", "I-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]
Neben den klassischen kutanen T-Zell-Lymphomen ( C-CTCL ) , wie der Mykosis fungoides und dem Sézary-Syndrom , kommen ungewoehnliche Varianten kutaner T-Zell-Lymphome vor , die als seltene " kutane T-Zell-Lymphome " bezeichnet werden koennen . Die Einordnung dieser seltenen kutanen T-Zell-Lymphome ist problematisch und umstritten . Neuere Klassifikationen der Lymphome allgemein wie die Revised European-American Lymphoma ( R.E.A.L. ) Classification stellen wohldefinierte klinisch-morphologische Entitaeten in den Vordergrund . In Anlehnung an den Grundgedanken dieser Klassifikation ist auch groessere Klarheit bei den seltenen kuktanen T-Zell-Lymphomen zu erzielen . In dieser Uebersicht wird der Versuch gemacht , die seltenen kutanen T-Zell-Lymphome aufzulisten und zu charakterisieren . Wir stellen dabei die folgende Einteilung vor , wobei insbesondere alle pleomorphen , immunoblastischen und grosszellig-anaplastischen CD30- kutanen T-Zell-Lymphome entsprechend ihrem Verlauf als progressive T-Zell-Lymphome zusammengefasst werden : 1 Klinische Sonderformen und Varianten ) der Mykosis fungoides 2 ) progressive kutane T-Zell-Lymphome ( P-CTCL ) einschliesslich der transformierten klassischen kutanen T-Zell-Lymphome ( TC-CTCL ) und der primaer-progressiven kutanen T-Zell-Lymphome ( PP-CTCL ) ; 3 angiozentrisches und angioimmunoblastisches kutanes T-Zell-Lymphom ; ) 4 ) grosszellig-anaplastisches , CD30+ kutanes T-Zell-Lymphom ; 5 HTLV-I-assoziierte adulte T-Zell-Leukaemie/Lymphom ( ) ATLL ) ; 6 kutane Manifestationen primaer extrakutaner ) T-Zell-Neoplasien 7 ) ; andere schwer klassifizierbare kutane T-Zell-Lymphome . ,
[ "Neben", "den", "klassischen", "kutanen", "T", "-", "Zell", "-", "Lymphomen", "(", "C", "-", "CTCL", ")", ",", "wie", "der", "Mykosis", "fungoides", "und", "dem", "Sézary", "-", "Syndrom", ",", "kommen", "ungewoehnliche", "Varianten", "kutaner", "T", "-", "Zell", "-", "Lymphome", "vor", ",", "die", "als", "seltene", "\"", "kutane", "T", "-", "Zell", "-", "Lymphome", "\"", "bezeichnet", "werden", "koennen", ".", "Die", "Einordnung", "dieser", "seltenen", "kutanen", "T", "-", "Zell", "-", "Lymphome", "ist", "problematisch", "und", "umstritten", ".", "Neuere", "Klassifikationen", "der", "Lymphome", "allgemein", "wie", "die", "Revised", "European", "-", "American", "Lymphoma", "(", "R.E.A.L.", ")", "Classification", "stellen", "wohldefinierte", "klinisch", "-", "morphologische", "Entitaeten", "in", "den", "Vordergrund", ".", "In", "Anlehnung", "an", "den", "Grundgedanken", "dieser", "Klassifikation", "ist", "auch", "groessere", "Klarheit", "bei", "den", "seltenen", "kuktanen", "T", "-", "Zell", "-", "Lymphomen", "zu", "erzielen", ".", "In", "dieser", "Uebersicht", "wird", "der", "Versuch", "gemacht", ",", "die", "seltenen", "kutanen", "T", "-", "Zell", "-", "Lymphome", "aufzulisten", "und", "zu", "charakterisieren", ".", "Wir", "stellen", "dabei", "die", "folgende", "Einteilung", "vor", ",", "wobei", "insbesondere", "alle", "pleomorphen", ",", "immunoblastischen", "und", "grosszellig", "-", "anaplastischen", "CD30-", "kutanen", "T", "-", "Zell", "-", "Lymphome", "entsprechend", "ihrem", "Verlauf", "als", "progressive", "T", "-", "Zell", "-", "Lymphome", "zusammengefasst", "werden", ":", "1", "Klinische", "Sonderformen", "und", "Varianten", ")", "der", "Mykosis", "fungoides", "2", ")", "progressive", "kutane", "T", "-", "Zell", "-", "Lymphome", "(", "P", "-", "CTCL", ")", "einschliesslich", "der", "transformierten", "klassischen", "kutanen", "T", "-", "Zell", "-", "Lymphome", "(", "TC", "-", "CTCL", ")", "und", "der", "primaer", "-", "progressiven", "kutanen", "T", "-", "Zell", "-", "Lymphome", "(", "PP", "-", "CTCL", ")", ";", "3", "angiozentrisches", "und", "angioimmunoblastisches", "kutanes", "T", "-", "Zell", "-", "Lymphom", ";", ")", "4", ")", "grosszellig", "-", "anaplastisches", ",", "CD30", "+", "kutanes", "T", "-", "Zell", "-", "Lymphom", ";", "5", "HTLV", "-", "I", "-", "assoziierte", "adulte", "T", "-", "Zell", "-", "Leukaemie", "/", "Lymphom", "(", ")", "ATLL", ")", ";", "6", "kutane", "Manifestationen", "primaer", "extrakutaner", ")", "T", "-", "Zell", "-", "Neoplasien", "7", ")", ";", "andere", "schwer", "klassifizierbare", "kutane", "T", "-", "Zell", "-", "Lymphome", ".", "," ]
[ "umlsterm" ]
Klassifikationen is an umlsterm, Lymphome is an umlsterm, Klassifikation is an umlsterm, kutanes T - Zell - Lymphom is an umlsterm, kutanes T - Zell - Lymphom is an umlsterm, ATLL is an umlsterm
DerHautarzt.60470096.ger.abstr_task1
Sentence: Neben den klassischen kutanen T-Zell-Lymphomen ( C-CTCL ) , wie der Mykosis fungoides und dem Sézary-Syndrom , kommen ungewoehnliche Varianten kutaner T-Zell-Lymphome vor , die als seltene " kutane T-Zell-Lymphome " bezeichnet werden koennen . Die Einordnung dieser seltenen kutanen T-Zell-Lymphome ist problematisch und umstritten . Neuere Klassifikationen der Lymphome allgemein wie die Revised European-American Lymphoma ( R.E.A.L. ) Classification stellen wohldefinierte klinisch-morphologische Entitaeten in den Vordergrund . In Anlehnung an den Grundgedanken dieser Klassifikation ist auch groessere Klarheit bei den seltenen kuktanen T-Zell-Lymphomen zu erzielen . In dieser Uebersicht wird der Versuch gemacht , die seltenen kutanen T-Zell-Lymphome aufzulisten und zu charakterisieren . Wir stellen dabei die folgende Einteilung vor , wobei insbesondere alle pleomorphen , immunoblastischen und grosszellig-anaplastischen CD30- kutanen T-Zell-Lymphome entsprechend ihrem Verlauf als progressive T-Zell-Lymphome zusammengefasst werden : 1 Klinische Sonderformen und Varianten ) der Mykosis fungoides 2 ) progressive kutane T-Zell-Lymphome ( P-CTCL ) einschliesslich der transformierten klassischen kutanen T-Zell-Lymphome ( TC-CTCL ) und der primaer-progressiven kutanen T-Zell-Lymphome ( PP-CTCL ) ; 3 angiozentrisches und angioimmunoblastisches kutanes T-Zell-Lymphom ; ) 4 ) grosszellig-anaplastisches , CD30+ kutanes T-Zell-Lymphom ; 5 HTLV-I-assoziierte adulte T-Zell-Leukaemie/Lymphom ( ) ATLL ) ; 6 kutane Manifestationen primaer extrakutaner ) T-Zell-Neoplasien 7 ) ; andere schwer klassifizierbare kutane T-Zell-Lymphome . , Instructions: please typing these entity words according to sentence: Klassifikationen, Lymphome, Klassifikation, kutanes T - Zell - Lymphom, kutanes T - Zell - Lymphom, ATLL Options: umlsterm
[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "I-umlsterm", "I-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "I-umlsterm", "I-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]
Neben den klassischen kutanen T-Zell-Lymphomen ( C-CTCL ) , wie der Mykosis fungoides und dem Sézary-Syndrom , kommen ungewoehnliche Varianten kutaner T-Zell-Lymphome vor , die als seltene " kutane T-Zell-Lymphome " bezeichnet werden koennen . Die Einordnung dieser seltenen kutanen T-Zell-Lymphome ist problematisch und umstritten . Neuere Klassifikationen der Lymphome allgemein wie die Revised European-American Lymphoma ( R.E.A.L. ) Classification stellen wohldefinierte klinisch-morphologische Entitaeten in den Vordergrund . In Anlehnung an den Grundgedanken dieser Klassifikation ist auch groessere Klarheit bei den seltenen kuktanen T-Zell-Lymphomen zu erzielen . In dieser Uebersicht wird der Versuch gemacht , die seltenen kutanen T-Zell-Lymphome aufzulisten und zu charakterisieren . Wir stellen dabei die folgende Einteilung vor , wobei insbesondere alle pleomorphen , immunoblastischen und grosszellig-anaplastischen CD30- kutanen T-Zell-Lymphome entsprechend ihrem Verlauf als progressive T-Zell-Lymphome zusammengefasst werden : 1 Klinische Sonderformen und Varianten ) der Mykosis fungoides 2 ) progressive kutane T-Zell-Lymphome ( P-CTCL ) einschliesslich der transformierten klassischen kutanen T-Zell-Lymphome ( TC-CTCL ) und der primaer-progressiven kutanen T-Zell-Lymphome ( PP-CTCL ) ; 3 angiozentrisches und angioimmunoblastisches kutanes T-Zell-Lymphom ; ) 4 ) grosszellig-anaplastisches , CD30+ kutanes T-Zell-Lymphom ; 5 HTLV-I-assoziierte adulte T-Zell-Leukaemie/Lymphom ( ) ATLL ) ; 6 kutane Manifestationen primaer extrakutaner ) T-Zell-Neoplasien 7 ) ; andere schwer klassifizierbare kutane T-Zell-Lymphome . ,
[ "Neben", "den", "klassischen", "kutanen", "T", "-", "Zell", "-", "Lymphomen", "(", "C", "-", "CTCL", ")", ",", "wie", "der", "Mykosis", "fungoides", "und", "dem", "Sézary", "-", "Syndrom", ",", "kommen", "ungewoehnliche", "Varianten", "kutaner", "T", "-", "Zell", "-", "Lymphome", "vor", ",", "die", "als", "seltene", "\"", "kutane", "T", "-", "Zell", "-", "Lymphome", "\"", "bezeichnet", "werden", "koennen", ".", "Die", "Einordnung", "dieser", "seltenen", "kutanen", "T", "-", "Zell", "-", "Lymphome", "ist", "problematisch", "und", "umstritten", ".", "Neuere", "Klassifikationen", "der", "Lymphome", "allgemein", "wie", "die", "Revised", "European", "-", "American", "Lymphoma", "(", "R.E.A.L.", ")", "Classification", "stellen", "wohldefinierte", "klinisch", "-", "morphologische", "Entitaeten", "in", "den", "Vordergrund", ".", "In", "Anlehnung", "an", "den", "Grundgedanken", "dieser", "Klassifikation", "ist", "auch", "groessere", "Klarheit", "bei", "den", "seltenen", "kuktanen", "T", "-", "Zell", "-", "Lymphomen", "zu", "erzielen", ".", "In", "dieser", "Uebersicht", "wird", "der", "Versuch", "gemacht", ",", "die", "seltenen", "kutanen", "T", "-", "Zell", "-", "Lymphome", "aufzulisten", "und", "zu", "charakterisieren", ".", "Wir", "stellen", "dabei", "die", "folgende", "Einteilung", "vor", ",", "wobei", "insbesondere", "alle", "pleomorphen", ",", "immunoblastischen", "und", "grosszellig", "-", "anaplastischen", "CD30-", "kutanen", "T", "-", "Zell", "-", "Lymphome", "entsprechend", "ihrem", "Verlauf", "als", "progressive", "T", "-", "Zell", "-", "Lymphome", "zusammengefasst", "werden", ":", "1", "Klinische", "Sonderformen", "und", "Varianten", ")", "der", "Mykosis", "fungoides", "2", ")", "progressive", "kutane", "T", "-", "Zell", "-", "Lymphome", "(", "P", "-", "CTCL", ")", "einschliesslich", "der", "transformierten", "klassischen", "kutanen", "T", "-", "Zell", "-", "Lymphome", "(", "TC", "-", "CTCL", ")", "und", "der", "primaer", "-", "progressiven", "kutanen", "T", "-", "Zell", "-", "Lymphome", "(", "PP", "-", "CTCL", ")", ";", "3", "angiozentrisches", "und", "angioimmunoblastisches", "kutanes", "T", "-", "Zell", "-", "Lymphom", ";", ")", "4", ")", "grosszellig", "-", "anaplastisches", ",", "CD30", "+", "kutanes", "T", "-", "Zell", "-", "Lymphom", ";", "5", "HTLV", "-", "I", "-", "assoziierte", "adulte", "T", "-", "Zell", "-", "Leukaemie", "/", "Lymphom", "(", ")", "ATLL", ")", ";", "6", "kutane", "Manifestationen", "primaer", "extrakutaner", ")", "T", "-", "Zell", "-", "Neoplasien", "7", ")", ";", "andere", "schwer", "klassifizierbare", "kutane", "T", "-", "Zell", "-", "Lymphome", ".", "," ]
[ "umlsterm" ]
Klassifikationen, Lymphome, Klassifikation, kutanes T - Zell - Lymphom, kutanes T - Zell - Lymphom, ATLL
DerHautarzt.60470096.ger.abstr_task2
Sentence: Neben den klassischen kutanen T-Zell-Lymphomen ( C-CTCL ) , wie der Mykosis fungoides und dem Sézary-Syndrom , kommen ungewoehnliche Varianten kutaner T-Zell-Lymphome vor , die als seltene " kutane T-Zell-Lymphome " bezeichnet werden koennen . Die Einordnung dieser seltenen kutanen T-Zell-Lymphome ist problematisch und umstritten . Neuere Klassifikationen der Lymphome allgemein wie die Revised European-American Lymphoma ( R.E.A.L. ) Classification stellen wohldefinierte klinisch-morphologische Entitaeten in den Vordergrund . In Anlehnung an den Grundgedanken dieser Klassifikation ist auch groessere Klarheit bei den seltenen kuktanen T-Zell-Lymphomen zu erzielen . In dieser Uebersicht wird der Versuch gemacht , die seltenen kutanen T-Zell-Lymphome aufzulisten und zu charakterisieren . Wir stellen dabei die folgende Einteilung vor , wobei insbesondere alle pleomorphen , immunoblastischen und grosszellig-anaplastischen CD30- kutanen T-Zell-Lymphome entsprechend ihrem Verlauf als progressive T-Zell-Lymphome zusammengefasst werden : 1 Klinische Sonderformen und Varianten ) der Mykosis fungoides 2 ) progressive kutane T-Zell-Lymphome ( P-CTCL ) einschliesslich der transformierten klassischen kutanen T-Zell-Lymphome ( TC-CTCL ) und der primaer-progressiven kutanen T-Zell-Lymphome ( PP-CTCL ) ; 3 angiozentrisches und angioimmunoblastisches kutanes T-Zell-Lymphom ; ) 4 ) grosszellig-anaplastisches , CD30+ kutanes T-Zell-Lymphom ; 5 HTLV-I-assoziierte adulte T-Zell-Leukaemie/Lymphom ( ) ATLL ) ; 6 kutane Manifestationen primaer extrakutaner ) T-Zell-Neoplasien 7 ) ; andere schwer klassifizierbare kutane T-Zell-Lymphome . , Instructions: please extract entity words from the input sentence
[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "I-umlsterm", "I-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "I-umlsterm", "I-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]
Neben den klassischen kutanen T-Zell-Lymphomen ( C-CTCL ) , wie der Mykosis fungoides und dem Sézary-Syndrom , kommen ungewoehnliche Varianten kutaner T-Zell-Lymphome vor , die als seltene " kutane T-Zell-Lymphome " bezeichnet werden koennen . Die Einordnung dieser seltenen kutanen T-Zell-Lymphome ist problematisch und umstritten . Neuere Klassifikationen der Lymphome allgemein wie die Revised European-American Lymphoma ( R.E.A.L. ) Classification stellen wohldefinierte klinisch-morphologische Entitaeten in den Vordergrund . In Anlehnung an den Grundgedanken dieser Klassifikation ist auch groessere Klarheit bei den seltenen kuktanen T-Zell-Lymphomen zu erzielen . In dieser Uebersicht wird der Versuch gemacht , die seltenen kutanen T-Zell-Lymphome aufzulisten und zu charakterisieren . Wir stellen dabei die folgende Einteilung vor , wobei insbesondere alle pleomorphen , immunoblastischen und grosszellig-anaplastischen CD30- kutanen T-Zell-Lymphome entsprechend ihrem Verlauf als progressive T-Zell-Lymphome zusammengefasst werden : 1 Klinische Sonderformen und Varianten ) der Mykosis fungoides 2 ) progressive kutane T-Zell-Lymphome ( P-CTCL ) einschliesslich der transformierten klassischen kutanen T-Zell-Lymphome ( TC-CTCL ) und der primaer-progressiven kutanen T-Zell-Lymphome ( PP-CTCL ) ; 3 angiozentrisches und angioimmunoblastisches kutanes T-Zell-Lymphom ; ) 4 ) grosszellig-anaplastisches , CD30+ kutanes T-Zell-Lymphom ; 5 HTLV-I-assoziierte adulte T-Zell-Leukaemie/Lymphom ( ) ATLL ) ; 6 kutane Manifestationen primaer extrakutaner ) T-Zell-Neoplasien 7 ) ; andere schwer klassifizierbare kutane T-Zell-Lymphome . ,
[ "Neben", "den", "klassischen", "kutanen", "T", "-", "Zell", "-", "Lymphomen", "(", "C", "-", "CTCL", ")", ",", "wie", "der", "Mykosis", "fungoides", "und", "dem", "Sézary", "-", "Syndrom", ",", "kommen", "ungewoehnliche", "Varianten", "kutaner", "T", "-", "Zell", "-", "Lymphome", "vor", ",", "die", "als", "seltene", "\"", "kutane", "T", "-", "Zell", "-", "Lymphome", "\"", "bezeichnet", "werden", "koennen", ".", "Die", "Einordnung", "dieser", "seltenen", "kutanen", "T", "-", "Zell", "-", "Lymphome", "ist", "problematisch", "und", "umstritten", ".", "Neuere", "Klassifikationen", "der", "Lymphome", "allgemein", "wie", "die", "Revised", "European", "-", "American", "Lymphoma", "(", "R.E.A.L.", ")", "Classification", "stellen", "wohldefinierte", "klinisch", "-", "morphologische", "Entitaeten", "in", "den", "Vordergrund", ".", "In", "Anlehnung", "an", "den", "Grundgedanken", "dieser", "Klassifikation", "ist", "auch", "groessere", "Klarheit", "bei", "den", "seltenen", "kuktanen", "T", "-", "Zell", "-", "Lymphomen", "zu", "erzielen", ".", "In", "dieser", "Uebersicht", "wird", "der", "Versuch", "gemacht", ",", "die", "seltenen", "kutanen", "T", "-", "Zell", "-", "Lymphome", "aufzulisten", "und", "zu", "charakterisieren", ".", "Wir", "stellen", "dabei", "die", "folgende", "Einteilung", "vor", ",", "wobei", "insbesondere", "alle", "pleomorphen", ",", "immunoblastischen", "und", "grosszellig", "-", "anaplastischen", "CD30-", "kutanen", "T", "-", "Zell", "-", "Lymphome", "entsprechend", "ihrem", "Verlauf", "als", "progressive", "T", "-", "Zell", "-", "Lymphome", "zusammengefasst", "werden", ":", "1", "Klinische", "Sonderformen", "und", "Varianten", ")", "der", "Mykosis", "fungoides", "2", ")", "progressive", "kutane", "T", "-", "Zell", "-", "Lymphome", "(", "P", "-", "CTCL", ")", "einschliesslich", "der", "transformierten", "klassischen", "kutanen", "T", "-", "Zell", "-", "Lymphome", "(", "TC", "-", "CTCL", ")", "und", "der", "primaer", "-", "progressiven", "kutanen", "T", "-", "Zell", "-", "Lymphome", "(", "PP", "-", "CTCL", ")", ";", "3", "angiozentrisches", "und", "angioimmunoblastisches", "kutanes", "T", "-", "Zell", "-", "Lymphom", ";", ")", "4", ")", "grosszellig", "-", "anaplastisches", ",", "CD30", "+", "kutanes", "T", "-", "Zell", "-", "Lymphom", ";", "5", "HTLV", "-", "I", "-", "assoziierte", "adulte", "T", "-", "Zell", "-", "Leukaemie", "/", "Lymphom", "(", ")", "ATLL", ")", ";", "6", "kutane", "Manifestationen", "primaer", "extrakutaner", ")", "T", "-", "Zell", "-", "Neoplasien", "7", ")", ";", "andere", "schwer", "klassifizierbare", "kutane", "T", "-", "Zell", "-", "Lymphome", ".", "," ]
[ "umlsterm" ]
Abstract is an umlsterm, benign intracranial hypertension is an umlsterm, causes is an umlsterm, syndrome is an umlsterm, obese is an umlsterm, women is an umlsterm, pseudotumor cerebri is an umlsterm, etiology is an umlsterm, sinus is an umlsterm
KlinischeNeuroradiologie.00100023.eng.abstr_task0
Sentence: Abstract : Chronic benign intracranial hypertension may have a variety of causes . Most frequent is this syndrome found in obese young women ( " pseudotumor cerebri " ) , still of unknown etiology . However , venous congestion due to sinus occlusion has to be ruled out . Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: umlsterm
[ "B-umlsterm", "O", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O" ]
Abstract : Chronic benign intracranial hypertension may have a variety of causes . Most frequent is this syndrome found in obese young women ( " pseudotumor cerebri " ) , still of unknown etiology . However , venous congestion due to sinus occlusion has to be ruled out .
[ "Abstract", ":", "Chronic", "benign", "intracranial", "hypertension", "may", "have", "a", "variety", "of", "causes", ".", "Most", "frequent", "is", "this", "syndrome", "found", "in", "obese", "young", "women", "(", "\"", "pseudotumor", "cerebri", "\"", ")", ",", "still", "of", "unknown", "etiology", ".", "However", ",", "venous", "congestion", "due", "to", "sinus", "occlusion", "has", "to", "be", "ruled", "out", "." ]
[ "umlsterm" ]
Abstract is an umlsterm, benign intracranial hypertension is an umlsterm, causes is an umlsterm, syndrome is an umlsterm, obese is an umlsterm, women is an umlsterm, pseudotumor cerebri is an umlsterm, etiology is an umlsterm, sinus is an umlsterm
KlinischeNeuroradiologie.00100023.eng.abstr_task1
Sentence: Abstract : Chronic benign intracranial hypertension may have a variety of causes . Most frequent is this syndrome found in obese young women ( " pseudotumor cerebri " ) , still of unknown etiology . However , venous congestion due to sinus occlusion has to be ruled out . Instructions: please typing these entity words according to sentence: Abstract, benign intracranial hypertension, causes, syndrome, obese, women, pseudotumor cerebri, etiology, sinus Options: umlsterm
[ "B-umlsterm", "O", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O" ]
Abstract : Chronic benign intracranial hypertension may have a variety of causes . Most frequent is this syndrome found in obese young women ( " pseudotumor cerebri " ) , still of unknown etiology . However , venous congestion due to sinus occlusion has to be ruled out .
[ "Abstract", ":", "Chronic", "benign", "intracranial", "hypertension", "may", "have", "a", "variety", "of", "causes", ".", "Most", "frequent", "is", "this", "syndrome", "found", "in", "obese", "young", "women", "(", "\"", "pseudotumor", "cerebri", "\"", ")", ",", "still", "of", "unknown", "etiology", ".", "However", ",", "venous", "congestion", "due", "to", "sinus", "occlusion", "has", "to", "be", "ruled", "out", "." ]
[ "umlsterm" ]
Abstract, benign intracranial hypertension, causes, syndrome, obese, women, pseudotumor cerebri, etiology, sinus
KlinischeNeuroradiologie.00100023.eng.abstr_task2
Sentence: Abstract : Chronic benign intracranial hypertension may have a variety of causes . Most frequent is this syndrome found in obese young women ( " pseudotumor cerebri " ) , still of unknown etiology . However , venous congestion due to sinus occlusion has to be ruled out . Instructions: please extract entity words from the input sentence
[ "B-umlsterm", "O", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O" ]
Abstract : Chronic benign intracranial hypertension may have a variety of causes . Most frequent is this syndrome found in obese young women ( " pseudotumor cerebri " ) , still of unknown etiology . However , venous congestion due to sinus occlusion has to be ruled out .
[ "Abstract", ":", "Chronic", "benign", "intracranial", "hypertension", "may", "have", "a", "variety", "of", "causes", ".", "Most", "frequent", "is", "this", "syndrome", "found", "in", "obese", "young", "women", "(", "\"", "pseudotumor", "cerebri", "\"", ")", ",", "still", "of", "unknown", "etiology", ".", "However", ",", "venous", "congestion", "due", "to", "sinus", "occlusion", "has", "to", "be", "ruled", "out", "." ]
[ "umlsterm" ]
eIF4F is a GENE-Y
22484424_task0
Sentence: eIF4F suppression in breast cancer affects maintenance and progression. Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: GENE-Y
[ "B-GENE-Y", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]
eIF4F suppression in breast cancer affects maintenance and progression.
[ "eIF4F", "suppression", "in", "breast", "cancer", "affects", "maintenance", "and", "progression", "." ]
[ "GENE-Y", "CHEMICAL" ]
eIF4F is a GENE-Y
22484424_task1
Sentence: eIF4F suppression in breast cancer affects maintenance and progression. Instructions: please typing these entity words according to sentence: eIF4F Options: GENE-Y
[ "B-GENE-Y", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]
eIF4F suppression in breast cancer affects maintenance and progression.
[ "eIF4F", "suppression", "in", "breast", "cancer", "affects", "maintenance", "and", "progression", "." ]
[ "GENE-Y", "CHEMICAL" ]
eIF4F
22484424_task2
Sentence: eIF4F suppression in breast cancer affects maintenance and progression. Instructions: please extract entity words from the input sentence
[ "B-GENE-Y", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]
eIF4F suppression in breast cancer affects maintenance and progression.
[ "eIF4F", "suppression", "in", "breast", "cancer", "affects", "maintenance", "and", "progression", "." ]
[ "GENE-Y", "CHEMICAL" ]
myosin heavy chain kinase is a Individual_protein, actin is a Individual_protein
613_task0
Sentence: Recruitment of a myosin heavy chain kinase to actin-rich protrusions in Dictyostelium. Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: Individual_protein
[ "O", "O", "O", "B-Individual_protein", "I-Individual_protein", "I-Individual_protein", "I-Individual_protein", "O", "B-Individual_protein", "O", "O", "O", "O", "O", "O" ]
Recruitment of a myosin heavy chain kinase to actin-rich protrusions in Dictyostelium.
[ "Recruitment", "of", "a", "myosin", "heavy", "chain", "kinase", "to", "actin", "-", "rich", "protrusions", "in", "Dictyostelium", "." ]
[ "Individual_protein" ]
myosin heavy chain kinase is a Individual_protein, actin is a Individual_protein
613_task1
Sentence: Recruitment of a myosin heavy chain kinase to actin-rich protrusions in Dictyostelium. Instructions: please typing these entity words according to sentence: myosin heavy chain kinase, actin Options: Individual_protein
[ "O", "O", "O", "B-Individual_protein", "I-Individual_protein", "I-Individual_protein", "I-Individual_protein", "O", "B-Individual_protein", "O", "O", "O", "O", "O", "O" ]
Recruitment of a myosin heavy chain kinase to actin-rich protrusions in Dictyostelium.
[ "Recruitment", "of", "a", "myosin", "heavy", "chain", "kinase", "to", "actin", "-", "rich", "protrusions", "in", "Dictyostelium", "." ]
[ "Individual_protein" ]
myosin heavy chain kinase, actin
613_task2
Sentence: Recruitment of a myosin heavy chain kinase to actin-rich protrusions in Dictyostelium. Instructions: please extract entity words from the input sentence
[ "O", "O", "O", "B-Individual_protein", "I-Individual_protein", "I-Individual_protein", "I-Individual_protein", "O", "B-Individual_protein", "O", "O", "O", "O", "O", "O" ]
Recruitment of a myosin heavy chain kinase to actin-rich protrusions in Dictyostelium.
[ "Recruitment", "of", "a", "myosin", "heavy", "chain", "kinase", "to", "actin", "-", "rich", "protrusions", "in", "Dictyostelium", "." ]
[ "Individual_protein" ]
absorption is an umlsterm, irrigation is an umlsterm, surgery is an umlsterm, indicators is an umlsterm, absorption is an umlsterm, fluid balance is an umlsterm, method is an umlsterm, surgical is an umlsterm, haematocrit is an umlsterm, Hct is an umlsterm, counter - regulatory is an umlsterm, sodium is an umlsterm, concentration is an umlsterm, ethanol is an umlsterm, irrigation is an umlsterm, marker is an umlsterm, air is an umlsterm, appliance is an umlsterm, clinical study is an umlsterm, patients is an umlsterm, spinal anaesthesia is an umlsterm, concentrations is an umlsterm, alcohol is an umlsterm, irrigation is an umlsterm, ethanol is an umlsterm, Purisole is an umlsterm, Gas is an umlsterm, nasopharynx is an umlsterm, cannula is an umlsterm, ethanol is an umlsterm, concentration is an umlsterm, anaesthetic is an umlsterm, gas is an umlsterm, monitor is an umlsterm, Normac is an umlsterm, irrigation is an umlsterm, use is an umlsterm, blood is an umlsterm, alcohol is an umlsterm, alcohol is an umlsterm, Alcotest is an umlsterm, ger is an umlsterm, haematocrit is an umlsterm, concentration is an umlsterm, blood gases is an umlsterm, measurements is an umlsterm, patients is an umlsterm, Hct is an umlsterm, irrigation is an umlsterm, alcohol is an umlsterm, contrast is an umlsterm, alcohol is an umlsterm, measurements is an umlsterm, alcotest is an umlsterm, Normac is an umlsterm, devices is an umlsterm, alcohol is an umlsterm, concentration is an umlsterm, Normac is an umlsterm, monitor is an umlsterm, blood is an umlsterm, alcohol is an umlsterm, concentrations is an umlsterm, irrigation is an umlsterm, absorption is an umlsterm
DerAnaesthesist.50440436.eng.abstr_task0
Sentence: The absorption of large volumes of irrigation fluid is a major problem in transurethral prostatic surgery ( TUR-P ) . Various indicators have been tested to monitor fluid absorption with regard to continuous registration and sufficient accuracy . The volumetric fluid balance is not suitable as a routine method because of its inaccuracy . Easily accessible parameters are unspecific because of surgical bleeding ( haematocrit [ Hct ] ) , or are interfered with by physiological counter-regulatory actions ( serum sodium [ Na ] concentration ) . In 1986 Hulten et al. suggested adding 2% ethanol to the irrigation fluid as a marker and investigated it intermittently in the expired air with an alcohol-test appliance . In a prospective clinical study of 17 patients undergoing TUR-P under spinal anaesthesia , expiratory concentrations of alcohol that was added to the irrigation fluid ( 2% ethanol in Purisole , Fresenius , Bad Homburg ) were monitored . Gas was continuously sampled from the nasopharynx through a nasal cannula and the ethanol concentration was measured using a modified diverting anaesthetic gas monitor ( Normac , Datex , Helsinki ) that allows continuous as well as early detection of the absorbed irrigation fluid with reliable accuracy for clinical use . In addition , at intervals of 10 minutes we measured blood alcohol , endtidal alcohol ( Alcotest 7110 , Drauml ; ger , Luebeck ) , haematocrit , serum Na concentration , and blood gases . Sixty-eight measurements were obtained from the 17 patients . As shown in other studies , serum Na ( r2 = 0.68 ) and Hct ( r2 = 0.39 ) correlated poorly with the irrigation fluid as determined by serum alcohol levels . In contrast , the expiratory alcohol measurements with the alcotest 7110 ( r2 = 0.93 ) and Normac devices ( r2 = 0.85 ) were closely related . Continuous monitoring of the expiratory alcohol concentration with a Normac monitor closely reflects blood alcohol concentrations , and may hence serve as a useful semiquantitative monitor of irrigation fluid absorption during TUR-P . Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: umlsterm
[ "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "B-umlsterm", "B-umlsterm", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O" ]
The absorption of large volumes of irrigation fluid is a major problem in transurethral prostatic surgery ( TUR-P ) . Various indicators have been tested to monitor fluid absorption with regard to continuous registration and sufficient accuracy . The volumetric fluid balance is not suitable as a routine method because of its inaccuracy . Easily accessible parameters are unspecific because of surgical bleeding ( haematocrit [ Hct ] ) , or are interfered with by physiological counter-regulatory actions ( serum sodium [ Na ] concentration ) . In 1986 Hulten et al. suggested adding 2% ethanol to the irrigation fluid as a marker and investigated it intermittently in the expired air with an alcohol-test appliance . In a prospective clinical study of 17 patients undergoing TUR-P under spinal anaesthesia , expiratory concentrations of alcohol that was added to the irrigation fluid ( 2% ethanol in Purisole , Fresenius , Bad Homburg ) were monitored . Gas was continuously sampled from the nasopharynx through a nasal cannula and the ethanol concentration was measured using a modified diverting anaesthetic gas monitor ( Normac , Datex , Helsinki ) that allows continuous as well as early detection of the absorbed irrigation fluid with reliable accuracy for clinical use . In addition , at intervals of 10 minutes we measured blood alcohol , endtidal alcohol ( Alcotest 7110 , Drauml ; ger , Luebeck ) , haematocrit , serum Na concentration , and blood gases . Sixty-eight measurements were obtained from the 17 patients . As shown in other studies , serum Na ( r2 = 0.68 ) and Hct ( r2 = 0.39 ) correlated poorly with the irrigation fluid as determined by serum alcohol levels . In contrast , the expiratory alcohol measurements with the alcotest 7110 ( r2 = 0.93 ) and Normac devices ( r2 = 0.85 ) were closely related . Continuous monitoring of the expiratory alcohol concentration with a Normac monitor closely reflects blood alcohol concentrations , and may hence serve as a useful semiquantitative monitor of irrigation fluid absorption during TUR-P .
[ "The", "absorption", "of", "large", "volumes", "of", "irrigation", "fluid", "is", "a", "major", "problem", "in", "transurethral", "prostatic", "surgery", "(", "TUR", "-", "P", ")", ".", "Various", "indicators", "have", "been", "tested", "to", "monitor", "fluid", "absorption", "with", "regard", "to", "continuous", "registration", "and", "sufficient", "accuracy", ".", "The", "volumetric", "fluid", "balance", "is", "not", "suitable", "as", "a", "routine", "method", "because", "of", "its", "inaccuracy", ".", "Easily", "accessible", "parameters", "are", "unspecific", "because", "of", "surgical", "bleeding", "(", "haematocrit", "[", "Hct", "]", ")", ",", "or", "are", "interfered", "with", "by", "physiological", "counter", "-", "regulatory", "actions", "(", "serum", "sodium", "[", "Na", "]", "concentration", ")", ".", "In", "1986", "Hulten", "et", "al", ".", "suggested", "adding", "2", "%", "ethanol", "to", "the", "irrigation", "fluid", "as", "a", "marker", "and", "investigated", "it", "intermittently", "in", "the", "expired", "air", "with", "an", "alcohol", "-", "test", "appliance", ".", "In", "a", "prospective", "clinical", "study", "of", "17", "patients", "undergoing", "TUR", "-", "P", "under", "spinal", "anaesthesia", ",", "expiratory", "concentrations", "of", "alcohol", "that", "was", "added", "to", "the", "irrigation", "fluid", "(", "2", "%", "ethanol", "in", "Purisole", ",", "Fresenius", ",", "Bad", "Homburg", ")", "were", "monitored", ".", "Gas", "was", "continuously", "sampled", "from", "the", "nasopharynx", "through", "a", "nasal", "cannula", "and", "the", "ethanol", "concentration", "was", "measured", "using", "a", "modified", "diverting", "anaesthetic", "gas", "monitor", "(", "Normac", ",", "Datex", ",", "Helsinki", ")", "that", "allows", "continuous", "as", "well", "as", "early", "detection", "of", "the", "absorbed", "irrigation", "fluid", "with", "reliable", "accuracy", "for", "clinical", "use", ".", "In", "addition", ",", "at", "intervals", "of", "10", "minutes", "we", "measured", "blood", "alcohol", ",", "endtidal", "alcohol", "(", "Alcotest", "7110", ",", "Drauml", ";", "ger", ",", "Luebeck", ")", ",", "haematocrit", ",", "serum", "Na", "concentration", ",", "and", "blood", "gases", ".", "Sixty", "-", "eight", "measurements", "were", "obtained", "from", "the", "17", "patients", ".", "As", "shown", "in", "other", "studies", ",", "serum", "Na", "(", "r2", "=", "0.68", ")", "and", "Hct", "(", "r2", "=", "0.39", ")", "correlated", "poorly", "with", "the", "irrigation", "fluid", "as", "determined", "by", "serum", "alcohol", "levels", ".", "In", "contrast", ",", "the", "expiratory", "alcohol", "measurements", "with", "the", "alcotest", "7110", "(", "r2", "=", "0.93", ")", "and", "Normac", "devices", "(", "r2", "=", "0.85", ")", "were", "closely", "related", ".", "Continuous", "monitoring", "of", "the", "expiratory", "alcohol", "concentration", "with", "a", "Normac", "monitor", "closely", "reflects", "blood", "alcohol", "concentrations", ",", "and", "may", "hence", "serve", "as", "a", "useful", "semiquantitative", "monitor", "of", "irrigation", "fluid", "absorption", "during", "TUR", "-", "P", "." ]
[ "umlsterm" ]
absorption is an umlsterm, irrigation is an umlsterm, surgery is an umlsterm, indicators is an umlsterm, absorption is an umlsterm, fluid balance is an umlsterm, method is an umlsterm, surgical is an umlsterm, haematocrit is an umlsterm, Hct is an umlsterm, counter - regulatory is an umlsterm, sodium is an umlsterm, concentration is an umlsterm, ethanol is an umlsterm, irrigation is an umlsterm, marker is an umlsterm, air is an umlsterm, appliance is an umlsterm, clinical study is an umlsterm, patients is an umlsterm, spinal anaesthesia is an umlsterm, concentrations is an umlsterm, alcohol is an umlsterm, irrigation is an umlsterm, ethanol is an umlsterm, Purisole is an umlsterm, Gas is an umlsterm, nasopharynx is an umlsterm, cannula is an umlsterm, ethanol is an umlsterm, concentration is an umlsterm, anaesthetic is an umlsterm, gas is an umlsterm, monitor is an umlsterm, Normac is an umlsterm, irrigation is an umlsterm, use is an umlsterm, blood is an umlsterm, alcohol is an umlsterm, alcohol is an umlsterm, Alcotest is an umlsterm, ger is an umlsterm, haematocrit is an umlsterm, concentration is an umlsterm, blood gases is an umlsterm, measurements is an umlsterm, patients is an umlsterm, Hct is an umlsterm, irrigation is an umlsterm, alcohol is an umlsterm, contrast is an umlsterm, alcohol is an umlsterm, measurements is an umlsterm, alcotest is an umlsterm, Normac is an umlsterm, devices is an umlsterm, alcohol is an umlsterm, concentration is an umlsterm, Normac is an umlsterm, monitor is an umlsterm, blood is an umlsterm, alcohol is an umlsterm, concentrations is an umlsterm, irrigation is an umlsterm, absorption is an umlsterm
DerAnaesthesist.50440436.eng.abstr_task1
Sentence: The absorption of large volumes of irrigation fluid is a major problem in transurethral prostatic surgery ( TUR-P ) . Various indicators have been tested to monitor fluid absorption with regard to continuous registration and sufficient accuracy . The volumetric fluid balance is not suitable as a routine method because of its inaccuracy . Easily accessible parameters are unspecific because of surgical bleeding ( haematocrit [ Hct ] ) , or are interfered with by physiological counter-regulatory actions ( serum sodium [ Na ] concentration ) . In 1986 Hulten et al. suggested adding 2% ethanol to the irrigation fluid as a marker and investigated it intermittently in the expired air with an alcohol-test appliance . In a prospective clinical study of 17 patients undergoing TUR-P under spinal anaesthesia , expiratory concentrations of alcohol that was added to the irrigation fluid ( 2% ethanol in Purisole , Fresenius , Bad Homburg ) were monitored . Gas was continuously sampled from the nasopharynx through a nasal cannula and the ethanol concentration was measured using a modified diverting anaesthetic gas monitor ( Normac , Datex , Helsinki ) that allows continuous as well as early detection of the absorbed irrigation fluid with reliable accuracy for clinical use . In addition , at intervals of 10 minutes we measured blood alcohol , endtidal alcohol ( Alcotest 7110 , Drauml ; ger , Luebeck ) , haematocrit , serum Na concentration , and blood gases . Sixty-eight measurements were obtained from the 17 patients . As shown in other studies , serum Na ( r2 = 0.68 ) and Hct ( r2 = 0.39 ) correlated poorly with the irrigation fluid as determined by serum alcohol levels . In contrast , the expiratory alcohol measurements with the alcotest 7110 ( r2 = 0.93 ) and Normac devices ( r2 = 0.85 ) were closely related . Continuous monitoring of the expiratory alcohol concentration with a Normac monitor closely reflects blood alcohol concentrations , and may hence serve as a useful semiquantitative monitor of irrigation fluid absorption during TUR-P . Instructions: please typing these entity words according to sentence: absorption, irrigation, surgery, indicators, absorption, fluid balance, method, surgical, haematocrit, Hct, counter - regulatory, sodium, concentration, ethanol, irrigation, marker, air, appliance, clinical study, patients, spinal anaesthesia, concentrations, alcohol, irrigation, ethanol, Purisole, Gas, nasopharynx, cannula, ethanol, concentration, anaesthetic, gas, monitor, Normac, irrigation, use, blood, alcohol, alcohol, Alcotest, ger, haematocrit, concentration, blood gases, measurements, patients, Hct, irrigation, alcohol, contrast, alcohol, measurements, alcotest, Normac, devices, alcohol, concentration, Normac, monitor, blood, alcohol, concentrations, irrigation, absorption Options: umlsterm
[ "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "B-umlsterm", "B-umlsterm", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O" ]
The absorption of large volumes of irrigation fluid is a major problem in transurethral prostatic surgery ( TUR-P ) . Various indicators have been tested to monitor fluid absorption with regard to continuous registration and sufficient accuracy . The volumetric fluid balance is not suitable as a routine method because of its inaccuracy . Easily accessible parameters are unspecific because of surgical bleeding ( haematocrit [ Hct ] ) , or are interfered with by physiological counter-regulatory actions ( serum sodium [ Na ] concentration ) . In 1986 Hulten et al. suggested adding 2% ethanol to the irrigation fluid as a marker and investigated it intermittently in the expired air with an alcohol-test appliance . In a prospective clinical study of 17 patients undergoing TUR-P under spinal anaesthesia , expiratory concentrations of alcohol that was added to the irrigation fluid ( 2% ethanol in Purisole , Fresenius , Bad Homburg ) were monitored . Gas was continuously sampled from the nasopharynx through a nasal cannula and the ethanol concentration was measured using a modified diverting anaesthetic gas monitor ( Normac , Datex , Helsinki ) that allows continuous as well as early detection of the absorbed irrigation fluid with reliable accuracy for clinical use . In addition , at intervals of 10 minutes we measured blood alcohol , endtidal alcohol ( Alcotest 7110 , Drauml ; ger , Luebeck ) , haematocrit , serum Na concentration , and blood gases . Sixty-eight measurements were obtained from the 17 patients . As shown in other studies , serum Na ( r2 = 0.68 ) and Hct ( r2 = 0.39 ) correlated poorly with the irrigation fluid as determined by serum alcohol levels . In contrast , the expiratory alcohol measurements with the alcotest 7110 ( r2 = 0.93 ) and Normac devices ( r2 = 0.85 ) were closely related . Continuous monitoring of the expiratory alcohol concentration with a Normac monitor closely reflects blood alcohol concentrations , and may hence serve as a useful semiquantitative monitor of irrigation fluid absorption during TUR-P .
[ "The", "absorption", "of", "large", "volumes", "of", "irrigation", "fluid", "is", "a", "major", "problem", "in", "transurethral", "prostatic", "surgery", "(", "TUR", "-", "P", ")", ".", "Various", "indicators", "have", "been", "tested", "to", "monitor", "fluid", "absorption", "with", "regard", "to", "continuous", "registration", "and", "sufficient", "accuracy", ".", "The", "volumetric", "fluid", "balance", "is", "not", "suitable", "as", "a", "routine", "method", "because", "of", "its", "inaccuracy", ".", "Easily", "accessible", "parameters", "are", "unspecific", "because", "of", "surgical", "bleeding", "(", "haematocrit", "[", "Hct", "]", ")", ",", "or", "are", "interfered", "with", "by", "physiological", "counter", "-", "regulatory", "actions", "(", "serum", "sodium", "[", "Na", "]", "concentration", ")", ".", "In", "1986", "Hulten", "et", "al", ".", "suggested", "adding", "2", "%", "ethanol", "to", "the", "irrigation", "fluid", "as", "a", "marker", "and", "investigated", "it", "intermittently", "in", "the", "expired", "air", "with", "an", "alcohol", "-", "test", "appliance", ".", "In", "a", "prospective", "clinical", "study", "of", "17", "patients", "undergoing", "TUR", "-", "P", "under", "spinal", "anaesthesia", ",", "expiratory", "concentrations", "of", "alcohol", "that", "was", "added", "to", "the", "irrigation", "fluid", "(", "2", "%", "ethanol", "in", "Purisole", ",", "Fresenius", ",", "Bad", "Homburg", ")", "were", "monitored", ".", "Gas", "was", "continuously", "sampled", "from", "the", "nasopharynx", "through", "a", "nasal", "cannula", "and", "the", "ethanol", "concentration", "was", "measured", "using", "a", "modified", "diverting", "anaesthetic", "gas", "monitor", "(", "Normac", ",", "Datex", ",", "Helsinki", ")", "that", "allows", "continuous", "as", "well", "as", "early", "detection", "of", "the", "absorbed", "irrigation", "fluid", "with", "reliable", "accuracy", "for", "clinical", "use", ".", "In", "addition", ",", "at", "intervals", "of", "10", "minutes", "we", "measured", "blood", "alcohol", ",", "endtidal", "alcohol", "(", "Alcotest", "7110", ",", "Drauml", ";", "ger", ",", "Luebeck", ")", ",", "haematocrit", ",", "serum", "Na", "concentration", ",", "and", "blood", "gases", ".", "Sixty", "-", "eight", "measurements", "were", "obtained", "from", "the", "17", "patients", ".", "As", "shown", "in", "other", "studies", ",", "serum", "Na", "(", "r2", "=", "0.68", ")", "and", "Hct", "(", "r2", "=", "0.39", ")", "correlated", "poorly", "with", "the", "irrigation", "fluid", "as", "determined", "by", "serum", "alcohol", "levels", ".", "In", "contrast", ",", "the", "expiratory", "alcohol", "measurements", "with", "the", "alcotest", "7110", "(", "r2", "=", "0.93", ")", "and", "Normac", "devices", "(", "r2", "=", "0.85", ")", "were", "closely", "related", ".", "Continuous", "monitoring", "of", "the", "expiratory", "alcohol", "concentration", "with", "a", "Normac", "monitor", "closely", "reflects", "blood", "alcohol", "concentrations", ",", "and", "may", "hence", "serve", "as", "a", "useful", "semiquantitative", "monitor", "of", "irrigation", "fluid", "absorption", "during", "TUR", "-", "P", "." ]
[ "umlsterm" ]
absorption, irrigation, surgery, indicators, absorption, fluid balance, method, surgical, haematocrit, Hct, counter - regulatory, sodium, concentration, ethanol, irrigation, marker, air, appliance, clinical study, patients, spinal anaesthesia, concentrations, alcohol, irrigation, ethanol, Purisole, Gas, nasopharynx, cannula, ethanol, concentration, anaesthetic, gas, monitor, Normac, irrigation, use, blood, alcohol, alcohol, Alcotest, ger, haematocrit, concentration, blood gases, measurements, patients, Hct, irrigation, alcohol, contrast, alcohol, measurements, alcotest, Normac, devices, alcohol, concentration, Normac, monitor, blood, alcohol, concentrations, irrigation, absorption
DerAnaesthesist.50440436.eng.abstr_task2
Sentence: The absorption of large volumes of irrigation fluid is a major problem in transurethral prostatic surgery ( TUR-P ) . Various indicators have been tested to monitor fluid absorption with regard to continuous registration and sufficient accuracy . The volumetric fluid balance is not suitable as a routine method because of its inaccuracy . Easily accessible parameters are unspecific because of surgical bleeding ( haematocrit [ Hct ] ) , or are interfered with by physiological counter-regulatory actions ( serum sodium [ Na ] concentration ) . In 1986 Hulten et al. suggested adding 2% ethanol to the irrigation fluid as a marker and investigated it intermittently in the expired air with an alcohol-test appliance . In a prospective clinical study of 17 patients undergoing TUR-P under spinal anaesthesia , expiratory concentrations of alcohol that was added to the irrigation fluid ( 2% ethanol in Purisole , Fresenius , Bad Homburg ) were monitored . Gas was continuously sampled from the nasopharynx through a nasal cannula and the ethanol concentration was measured using a modified diverting anaesthetic gas monitor ( Normac , Datex , Helsinki ) that allows continuous as well as early detection of the absorbed irrigation fluid with reliable accuracy for clinical use . In addition , at intervals of 10 minutes we measured blood alcohol , endtidal alcohol ( Alcotest 7110 , Drauml ; ger , Luebeck ) , haematocrit , serum Na concentration , and blood gases . Sixty-eight measurements were obtained from the 17 patients . As shown in other studies , serum Na ( r2 = 0.68 ) and Hct ( r2 = 0.39 ) correlated poorly with the irrigation fluid as determined by serum alcohol levels . In contrast , the expiratory alcohol measurements with the alcotest 7110 ( r2 = 0.93 ) and Normac devices ( r2 = 0.85 ) were closely related . Continuous monitoring of the expiratory alcohol concentration with a Normac monitor closely reflects blood alcohol concentrations , and may hence serve as a useful semiquantitative monitor of irrigation fluid absorption during TUR-P . Instructions: please extract entity words from the input sentence
[ "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "B-umlsterm", "B-umlsterm", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O" ]
The absorption of large volumes of irrigation fluid is a major problem in transurethral prostatic surgery ( TUR-P ) . Various indicators have been tested to monitor fluid absorption with regard to continuous registration and sufficient accuracy . The volumetric fluid balance is not suitable as a routine method because of its inaccuracy . Easily accessible parameters are unspecific because of surgical bleeding ( haematocrit [ Hct ] ) , or are interfered with by physiological counter-regulatory actions ( serum sodium [ Na ] concentration ) . In 1986 Hulten et al. suggested adding 2% ethanol to the irrigation fluid as a marker and investigated it intermittently in the expired air with an alcohol-test appliance . In a prospective clinical study of 17 patients undergoing TUR-P under spinal anaesthesia , expiratory concentrations of alcohol that was added to the irrigation fluid ( 2% ethanol in Purisole , Fresenius , Bad Homburg ) were monitored . Gas was continuously sampled from the nasopharynx through a nasal cannula and the ethanol concentration was measured using a modified diverting anaesthetic gas monitor ( Normac , Datex , Helsinki ) that allows continuous as well as early detection of the absorbed irrigation fluid with reliable accuracy for clinical use . In addition , at intervals of 10 minutes we measured blood alcohol , endtidal alcohol ( Alcotest 7110 , Drauml ; ger , Luebeck ) , haematocrit , serum Na concentration , and blood gases . Sixty-eight measurements were obtained from the 17 patients . As shown in other studies , serum Na ( r2 = 0.68 ) and Hct ( r2 = 0.39 ) correlated poorly with the irrigation fluid as determined by serum alcohol levels . In contrast , the expiratory alcohol measurements with the alcotest 7110 ( r2 = 0.93 ) and Normac devices ( r2 = 0.85 ) were closely related . Continuous monitoring of the expiratory alcohol concentration with a Normac monitor closely reflects blood alcohol concentrations , and may hence serve as a useful semiquantitative monitor of irrigation fluid absorption during TUR-P .
[ "The", "absorption", "of", "large", "volumes", "of", "irrigation", "fluid", "is", "a", "major", "problem", "in", "transurethral", "prostatic", "surgery", "(", "TUR", "-", "P", ")", ".", "Various", "indicators", "have", "been", "tested", "to", "monitor", "fluid", "absorption", "with", "regard", "to", "continuous", "registration", "and", "sufficient", "accuracy", ".", "The", "volumetric", "fluid", "balance", "is", "not", "suitable", "as", "a", "routine", "method", "because", "of", "its", "inaccuracy", ".", "Easily", "accessible", "parameters", "are", "unspecific", "because", "of", "surgical", "bleeding", "(", "haematocrit", "[", "Hct", "]", ")", ",", "or", "are", "interfered", "with", "by", "physiological", "counter", "-", "regulatory", "actions", "(", "serum", "sodium", "[", "Na", "]", "concentration", ")", ".", "In", "1986", "Hulten", "et", "al", ".", "suggested", "adding", "2", "%", "ethanol", "to", "the", "irrigation", "fluid", "as", "a", "marker", "and", "investigated", "it", "intermittently", "in", "the", "expired", "air", "with", "an", "alcohol", "-", "test", "appliance", ".", "In", "a", "prospective", "clinical", "study", "of", "17", "patients", "undergoing", "TUR", "-", "P", "under", "spinal", "anaesthesia", ",", "expiratory", "concentrations", "of", "alcohol", "that", "was", "added", "to", "the", "irrigation", "fluid", "(", "2", "%", "ethanol", "in", "Purisole", ",", "Fresenius", ",", "Bad", "Homburg", ")", "were", "monitored", ".", "Gas", "was", "continuously", "sampled", "from", "the", "nasopharynx", "through", "a", "nasal", "cannula", "and", "the", "ethanol", "concentration", "was", "measured", "using", "a", "modified", "diverting", "anaesthetic", "gas", "monitor", "(", "Normac", ",", "Datex", ",", "Helsinki", ")", "that", "allows", "continuous", "as", "well", "as", "early", "detection", "of", "the", "absorbed", "irrigation", "fluid", "with", "reliable", "accuracy", "for", "clinical", "use", ".", "In", "addition", ",", "at", "intervals", "of", "10", "minutes", "we", "measured", "blood", "alcohol", ",", "endtidal", "alcohol", "(", "Alcotest", "7110", ",", "Drauml", ";", "ger", ",", "Luebeck", ")", ",", "haematocrit", ",", "serum", "Na", "concentration", ",", "and", "blood", "gases", ".", "Sixty", "-", "eight", "measurements", "were", "obtained", "from", "the", "17", "patients", ".", "As", "shown", "in", "other", "studies", ",", "serum", "Na", "(", "r2", "=", "0.68", ")", "and", "Hct", "(", "r2", "=", "0.39", ")", "correlated", "poorly", "with", "the", "irrigation", "fluid", "as", "determined", "by", "serum", "alcohol", "levels", ".", "In", "contrast", ",", "the", "expiratory", "alcohol", "measurements", "with", "the", "alcotest", "7110", "(", "r2", "=", "0.93", ")", "and", "Normac", "devices", "(", "r2", "=", "0.85", ")", "were", "closely", "related", ".", "Continuous", "monitoring", "of", "the", "expiratory", "alcohol", "concentration", "with", "a", "Normac", "monitor", "closely", "reflects", "blood", "alcohol", "concentrations", ",", "and", "may", "hence", "serve", "as", "a", "useful", "semiquantitative", "monitor", "of", "irrigation", "fluid", "absorption", "during", "TUR", "-", "P", "." ]
[ "umlsterm" ]
retention is a Outcome_Other, lumiracoxib is a Intervention_Pharmacological, celecoxib is a Intervention_Pharmacological, patients with osteoarthritis . is a Participant_Condition, patients with osteoarthritis ( OA ) . is a Participant_Age, lumiracoxib at doses of 100 mg once daily ( o.d . ) and 100 mg twice daily is a Intervention_Pharmacological, celecoxib 200 mg o.d . is a Intervention_Pharmacological, non - inferiority is a Outcome_Physical, 1-year retention on treatment rate is a Outcome_Pain, Retention rates is a Outcome_Physical, tolerated is a Outcome_Physical
34849_task0
Sentence: Long-term retention on treatment with lumiracoxib 100 mg once or twice daily compared with celecoxib 200 mg once daily : a randomised controlled trial in patients with osteoarthritis . BACKGROUND The efficacy , safety and tolerability of lumiracoxib , a novel selective cyclooxygenase-2 ( COX-2 ) inhibitor , has been demonstrated in previous studies of patients with osteoarthritis ( OA ) . As it is important to establish the long-term safety and efficacy of treatments for a chronic disease such as OA , the present study compared the effects of lumiracoxib at doses of 100 mg once daily ( o.d . ) and 100 mg twice daily ( b.i.d . ) with those of celecoxib 200 mg o.d . on retention on treatment over 1 year . METHODS In this 52-week , multicentre , randomised , double-blind , parallel-group study , male and female patients ( aged at least 40 years ) with symptomatic primary OA of the hip , knee , hand or spine were randomised ( 1:2:1 ) to lumiracoxib 100 mg o.d . ( n = 755 ) , lumiracoxib 100 mg b.i.d . ( n = 1,519 ) or celecoxib 200 mg o.d . ( n = 758 ) . The primary objective of the study was to demonstrate non-inferiority of lumiracoxib at either dose compared with celecoxib 200 mg o.d . with respect to the 1-year retention on treatment rate . Secondary outcome variables included OA pain in the target joint , patient 's and physician 's global assessments of disease activity , Short Arthritis assessment Scale ( SAS ) total score , rescue medication use , and safety and tolerability . RESULTS Retention rates at 1 year were similar for the lumiracoxib 100 mg o.d. , lumiracoxib 100 mg b.i.d . and celecoxib 200 mg o.d . groups ( 46.9 % vs 47.5 % vs 45.3 % , respectively ) . It was demonstrated that retention on treatment with lumiracoxib at either dose was non-inferior to celecoxib 200 mg o.d . Similarly , Kaplan-Meier curves for the probability of premature discontinuation from the study for any reason were similar across the treatment groups . All three treatments generally yielded comparable results for the secondary efficacy variables and all treatments were well tolerated . CONCLUSION Long-term treatment with lumiracoxib 100 mg o.d. , the recommended dose for OA , was as effective and well tolerated as celecoxib 200 mg o.d . in patients with OA . TRIAL REGISTRATION clinicaltrials.gov NCT00145301 . Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: Intervention_Pharmacological, Participant_Condition, Outcome_Physical, Participant_Age, Outcome_Pain, Outcome_Other
[ "O", "O", "O", "B-Outcome_Other", "O", "O", "O", "B-Intervention_Pharmacological", "O", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Pharmacological", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Participant_Age", "I-Participant_Age", "I-Participant_Age", "I-Participant_Age", "I-Participant_Age", "I-Participant_Age", "I-Participant_Age", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Pain", "I-Outcome_Pain", "I-Outcome_Pain", "I-Outcome_Pain", "I-Outcome_Pain", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]
Long-term retention on treatment with lumiracoxib 100 mg once or twice daily compared with celecoxib 200 mg once daily : a randomised controlled trial in patients with osteoarthritis . BACKGROUND The efficacy , safety and tolerability of lumiracoxib , a novel selective cyclooxygenase-2 ( COX-2 ) inhibitor , has been demonstrated in previous studies of patients with osteoarthritis ( OA ) . As it is important to establish the long-term safety and efficacy of treatments for a chronic disease such as OA , the present study compared the effects of lumiracoxib at doses of 100 mg once daily ( o.d . ) and 100 mg twice daily ( b.i.d . ) with those of celecoxib 200 mg o.d . on retention on treatment over 1 year . METHODS In this 52-week , multicentre , randomised , double-blind , parallel-group study , male and female patients ( aged at least 40 years ) with symptomatic primary OA of the hip , knee , hand or spine were randomised ( 1:2:1 ) to lumiracoxib 100 mg o.d . ( n = 755 ) , lumiracoxib 100 mg b.i.d . ( n = 1,519 ) or celecoxib 200 mg o.d . ( n = 758 ) . The primary objective of the study was to demonstrate non-inferiority of lumiracoxib at either dose compared with celecoxib 200 mg o.d . with respect to the 1-year retention on treatment rate . Secondary outcome variables included OA pain in the target joint , patient 's and physician 's global assessments of disease activity , Short Arthritis assessment Scale ( SAS ) total score , rescue medication use , and safety and tolerability . RESULTS Retention rates at 1 year were similar for the lumiracoxib 100 mg o.d. , lumiracoxib 100 mg b.i.d . and celecoxib 200 mg o.d . groups ( 46.9 % vs 47.5 % vs 45.3 % , respectively ) . It was demonstrated that retention on treatment with lumiracoxib at either dose was non-inferior to celecoxib 200 mg o.d . Similarly , Kaplan-Meier curves for the probability of premature discontinuation from the study for any reason were similar across the treatment groups . All three treatments generally yielded comparable results for the secondary efficacy variables and all treatments were well tolerated . CONCLUSION Long-term treatment with lumiracoxib 100 mg o.d. , the recommended dose for OA , was as effective and well tolerated as celecoxib 200 mg o.d . in patients with OA . TRIAL REGISTRATION clinicaltrials.gov NCT00145301 .
[ "Long", "-", "term", "retention", "on", "treatment", "with", "lumiracoxib", "100", "mg", "once", "or", "twice", "daily", "compared", "with", "celecoxib", "200", "mg", "once", "daily", ":", "a", "randomised", "controlled", "trial", "in", "patients", "with", "osteoarthritis", ".", "BACKGROUND", "The", "efficacy", ",", "safety", "and", "tolerability", "of", "lumiracoxib", ",", "a", "novel", "selective", "cyclooxygenase-2", "(", "COX-2", ")", "inhibitor", ",", "has", "been", "demonstrated", "in", "previous", "studies", "of", "patients", "with", "osteoarthritis", "(", "OA", ")", ".", "As", "it", "is", "important", "to", "establish", "the", "long", "-", "term", "safety", "and", "efficacy", "of", "treatments", "for", "a", "chronic", "disease", "such", "as", "OA", ",", "the", "present", "study", "compared", "the", "effects", "of", "lumiracoxib", "at", "doses", "of", "100", "mg", "once", "daily", "(", "o.d", ".", ")", "and", "100", "mg", "twice", "daily", "(", "b.i.d", ".", ")", "with", "those", "of", "celecoxib", "200", "mg", "o.d", ".", "on", "retention", "on", "treatment", "over", "1", "year", ".", "METHODS", "In", "this", "52-week", ",", "multicentre", ",", "randomised", ",", "double", "-", "blind", ",", "parallel", "-", "group", "study", ",", "male", "and", "female", "patients", "(", "aged", "at", "least", "40", "years", ")", "with", "symptomatic", "primary", "OA", "of", "the", "hip", ",", "knee", ",", "hand", "or", "spine", "were", "randomised", "(", "1:2:1", ")", "to", "lumiracoxib", "100", "mg", "o.d", ".", "(", "n", "=", "755", ")", ",", "lumiracoxib", "100", "mg", "b.i.d", ".", "(", "n", "=", "1,519", ")", "or", "celecoxib", "200", "mg", "o.d", ".", "(", "n", "=", "758", ")", ".", "The", "primary", "objective", "of", "the", "study", "was", "to", "demonstrate", "non", "-", "inferiority", "of", "lumiracoxib", "at", "either", "dose", "compared", "with", "celecoxib", "200", "mg", "o.d", ".", "with", "respect", "to", "the", "1-year", "retention", "on", "treatment", "rate", ".", "Secondary", "outcome", "variables", "included", "OA", "pain", "in", "the", "target", "joint", ",", "patient", "'", "s", "and", "physician", "'", "s", "global", "assessments", "of", "disease", "activity", ",", "Short", "Arthritis", "assessment", "Scale", "(", "SAS", ")", "total", "score", ",", "rescue", "medication", "use", ",", "and", "safety", "and", "tolerability", ".", "RESULTS", "Retention", "rates", "at", "1", "year", "were", "similar", "for", "the", "lumiracoxib", "100", "mg", "o.d", ".", ",", "lumiracoxib", "100", "mg", "b.i.d", ".", "and", "celecoxib", "200", "mg", "o.d", ".", "groups", "(", "46.9", "%", "vs", "47.5", "%", "vs", "45.3", "%", ",", "respectively", ")", ".", "It", "was", "demonstrated", "that", "retention", "on", "treatment", "with", "lumiracoxib", "at", "either", "dose", "was", "non", "-", "inferior", "to", "celecoxib", "200", "mg", "o.d", ".", "Similarly", ",", "Kaplan", "-", "Meier", "curves", "for", "the", "probability", "of", "premature", "discontinuation", "from", "the", "study", "for", "any", "reason", "were", "similar", "across", "the", "treatment", "groups", ".", "All", "three", "treatments", "generally", "yielded", "comparable", "results", "for", "the", "secondary", "efficacy", "variables", "and", "all", "treatments", "were", "well", "tolerated", ".", "CONCLUSION", "Long", "-", "term", "treatment", "with", "lumiracoxib", "100", "mg", "o.d", ".", ",", "the", "recommended", "dose", "for", "OA", ",", "was", "as", "effective", "and", "well", "tolerated", "as", "celecoxib", "200", "mg", "o.d", ".", "in", "patients", "with", "OA", ".", "TRIAL", "REGISTRATION", "clinicaltrials.gov", "NCT00145301", "." ]
[ "Intervention_Pharmacological", "Participant_Age", "Outcome_Pain", "Participant_Condition", "Outcome_Physical", "Outcome_Other" ]
retention is a Outcome_Other, lumiracoxib is a Intervention_Pharmacological, celecoxib is a Intervention_Pharmacological, patients with osteoarthritis . is a Participant_Condition, patients with osteoarthritis ( OA ) . is a Participant_Age, lumiracoxib at doses of 100 mg once daily ( o.d . ) and 100 mg twice daily is a Intervention_Pharmacological, celecoxib 200 mg o.d . is a Intervention_Pharmacological, non - inferiority is a Outcome_Physical, 1-year retention on treatment rate is a Outcome_Pain, Retention rates is a Outcome_Physical, tolerated is a Outcome_Physical
34849_task1
Sentence: Long-term retention on treatment with lumiracoxib 100 mg once or twice daily compared with celecoxib 200 mg once daily : a randomised controlled trial in patients with osteoarthritis . BACKGROUND The efficacy , safety and tolerability of lumiracoxib , a novel selective cyclooxygenase-2 ( COX-2 ) inhibitor , has been demonstrated in previous studies of patients with osteoarthritis ( OA ) . As it is important to establish the long-term safety and efficacy of treatments for a chronic disease such as OA , the present study compared the effects of lumiracoxib at doses of 100 mg once daily ( o.d . ) and 100 mg twice daily ( b.i.d . ) with those of celecoxib 200 mg o.d . on retention on treatment over 1 year . METHODS In this 52-week , multicentre , randomised , double-blind , parallel-group study , male and female patients ( aged at least 40 years ) with symptomatic primary OA of the hip , knee , hand or spine were randomised ( 1:2:1 ) to lumiracoxib 100 mg o.d . ( n = 755 ) , lumiracoxib 100 mg b.i.d . ( n = 1,519 ) or celecoxib 200 mg o.d . ( n = 758 ) . The primary objective of the study was to demonstrate non-inferiority of lumiracoxib at either dose compared with celecoxib 200 mg o.d . with respect to the 1-year retention on treatment rate . Secondary outcome variables included OA pain in the target joint , patient 's and physician 's global assessments of disease activity , Short Arthritis assessment Scale ( SAS ) total score , rescue medication use , and safety and tolerability . RESULTS Retention rates at 1 year were similar for the lumiracoxib 100 mg o.d. , lumiracoxib 100 mg b.i.d . and celecoxib 200 mg o.d . groups ( 46.9 % vs 47.5 % vs 45.3 % , respectively ) . It was demonstrated that retention on treatment with lumiracoxib at either dose was non-inferior to celecoxib 200 mg o.d . Similarly , Kaplan-Meier curves for the probability of premature discontinuation from the study for any reason were similar across the treatment groups . All three treatments generally yielded comparable results for the secondary efficacy variables and all treatments were well tolerated . CONCLUSION Long-term treatment with lumiracoxib 100 mg o.d. , the recommended dose for OA , was as effective and well tolerated as celecoxib 200 mg o.d . in patients with OA . TRIAL REGISTRATION clinicaltrials.gov NCT00145301 . Instructions: please typing these entity words according to sentence: retention, lumiracoxib, celecoxib, patients with osteoarthritis ., patients with osteoarthritis ( OA ) ., lumiracoxib at doses of 100 mg once daily ( o.d . ) and 100 mg twice daily, celecoxib 200 mg o.d ., non - inferiority, 1-year retention on treatment rate, Retention rates, tolerated Options: Intervention_Pharmacological, Participant_Condition, Outcome_Physical, Participant_Age, Outcome_Pain, Outcome_Other
[ "O", "O", "O", "B-Outcome_Other", "O", "O", "O", "B-Intervention_Pharmacological", "O", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Pharmacological", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Participant_Age", "I-Participant_Age", "I-Participant_Age", "I-Participant_Age", "I-Participant_Age", "I-Participant_Age", "I-Participant_Age", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Pain", "I-Outcome_Pain", "I-Outcome_Pain", "I-Outcome_Pain", "I-Outcome_Pain", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]
Long-term retention on treatment with lumiracoxib 100 mg once or twice daily compared with celecoxib 200 mg once daily : a randomised controlled trial in patients with osteoarthritis . BACKGROUND The efficacy , safety and tolerability of lumiracoxib , a novel selective cyclooxygenase-2 ( COX-2 ) inhibitor , has been demonstrated in previous studies of patients with osteoarthritis ( OA ) . As it is important to establish the long-term safety and efficacy of treatments for a chronic disease such as OA , the present study compared the effects of lumiracoxib at doses of 100 mg once daily ( o.d . ) and 100 mg twice daily ( b.i.d . ) with those of celecoxib 200 mg o.d . on retention on treatment over 1 year . METHODS In this 52-week , multicentre , randomised , double-blind , parallel-group study , male and female patients ( aged at least 40 years ) with symptomatic primary OA of the hip , knee , hand or spine were randomised ( 1:2:1 ) to lumiracoxib 100 mg o.d . ( n = 755 ) , lumiracoxib 100 mg b.i.d . ( n = 1,519 ) or celecoxib 200 mg o.d . ( n = 758 ) . The primary objective of the study was to demonstrate non-inferiority of lumiracoxib at either dose compared with celecoxib 200 mg o.d . with respect to the 1-year retention on treatment rate . Secondary outcome variables included OA pain in the target joint , patient 's and physician 's global assessments of disease activity , Short Arthritis assessment Scale ( SAS ) total score , rescue medication use , and safety and tolerability . RESULTS Retention rates at 1 year were similar for the lumiracoxib 100 mg o.d. , lumiracoxib 100 mg b.i.d . and celecoxib 200 mg o.d . groups ( 46.9 % vs 47.5 % vs 45.3 % , respectively ) . It was demonstrated that retention on treatment with lumiracoxib at either dose was non-inferior to celecoxib 200 mg o.d . Similarly , Kaplan-Meier curves for the probability of premature discontinuation from the study for any reason were similar across the treatment groups . All three treatments generally yielded comparable results for the secondary efficacy variables and all treatments were well tolerated . CONCLUSION Long-term treatment with lumiracoxib 100 mg o.d. , the recommended dose for OA , was as effective and well tolerated as celecoxib 200 mg o.d . in patients with OA . TRIAL REGISTRATION clinicaltrials.gov NCT00145301 .
[ "Long", "-", "term", "retention", "on", "treatment", "with", "lumiracoxib", "100", "mg", "once", "or", "twice", "daily", "compared", "with", "celecoxib", "200", "mg", "once", "daily", ":", "a", "randomised", "controlled", "trial", "in", "patients", "with", "osteoarthritis", ".", "BACKGROUND", "The", "efficacy", ",", "safety", "and", "tolerability", "of", "lumiracoxib", ",", "a", "novel", "selective", "cyclooxygenase-2", "(", "COX-2", ")", "inhibitor", ",", "has", "been", "demonstrated", "in", "previous", "studies", "of", "patients", "with", "osteoarthritis", "(", "OA", ")", ".", "As", "it", "is", "important", "to", "establish", "the", "long", "-", "term", "safety", "and", "efficacy", "of", "treatments", "for", "a", "chronic", "disease", "such", "as", "OA", ",", "the", "present", "study", "compared", "the", "effects", "of", "lumiracoxib", "at", "doses", "of", "100", "mg", "once", "daily", "(", "o.d", ".", ")", "and", "100", "mg", "twice", "daily", "(", "b.i.d", ".", ")", "with", "those", "of", "celecoxib", "200", "mg", "o.d", ".", "on", "retention", "on", "treatment", "over", "1", "year", ".", "METHODS", "In", "this", "52-week", ",", "multicentre", ",", "randomised", ",", "double", "-", "blind", ",", "parallel", "-", "group", "study", ",", "male", "and", "female", "patients", "(", "aged", "at", "least", "40", "years", ")", "with", "symptomatic", "primary", "OA", "of", "the", "hip", ",", "knee", ",", "hand", "or", "spine", "were", "randomised", "(", "1:2:1", ")", "to", "lumiracoxib", "100", "mg", "o.d", ".", "(", "n", "=", "755", ")", ",", "lumiracoxib", "100", "mg", "b.i.d", ".", "(", "n", "=", "1,519", ")", "or", "celecoxib", "200", "mg", "o.d", ".", "(", "n", "=", "758", ")", ".", "The", "primary", "objective", "of", "the", "study", "was", "to", "demonstrate", "non", "-", "inferiority", "of", "lumiracoxib", "at", "either", "dose", "compared", "with", "celecoxib", "200", "mg", "o.d", ".", "with", "respect", "to", "the", "1-year", "retention", "on", "treatment", "rate", ".", "Secondary", "outcome", "variables", "included", "OA", "pain", "in", "the", "target", "joint", ",", "patient", "'", "s", "and", "physician", "'", "s", "global", "assessments", "of", "disease", "activity", ",", "Short", "Arthritis", "assessment", "Scale", "(", "SAS", ")", "total", "score", ",", "rescue", "medication", "use", ",", "and", "safety", "and", "tolerability", ".", "RESULTS", "Retention", "rates", "at", "1", "year", "were", "similar", "for", "the", "lumiracoxib", "100", "mg", "o.d", ".", ",", "lumiracoxib", "100", "mg", "b.i.d", ".", "and", "celecoxib", "200", "mg", "o.d", ".", "groups", "(", "46.9", "%", "vs", "47.5", "%", "vs", "45.3", "%", ",", "respectively", ")", ".", "It", "was", "demonstrated", "that", "retention", "on", "treatment", "with", "lumiracoxib", "at", "either", "dose", "was", "non", "-", "inferior", "to", "celecoxib", "200", "mg", "o.d", ".", "Similarly", ",", "Kaplan", "-", "Meier", "curves", "for", "the", "probability", "of", "premature", "discontinuation", "from", "the", "study", "for", "any", "reason", "were", "similar", "across", "the", "treatment", "groups", ".", "All", "three", "treatments", "generally", "yielded", "comparable", "results", "for", "the", "secondary", "efficacy", "variables", "and", "all", "treatments", "were", "well", "tolerated", ".", "CONCLUSION", "Long", "-", "term", "treatment", "with", "lumiracoxib", "100", "mg", "o.d", ".", ",", "the", "recommended", "dose", "for", "OA", ",", "was", "as", "effective", "and", "well", "tolerated", "as", "celecoxib", "200", "mg", "o.d", ".", "in", "patients", "with", "OA", ".", "TRIAL", "REGISTRATION", "clinicaltrials.gov", "NCT00145301", "." ]
[ "Intervention_Pharmacological", "Participant_Age", "Outcome_Pain", "Participant_Condition", "Outcome_Physical", "Outcome_Other" ]
retention, lumiracoxib, celecoxib, patients with osteoarthritis ., patients with osteoarthritis ( OA ) ., lumiracoxib at doses of 100 mg once daily ( o.d . ) and 100 mg twice daily, celecoxib 200 mg o.d ., non - inferiority, 1-year retention on treatment rate, Retention rates, tolerated
34849_task2
Sentence: Long-term retention on treatment with lumiracoxib 100 mg once or twice daily compared with celecoxib 200 mg once daily : a randomised controlled trial in patients with osteoarthritis . BACKGROUND The efficacy , safety and tolerability of lumiracoxib , a novel selective cyclooxygenase-2 ( COX-2 ) inhibitor , has been demonstrated in previous studies of patients with osteoarthritis ( OA ) . As it is important to establish the long-term safety and efficacy of treatments for a chronic disease such as OA , the present study compared the effects of lumiracoxib at doses of 100 mg once daily ( o.d . ) and 100 mg twice daily ( b.i.d . ) with those of celecoxib 200 mg o.d . on retention on treatment over 1 year . METHODS In this 52-week , multicentre , randomised , double-blind , parallel-group study , male and female patients ( aged at least 40 years ) with symptomatic primary OA of the hip , knee , hand or spine were randomised ( 1:2:1 ) to lumiracoxib 100 mg o.d . ( n = 755 ) , lumiracoxib 100 mg b.i.d . ( n = 1,519 ) or celecoxib 200 mg o.d . ( n = 758 ) . The primary objective of the study was to demonstrate non-inferiority of lumiracoxib at either dose compared with celecoxib 200 mg o.d . with respect to the 1-year retention on treatment rate . Secondary outcome variables included OA pain in the target joint , patient 's and physician 's global assessments of disease activity , Short Arthritis assessment Scale ( SAS ) total score , rescue medication use , and safety and tolerability . RESULTS Retention rates at 1 year were similar for the lumiracoxib 100 mg o.d. , lumiracoxib 100 mg b.i.d . and celecoxib 200 mg o.d . groups ( 46.9 % vs 47.5 % vs 45.3 % , respectively ) . It was demonstrated that retention on treatment with lumiracoxib at either dose was non-inferior to celecoxib 200 mg o.d . Similarly , Kaplan-Meier curves for the probability of premature discontinuation from the study for any reason were similar across the treatment groups . All three treatments generally yielded comparable results for the secondary efficacy variables and all treatments were well tolerated . CONCLUSION Long-term treatment with lumiracoxib 100 mg o.d. , the recommended dose for OA , was as effective and well tolerated as celecoxib 200 mg o.d . in patients with OA . TRIAL REGISTRATION clinicaltrials.gov NCT00145301 . Instructions: please extract entity words from the input sentence
[ "O", "O", "O", "B-Outcome_Other", "O", "O", "O", "B-Intervention_Pharmacological", "O", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Pharmacological", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Participant_Age", "I-Participant_Age", "I-Participant_Age", "I-Participant_Age", "I-Participant_Age", "I-Participant_Age", "I-Participant_Age", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Pain", "I-Outcome_Pain", "I-Outcome_Pain", "I-Outcome_Pain", "I-Outcome_Pain", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]
Long-term retention on treatment with lumiracoxib 100 mg once or twice daily compared with celecoxib 200 mg once daily : a randomised controlled trial in patients with osteoarthritis . BACKGROUND The efficacy , safety and tolerability of lumiracoxib , a novel selective cyclooxygenase-2 ( COX-2 ) inhibitor , has been demonstrated in previous studies of patients with osteoarthritis ( OA ) . As it is important to establish the long-term safety and efficacy of treatments for a chronic disease such as OA , the present study compared the effects of lumiracoxib at doses of 100 mg once daily ( o.d . ) and 100 mg twice daily ( b.i.d . ) with those of celecoxib 200 mg o.d . on retention on treatment over 1 year . METHODS In this 52-week , multicentre , randomised , double-blind , parallel-group study , male and female patients ( aged at least 40 years ) with symptomatic primary OA of the hip , knee , hand or spine were randomised ( 1:2:1 ) to lumiracoxib 100 mg o.d . ( n = 755 ) , lumiracoxib 100 mg b.i.d . ( n = 1,519 ) or celecoxib 200 mg o.d . ( n = 758 ) . The primary objective of the study was to demonstrate non-inferiority of lumiracoxib at either dose compared with celecoxib 200 mg o.d . with respect to the 1-year retention on treatment rate . Secondary outcome variables included OA pain in the target joint , patient 's and physician 's global assessments of disease activity , Short Arthritis assessment Scale ( SAS ) total score , rescue medication use , and safety and tolerability . RESULTS Retention rates at 1 year were similar for the lumiracoxib 100 mg o.d. , lumiracoxib 100 mg b.i.d . and celecoxib 200 mg o.d . groups ( 46.9 % vs 47.5 % vs 45.3 % , respectively ) . It was demonstrated that retention on treatment with lumiracoxib at either dose was non-inferior to celecoxib 200 mg o.d . Similarly , Kaplan-Meier curves for the probability of premature discontinuation from the study for any reason were similar across the treatment groups . All three treatments generally yielded comparable results for the secondary efficacy variables and all treatments were well tolerated . CONCLUSION Long-term treatment with lumiracoxib 100 mg o.d. , the recommended dose for OA , was as effective and well tolerated as celecoxib 200 mg o.d . in patients with OA . TRIAL REGISTRATION clinicaltrials.gov NCT00145301 .
[ "Long", "-", "term", "retention", "on", "treatment", "with", "lumiracoxib", "100", "mg", "once", "or", "twice", "daily", "compared", "with", "celecoxib", "200", "mg", "once", "daily", ":", "a", "randomised", "controlled", "trial", "in", "patients", "with", "osteoarthritis", ".", "BACKGROUND", "The", "efficacy", ",", "safety", "and", "tolerability", "of", "lumiracoxib", ",", "a", "novel", "selective", "cyclooxygenase-2", "(", "COX-2", ")", "inhibitor", ",", "has", "been", "demonstrated", "in", "previous", "studies", "of", "patients", "with", "osteoarthritis", "(", "OA", ")", ".", "As", "it", "is", "important", "to", "establish", "the", "long", "-", "term", "safety", "and", "efficacy", "of", "treatments", "for", "a", "chronic", "disease", "such", "as", "OA", ",", "the", "present", "study", "compared", "the", "effects", "of", "lumiracoxib", "at", "doses", "of", "100", "mg", "once", "daily", "(", "o.d", ".", ")", "and", "100", "mg", "twice", "daily", "(", "b.i.d", ".", ")", "with", "those", "of", "celecoxib", "200", "mg", "o.d", ".", "on", "retention", "on", "treatment", "over", "1", "year", ".", "METHODS", "In", "this", "52-week", ",", "multicentre", ",", "randomised", ",", "double", "-", "blind", ",", "parallel", "-", "group", "study", ",", "male", "and", "female", "patients", "(", "aged", "at", "least", "40", "years", ")", "with", "symptomatic", "primary", "OA", "of", "the", "hip", ",", "knee", ",", "hand", "or", "spine", "were", "randomised", "(", "1:2:1", ")", "to", "lumiracoxib", "100", "mg", "o.d", ".", "(", "n", "=", "755", ")", ",", "lumiracoxib", "100", "mg", "b.i.d", ".", "(", "n", "=", "1,519", ")", "or", "celecoxib", "200", "mg", "o.d", ".", "(", "n", "=", "758", ")", ".", "The", "primary", "objective", "of", "the", "study", "was", "to", "demonstrate", "non", "-", "inferiority", "of", "lumiracoxib", "at", "either", "dose", "compared", "with", "celecoxib", "200", "mg", "o.d", ".", "with", "respect", "to", "the", "1-year", "retention", "on", "treatment", "rate", ".", "Secondary", "outcome", "variables", "included", "OA", "pain", "in", "the", "target", "joint", ",", "patient", "'", "s", "and", "physician", "'", "s", "global", "assessments", "of", "disease", "activity", ",", "Short", "Arthritis", "assessment", "Scale", "(", "SAS", ")", "total", "score", ",", "rescue", "medication", "use", ",", "and", "safety", "and", "tolerability", ".", "RESULTS", "Retention", "rates", "at", "1", "year", "were", "similar", "for", "the", "lumiracoxib", "100", "mg", "o.d", ".", ",", "lumiracoxib", "100", "mg", "b.i.d", ".", "and", "celecoxib", "200", "mg", "o.d", ".", "groups", "(", "46.9", "%", "vs", "47.5", "%", "vs", "45.3", "%", ",", "respectively", ")", ".", "It", "was", "demonstrated", "that", "retention", "on", "treatment", "with", "lumiracoxib", "at", "either", "dose", "was", "non", "-", "inferior", "to", "celecoxib", "200", "mg", "o.d", ".", "Similarly", ",", "Kaplan", "-", "Meier", "curves", "for", "the", "probability", "of", "premature", "discontinuation", "from", "the", "study", "for", "any", "reason", "were", "similar", "across", "the", "treatment", "groups", ".", "All", "three", "treatments", "generally", "yielded", "comparable", "results", "for", "the", "secondary", "efficacy", "variables", "and", "all", "treatments", "were", "well", "tolerated", ".", "CONCLUSION", "Long", "-", "term", "treatment", "with", "lumiracoxib", "100", "mg", "o.d", ".", ",", "the", "recommended", "dose", "for", "OA", ",", "was", "as", "effective", "and", "well", "tolerated", "as", "celecoxib", "200", "mg", "o.d", ".", "in", "patients", "with", "OA", ".", "TRIAL", "REGISTRATION", "clinicaltrials.gov", "NCT00145301", "." ]
[ "Intervention_Pharmacological", "Participant_Age", "Outcome_Pain", "Participant_Condition", "Outcome_Physical", "Outcome_Other" ]
factor VII is a Protein, factor VII is a Protein, factor VII is a Protein, factor XIIa is a Protein, factor VII is a Protein, factor VIIa is a Protein, aspartic acid residue is a Entity, bovine factor VII is a Entity, factor VII is a Protein
105_task0
Sentence: Bovine factor VII. Its purification and complete amino acid sequence. A modified method for purification of blood clotting factor VII from bovine plasma was developed, and its complete amino acid sequence was established. The isolated factor VII was activated with factor XIIa, and the resulting two-chain factor VII (factor VIIa) was reduced and S-pyridylethylated or S-aminoethylated. The amino acid sequences of the S-alkylated heavy and light chains were determined by sequencing the fragments obtained from enzymatic and chemical cleavages. Fast atom bombardment mass spectrometry was also used to establish the COOH-terminal sequence of the heavy chain. The light chain consists of 152 residues with one carbohydrate chain at Asn145, and 11 gamma-carboxyglutamic acid residues are found within the NH2-terminal 35 residues. The light chain contains 0.2-0.3 mol of beta-hydroxyaspartic acid/mol of protein, indicating that an aspartic acid residue in bovine factor VII is incompletely hydroxylated. Moreover, a pentapeptide, Ala-Ser*-Ser-Pro-Cys (positions 51-55), isolated from an enzymatic digest of the light chain, contained an unknown serine derivative, but its structure is still unclear. On the other hand, the heavy chain is composed of 255 residues and one asparagine-linked carbohydrate chain at Asn203. Bovine factor VII, with a total of 407 residues, has 71% sequence identity with the human molecule (406 residues) predicted from the cDNA sequence (Hagen, F. S., Gray, C. L., O'Hara, P., Grant, F. J., Saari, G. C., Woodbury, R. G., Hart, C. E., Insley, M., Kisiel, W., Kurachi, K., and Davie, E. W. (1986) Proc. Natl. Acad. Sci. U. S. A. 83, 2412-2416). Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: Entity, Protein
[ "O", "B-Protein", "I-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "O", "O", "O", "B-Protein", "I-Protein", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "O", "B-Protein", "I-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Entity", "I-Entity", "I-Entity", "O", "B-Entity", "I-Entity", "I-Entity", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]
Bovine factor VII. Its purification and complete amino acid sequence. A modified method for purification of blood clotting factor VII from bovine plasma was developed, and its complete amino acid sequence was established. The isolated factor VII was activated with factor XIIa, and the resulting two-chain factor VII (factor VIIa) was reduced and S-pyridylethylated or S-aminoethylated. The amino acid sequences of the S-alkylated heavy and light chains were determined by sequencing the fragments obtained from enzymatic and chemical cleavages. Fast atom bombardment mass spectrometry was also used to establish the COOH-terminal sequence of the heavy chain. The light chain consists of 152 residues with one carbohydrate chain at Asn145, and 11 gamma-carboxyglutamic acid residues are found within the NH2-terminal 35 residues. The light chain contains 0.2-0.3 mol of beta-hydroxyaspartic acid/mol of protein, indicating that an aspartic acid residue in bovine factor VII is incompletely hydroxylated. Moreover, a pentapeptide, Ala-Ser*-Ser-Pro-Cys (positions 51-55), isolated from an enzymatic digest of the light chain, contained an unknown serine derivative, but its structure is still unclear. On the other hand, the heavy chain is composed of 255 residues and one asparagine-linked carbohydrate chain at Asn203. Bovine factor VII, with a total of 407 residues, has 71% sequence identity with the human molecule (406 residues) predicted from the cDNA sequence (Hagen, F. S., Gray, C. L., O'Hara, P., Grant, F. J., Saari, G. C., Woodbury, R. G., Hart, C. E., Insley, M., Kisiel, W., Kurachi, K., and Davie, E. W. (1986) Proc. Natl. Acad. Sci. U. S. A. 83, 2412-2416).
[ "Bovine", "factor", "VII", ".", "Its", "purification", "and", "complete", "amino", "acid", "sequence", ".", "\n", "A", "modified", "method", "for", "purification", "of", "blood", "clotting", "factor", "VII", "from", "bovine", "plasma", "was", "developed", ",", "and", "its", "complete", "amino", "acid", "sequence", "was", "established", ".", " ", "The", "isolated", "factor", "VII", "was", "activated", "with", "factor", "XIIa", ",", "and", "the", "resulting", "two", "-", "chain", "factor", "VII", "(", "factor", "VIIa", ")", "was", "reduced", "and", "S", "-", "pyridylethylated", "or", "S", "-", "aminoethylated", ".", " ", "The", "amino", "acid", "sequences", "of", "the", "S", "-", "alkylated", "heavy", "and", "light", "chains", "were", "determined", "by", "sequencing", "the", "fragments", "obtained", "from", "enzymatic", "and", "chemical", "cleavages", ".", " ", "Fast", "atom", "bombardment", "mass", "spectrometry", "was", "also", "used", "to", "establish", "the", "COOH", "-", "terminal", "sequence", "of", "the", "heavy", "chain", ".", " ", "The", "light", "chain", "consists", "of", "152", "residues", "with", "one", "carbohydrate", "chain", "at", "Asn145", ",", "and", "11", "gamma", "-", "carboxyglutamic", "acid", "residues", "are", "found", "within", "the", "NH2-terminal", "35", "residues", ".", " ", "The", "light", "chain", "contains", "0.2", "-", "0.3", "mol", "of", "beta", "-", "hydroxyaspartic", "acid", "/", "mol", "of", "protein", ",", "indicating", "that", "an", "aspartic", "acid", "residue", "in", "bovine", "factor", "VII", "is", "incompletely", "hydroxylated", ".", "Moreover", ",", "a", "pentapeptide", ",", "Ala", "-", "Ser*-Ser", "-", "Pro", "-", "Cys", "(", "positions", "51", "-", "55", ")", ",", "isolated", "from", "an", "enzymatic", "digest", "of", "the", "light", "chain", ",", "contained", "an", "unknown", "serine", "derivative", ",", "but", "its", "structure", "is", "still", "unclear", ".", " ", "On", "the", "other", "hand", ",", "the", "heavy", "chain", "is", "composed", "of", "255", "residues", "and", "one", "asparagine", "-", "linked", "carbohydrate", "chain", "at", "Asn203", ".", " ", "Bovine", "factor", "VII", ",", "with", "a", "total", "of", "407", "residues", ",", "has", "71", "%", "sequence", "identity", "with", "the", "human", "molecule", "(", "406", "residues", ")", "predicted", "from", "the", "cDNA", "sequence", "(", "Hagen", ",", "F.", "S.", ",", "Gray", ",", "C.", "L.", ",", "O'Hara", ",", "P.", ",", "Grant", ",", "F.", "J.", ",", "Saari", ",", "G.", "C.", ",", "Woodbury", ",", "R.", "G.", ",", "Hart", ",", "C.", "E.", ",", "Insley", ",", "M.", ",", "Kisiel", ",", "W.", ",", "Kurachi", ",", "K.", ",", "and", "Davie", ",", "E.", "W.", "(", "1986", ")", "Proc", ".", "Natl", ".", "Acad", ".", "Sci", ".", "U.", "S.", "A.", "83", ",", "2412", "-", "2416", ")", "." ]
[ "Entity", "Protein" ]
factor VII is a Protein, factor VII is a Protein, factor VII is a Protein, factor XIIa is a Protein, factor VII is a Protein, factor VIIa is a Protein, aspartic acid residue is a Entity, bovine factor VII is a Entity, factor VII is a Protein
105_task1
Sentence: Bovine factor VII. Its purification and complete amino acid sequence. A modified method for purification of blood clotting factor VII from bovine plasma was developed, and its complete amino acid sequence was established. The isolated factor VII was activated with factor XIIa, and the resulting two-chain factor VII (factor VIIa) was reduced and S-pyridylethylated or S-aminoethylated. The amino acid sequences of the S-alkylated heavy and light chains were determined by sequencing the fragments obtained from enzymatic and chemical cleavages. Fast atom bombardment mass spectrometry was also used to establish the COOH-terminal sequence of the heavy chain. The light chain consists of 152 residues with one carbohydrate chain at Asn145, and 11 gamma-carboxyglutamic acid residues are found within the NH2-terminal 35 residues. The light chain contains 0.2-0.3 mol of beta-hydroxyaspartic acid/mol of protein, indicating that an aspartic acid residue in bovine factor VII is incompletely hydroxylated. Moreover, a pentapeptide, Ala-Ser*-Ser-Pro-Cys (positions 51-55), isolated from an enzymatic digest of the light chain, contained an unknown serine derivative, but its structure is still unclear. On the other hand, the heavy chain is composed of 255 residues and one asparagine-linked carbohydrate chain at Asn203. Bovine factor VII, with a total of 407 residues, has 71% sequence identity with the human molecule (406 residues) predicted from the cDNA sequence (Hagen, F. S., Gray, C. L., O'Hara, P., Grant, F. J., Saari, G. C., Woodbury, R. G., Hart, C. E., Insley, M., Kisiel, W., Kurachi, K., and Davie, E. W. (1986) Proc. Natl. Acad. Sci. U. S. A. 83, 2412-2416). Instructions: please typing these entity words according to sentence: factor VII, factor VII, factor VII, factor XIIa, factor VII, factor VIIa, aspartic acid residue, bovine factor VII, factor VII Options: Entity, Protein
[ "O", "B-Protein", "I-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "O", "O", "O", "B-Protein", "I-Protein", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "O", "B-Protein", "I-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Entity", "I-Entity", "I-Entity", "O", "B-Entity", "I-Entity", "I-Entity", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]
Bovine factor VII. Its purification and complete amino acid sequence. A modified method for purification of blood clotting factor VII from bovine plasma was developed, and its complete amino acid sequence was established. The isolated factor VII was activated with factor XIIa, and the resulting two-chain factor VII (factor VIIa) was reduced and S-pyridylethylated or S-aminoethylated. The amino acid sequences of the S-alkylated heavy and light chains were determined by sequencing the fragments obtained from enzymatic and chemical cleavages. Fast atom bombardment mass spectrometry was also used to establish the COOH-terminal sequence of the heavy chain. The light chain consists of 152 residues with one carbohydrate chain at Asn145, and 11 gamma-carboxyglutamic acid residues are found within the NH2-terminal 35 residues. The light chain contains 0.2-0.3 mol of beta-hydroxyaspartic acid/mol of protein, indicating that an aspartic acid residue in bovine factor VII is incompletely hydroxylated. Moreover, a pentapeptide, Ala-Ser*-Ser-Pro-Cys (positions 51-55), isolated from an enzymatic digest of the light chain, contained an unknown serine derivative, but its structure is still unclear. On the other hand, the heavy chain is composed of 255 residues and one asparagine-linked carbohydrate chain at Asn203. Bovine factor VII, with a total of 407 residues, has 71% sequence identity with the human molecule (406 residues) predicted from the cDNA sequence (Hagen, F. S., Gray, C. L., O'Hara, P., Grant, F. J., Saari, G. C., Woodbury, R. G., Hart, C. E., Insley, M., Kisiel, W., Kurachi, K., and Davie, E. W. (1986) Proc. Natl. Acad. Sci. U. S. A. 83, 2412-2416).
[ "Bovine", "factor", "VII", ".", "Its", "purification", "and", "complete", "amino", "acid", "sequence", ".", "\n", "A", "modified", "method", "for", "purification", "of", "blood", "clotting", "factor", "VII", "from", "bovine", "plasma", "was", "developed", ",", "and", "its", "complete", "amino", "acid", "sequence", "was", "established", ".", " ", "The", "isolated", "factor", "VII", "was", "activated", "with", "factor", "XIIa", ",", "and", "the", "resulting", "two", "-", "chain", "factor", "VII", "(", "factor", "VIIa", ")", "was", "reduced", "and", "S", "-", "pyridylethylated", "or", "S", "-", "aminoethylated", ".", " ", "The", "amino", "acid", "sequences", "of", "the", "S", "-", "alkylated", "heavy", "and", "light", "chains", "were", "determined", "by", "sequencing", "the", "fragments", "obtained", "from", "enzymatic", "and", "chemical", "cleavages", ".", " ", "Fast", "atom", "bombardment", "mass", "spectrometry", "was", "also", "used", "to", "establish", "the", "COOH", "-", "terminal", "sequence", "of", "the", "heavy", "chain", ".", " ", "The", "light", "chain", "consists", "of", "152", "residues", "with", "one", "carbohydrate", "chain", "at", "Asn145", ",", "and", "11", "gamma", "-", "carboxyglutamic", "acid", "residues", "are", "found", "within", "the", "NH2-terminal", "35", "residues", ".", " ", "The", "light", "chain", "contains", "0.2", "-", "0.3", "mol", "of", "beta", "-", "hydroxyaspartic", "acid", "/", "mol", "of", "protein", ",", "indicating", "that", "an", "aspartic", "acid", "residue", "in", "bovine", "factor", "VII", "is", "incompletely", "hydroxylated", ".", "Moreover", ",", "a", "pentapeptide", ",", "Ala", "-", "Ser*-Ser", "-", "Pro", "-", "Cys", "(", "positions", "51", "-", "55", ")", ",", "isolated", "from", "an", "enzymatic", "digest", "of", "the", "light", "chain", ",", "contained", "an", "unknown", "serine", "derivative", ",", "but", "its", "structure", "is", "still", "unclear", ".", " ", "On", "the", "other", "hand", ",", "the", "heavy", "chain", "is", "composed", "of", "255", "residues", "and", "one", "asparagine", "-", "linked", "carbohydrate", "chain", "at", "Asn203", ".", " ", "Bovine", "factor", "VII", ",", "with", "a", "total", "of", "407", "residues", ",", "has", "71", "%", "sequence", "identity", "with", "the", "human", "molecule", "(", "406", "residues", ")", "predicted", "from", "the", "cDNA", "sequence", "(", "Hagen", ",", "F.", "S.", ",", "Gray", ",", "C.", "L.", ",", "O'Hara", ",", "P.", ",", "Grant", ",", "F.", "J.", ",", "Saari", ",", "G.", "C.", ",", "Woodbury", ",", "R.", "G.", ",", "Hart", ",", "C.", "E.", ",", "Insley", ",", "M.", ",", "Kisiel", ",", "W.", ",", "Kurachi", ",", "K.", ",", "and", "Davie", ",", "E.", "W.", "(", "1986", ")", "Proc", ".", "Natl", ".", "Acad", ".", "Sci", ".", "U.", "S.", "A.", "83", ",", "2412", "-", "2416", ")", "." ]
[ "Entity", "Protein" ]
factor VII, factor VII, factor VII, factor XIIa, factor VII, factor VIIa, aspartic acid residue, bovine factor VII, factor VII
105_task2
Sentence: Bovine factor VII. Its purification and complete amino acid sequence. A modified method for purification of blood clotting factor VII from bovine plasma was developed, and its complete amino acid sequence was established. The isolated factor VII was activated with factor XIIa, and the resulting two-chain factor VII (factor VIIa) was reduced and S-pyridylethylated or S-aminoethylated. The amino acid sequences of the S-alkylated heavy and light chains were determined by sequencing the fragments obtained from enzymatic and chemical cleavages. Fast atom bombardment mass spectrometry was also used to establish the COOH-terminal sequence of the heavy chain. The light chain consists of 152 residues with one carbohydrate chain at Asn145, and 11 gamma-carboxyglutamic acid residues are found within the NH2-terminal 35 residues. The light chain contains 0.2-0.3 mol of beta-hydroxyaspartic acid/mol of protein, indicating that an aspartic acid residue in bovine factor VII is incompletely hydroxylated. Moreover, a pentapeptide, Ala-Ser*-Ser-Pro-Cys (positions 51-55), isolated from an enzymatic digest of the light chain, contained an unknown serine derivative, but its structure is still unclear. On the other hand, the heavy chain is composed of 255 residues and one asparagine-linked carbohydrate chain at Asn203. Bovine factor VII, with a total of 407 residues, has 71% sequence identity with the human molecule (406 residues) predicted from the cDNA sequence (Hagen, F. S., Gray, C. L., O'Hara, P., Grant, F. J., Saari, G. C., Woodbury, R. G., Hart, C. E., Insley, M., Kisiel, W., Kurachi, K., and Davie, E. W. (1986) Proc. Natl. Acad. Sci. U. S. A. 83, 2412-2416). Instructions: please extract entity words from the input sentence
[ "O", "B-Protein", "I-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "O", "O", "O", "B-Protein", "I-Protein", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "O", "B-Protein", "I-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Entity", "I-Entity", "I-Entity", "O", "B-Entity", "I-Entity", "I-Entity", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]
Bovine factor VII. Its purification and complete amino acid sequence. A modified method for purification of blood clotting factor VII from bovine plasma was developed, and its complete amino acid sequence was established. The isolated factor VII was activated with factor XIIa, and the resulting two-chain factor VII (factor VIIa) was reduced and S-pyridylethylated or S-aminoethylated. The amino acid sequences of the S-alkylated heavy and light chains were determined by sequencing the fragments obtained from enzymatic and chemical cleavages. Fast atom bombardment mass spectrometry was also used to establish the COOH-terminal sequence of the heavy chain. The light chain consists of 152 residues with one carbohydrate chain at Asn145, and 11 gamma-carboxyglutamic acid residues are found within the NH2-terminal 35 residues. The light chain contains 0.2-0.3 mol of beta-hydroxyaspartic acid/mol of protein, indicating that an aspartic acid residue in bovine factor VII is incompletely hydroxylated. Moreover, a pentapeptide, Ala-Ser*-Ser-Pro-Cys (positions 51-55), isolated from an enzymatic digest of the light chain, contained an unknown serine derivative, but its structure is still unclear. On the other hand, the heavy chain is composed of 255 residues and one asparagine-linked carbohydrate chain at Asn203. Bovine factor VII, with a total of 407 residues, has 71% sequence identity with the human molecule (406 residues) predicted from the cDNA sequence (Hagen, F. S., Gray, C. L., O'Hara, P., Grant, F. J., Saari, G. C., Woodbury, R. G., Hart, C. E., Insley, M., Kisiel, W., Kurachi, K., and Davie, E. W. (1986) Proc. Natl. Acad. Sci. U. S. A. 83, 2412-2416).
[ "Bovine", "factor", "VII", ".", "Its", "purification", "and", "complete", "amino", "acid", "sequence", ".", "\n", "A", "modified", "method", "for", "purification", "of", "blood", "clotting", "factor", "VII", "from", "bovine", "plasma", "was", "developed", ",", "and", "its", "complete", "amino", "acid", "sequence", "was", "established", ".", " ", "The", "isolated", "factor", "VII", "was", "activated", "with", "factor", "XIIa", ",", "and", "the", "resulting", "two", "-", "chain", "factor", "VII", "(", "factor", "VIIa", ")", "was", "reduced", "and", "S", "-", "pyridylethylated", "or", "S", "-", "aminoethylated", ".", " ", "The", "amino", "acid", "sequences", "of", "the", "S", "-", "alkylated", "heavy", "and", "light", "chains", "were", "determined", "by", "sequencing", "the", "fragments", "obtained", "from", "enzymatic", "and", "chemical", "cleavages", ".", " ", "Fast", "atom", "bombardment", "mass", "spectrometry", "was", "also", "used", "to", "establish", "the", "COOH", "-", "terminal", "sequence", "of", "the", "heavy", "chain", ".", " ", "The", "light", "chain", "consists", "of", "152", "residues", "with", "one", "carbohydrate", "chain", "at", "Asn145", ",", "and", "11", "gamma", "-", "carboxyglutamic", "acid", "residues", "are", "found", "within", "the", "NH2-terminal", "35", "residues", ".", " ", "The", "light", "chain", "contains", "0.2", "-", "0.3", "mol", "of", "beta", "-", "hydroxyaspartic", "acid", "/", "mol", "of", "protein", ",", "indicating", "that", "an", "aspartic", "acid", "residue", "in", "bovine", "factor", "VII", "is", "incompletely", "hydroxylated", ".", "Moreover", ",", "a", "pentapeptide", ",", "Ala", "-", "Ser*-Ser", "-", "Pro", "-", "Cys", "(", "positions", "51", "-", "55", ")", ",", "isolated", "from", "an", "enzymatic", "digest", "of", "the", "light", "chain", ",", "contained", "an", "unknown", "serine", "derivative", ",", "but", "its", "structure", "is", "still", "unclear", ".", " ", "On", "the", "other", "hand", ",", "the", "heavy", "chain", "is", "composed", "of", "255", "residues", "and", "one", "asparagine", "-", "linked", "carbohydrate", "chain", "at", "Asn203", ".", " ", "Bovine", "factor", "VII", ",", "with", "a", "total", "of", "407", "residues", ",", "has", "71", "%", "sequence", "identity", "with", "the", "human", "molecule", "(", "406", "residues", ")", "predicted", "from", "the", "cDNA", "sequence", "(", "Hagen", ",", "F.", "S.", ",", "Gray", ",", "C.", "L.", ",", "O'Hara", ",", "P.", ",", "Grant", ",", "F.", "J.", ",", "Saari", ",", "G.", "C.", ",", "Woodbury", ",", "R.", "G.", ",", "Hart", ",", "C.", "E.", ",", "Insley", ",", "M.", ",", "Kisiel", ",", "W.", ",", "Kurachi", ",", "K.", ",", "and", "Davie", ",", "E.", "W.", "(", "1986", ")", "Proc", ".", "Natl", ".", "Acad", ".", "Sci", ".", "U.", "S.", "A.", "83", ",", "2412", "-", "2416", ")", "." ]
[ "Entity", "Protein" ]
Goettingen is an umlsterm, Stadtkrankenhaus is an umlsterm, Arbeit is an umlsterm
DerChirurg.60671276.ger.abstr_task0
Sentence: Zusammenfassung . In der Reihe saechsischer Chirurgenschulen nimmt Albert Fromme in Dresden einen wichtigen Platz ein . Auf der Basis seiner ueber 10 jaehrigen Taetigkeit als Hochschullehrer in Goettingen konnte er dann auch in einem grossen Stadtkrankenhaus neben seiner umfangreichen klinischen und wissenschaftlichen Arbeit einen grossen Kreis von Chirurgen heranbilden . Fromme gelangte bis an die Spitze der deutschen Chirurgen und kroente seine Laufbahn mit dem Ordinariat und Rektorat der Medizinischen Akademie " Carl Gustav Carus " in Dresden . Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: umlsterm
[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]
Zusammenfassung . In der Reihe saechsischer Chirurgenschulen nimmt Albert Fromme in Dresden einen wichtigen Platz ein . Auf der Basis seiner ueber 10 jaehrigen Taetigkeit als Hochschullehrer in Goettingen konnte er dann auch in einem grossen Stadtkrankenhaus neben seiner umfangreichen klinischen und wissenschaftlichen Arbeit einen grossen Kreis von Chirurgen heranbilden . Fromme gelangte bis an die Spitze der deutschen Chirurgen und kroente seine Laufbahn mit dem Ordinariat und Rektorat der Medizinischen Akademie " Carl Gustav Carus " in Dresden .
[ "Zusammenfassung", ".", "In", "der", "Reihe", "saechsischer", "Chirurgenschulen", "nimmt", "Albert", "Fromme", "in", "Dresden", "einen", "wichtigen", "Platz", "ein", ".", "Auf", "der", "Basis", "seiner", "ueber", "10", "jaehrigen", "Taetigkeit", "als", "Hochschullehrer", "in", "Goettingen", "konnte", "er", "dann", "auch", "in", "einem", "grossen", "Stadtkrankenhaus", "neben", "seiner", "umfangreichen", "klinischen", "und", "wissenschaftlichen", "Arbeit", "einen", "grossen", "Kreis", "von", "Chirurgen", "heranbilden", ".", "Fromme", "gelangte", "bis", "an", "die", "Spitze", "der", "deutschen", "Chirurgen", "und", "kroente", "seine", "Laufbahn", "mit", "dem", "Ordinariat", "und", "Rektorat", "der", "Medizinischen", "Akademie", "\"", "Carl", "Gustav", "Carus", "\"", "in", "Dresden", "." ]
[ "umlsterm" ]
Goettingen is an umlsterm, Stadtkrankenhaus is an umlsterm, Arbeit is an umlsterm
DerChirurg.60671276.ger.abstr_task1
Sentence: Zusammenfassung . In der Reihe saechsischer Chirurgenschulen nimmt Albert Fromme in Dresden einen wichtigen Platz ein . Auf der Basis seiner ueber 10 jaehrigen Taetigkeit als Hochschullehrer in Goettingen konnte er dann auch in einem grossen Stadtkrankenhaus neben seiner umfangreichen klinischen und wissenschaftlichen Arbeit einen grossen Kreis von Chirurgen heranbilden . Fromme gelangte bis an die Spitze der deutschen Chirurgen und kroente seine Laufbahn mit dem Ordinariat und Rektorat der Medizinischen Akademie " Carl Gustav Carus " in Dresden . Instructions: please typing these entity words according to sentence: Goettingen, Stadtkrankenhaus, Arbeit Options: umlsterm
[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]
Zusammenfassung . In der Reihe saechsischer Chirurgenschulen nimmt Albert Fromme in Dresden einen wichtigen Platz ein . Auf der Basis seiner ueber 10 jaehrigen Taetigkeit als Hochschullehrer in Goettingen konnte er dann auch in einem grossen Stadtkrankenhaus neben seiner umfangreichen klinischen und wissenschaftlichen Arbeit einen grossen Kreis von Chirurgen heranbilden . Fromme gelangte bis an die Spitze der deutschen Chirurgen und kroente seine Laufbahn mit dem Ordinariat und Rektorat der Medizinischen Akademie " Carl Gustav Carus " in Dresden .
[ "Zusammenfassung", ".", "In", "der", "Reihe", "saechsischer", "Chirurgenschulen", "nimmt", "Albert", "Fromme", "in", "Dresden", "einen", "wichtigen", "Platz", "ein", ".", "Auf", "der", "Basis", "seiner", "ueber", "10", "jaehrigen", "Taetigkeit", "als", "Hochschullehrer", "in", "Goettingen", "konnte", "er", "dann", "auch", "in", "einem", "grossen", "Stadtkrankenhaus", "neben", "seiner", "umfangreichen", "klinischen", "und", "wissenschaftlichen", "Arbeit", "einen", "grossen", "Kreis", "von", "Chirurgen", "heranbilden", ".", "Fromme", "gelangte", "bis", "an", "die", "Spitze", "der", "deutschen", "Chirurgen", "und", "kroente", "seine", "Laufbahn", "mit", "dem", "Ordinariat", "und", "Rektorat", "der", "Medizinischen", "Akademie", "\"", "Carl", "Gustav", "Carus", "\"", "in", "Dresden", "." ]
[ "umlsterm" ]
Goettingen, Stadtkrankenhaus, Arbeit
DerChirurg.60671276.ger.abstr_task2
Sentence: Zusammenfassung . In der Reihe saechsischer Chirurgenschulen nimmt Albert Fromme in Dresden einen wichtigen Platz ein . Auf der Basis seiner ueber 10 jaehrigen Taetigkeit als Hochschullehrer in Goettingen konnte er dann auch in einem grossen Stadtkrankenhaus neben seiner umfangreichen klinischen und wissenschaftlichen Arbeit einen grossen Kreis von Chirurgen heranbilden . Fromme gelangte bis an die Spitze der deutschen Chirurgen und kroente seine Laufbahn mit dem Ordinariat und Rektorat der Medizinischen Akademie " Carl Gustav Carus " in Dresden . Instructions: please extract entity words from the input sentence
[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]
Zusammenfassung . In der Reihe saechsischer Chirurgenschulen nimmt Albert Fromme in Dresden einen wichtigen Platz ein . Auf der Basis seiner ueber 10 jaehrigen Taetigkeit als Hochschullehrer in Goettingen konnte er dann auch in einem grossen Stadtkrankenhaus neben seiner umfangreichen klinischen und wissenschaftlichen Arbeit einen grossen Kreis von Chirurgen heranbilden . Fromme gelangte bis an die Spitze der deutschen Chirurgen und kroente seine Laufbahn mit dem Ordinariat und Rektorat der Medizinischen Akademie " Carl Gustav Carus " in Dresden .
[ "Zusammenfassung", ".", "In", "der", "Reihe", "saechsischer", "Chirurgenschulen", "nimmt", "Albert", "Fromme", "in", "Dresden", "einen", "wichtigen", "Platz", "ein", ".", "Auf", "der", "Basis", "seiner", "ueber", "10", "jaehrigen", "Taetigkeit", "als", "Hochschullehrer", "in", "Goettingen", "konnte", "er", "dann", "auch", "in", "einem", "grossen", "Stadtkrankenhaus", "neben", "seiner", "umfangreichen", "klinischen", "und", "wissenschaftlichen", "Arbeit", "einen", "grossen", "Kreis", "von", "Chirurgen", "heranbilden", ".", "Fromme", "gelangte", "bis", "an", "die", "Spitze", "der", "deutschen", "Chirurgen", "und", "kroente", "seine", "Laufbahn", "mit", "dem", "Ordinariat", "und", "Rektorat", "der", "Medizinischen", "Akademie", "\"", "Carl", "Gustav", "Carus", "\"", "in", "Dresden", "." ]
[ "umlsterm" ]
myasthenia gravis is an umlsterm, weakness is an umlsterm, striated muscles is an umlsterm, exercise is an umlsterm, Ocular muscle is an umlsterm, ptosis is an umlsterm, diplopia is an umlsterm, signs is an umlsterm, disease is an umlsterm, muscles is an umlsterm, striated muscles is an umlsterm, muscle is an umlsterm, diagnosis is an umlsterm, neurasthenia is an umlsterm, treatment is an umlsterm, myasthenia gravis is an umlsterm, disease is an umlsterm, diagnosis is an umlsterm, disease is an umlsterm, diagnosis is an umlsterm, side effects is an umlsterm, therapy is an umlsterm, diagnosis is an umlsterm, history is an umlsterm, clinical examination is an umlsterm, tests is an umlsterm, muscle is an umlsterm, injection is an umlsterm, edrophonium is an umlsterm, Tensilon is an umlsterm, testing is an umlsterm, test is an umlsterm, testing is an umlsterm, antibodies is an umlsterm, diagnosis is an umlsterm, edrophonium is an umlsterm, test is an umlsterm, test is an umlsterm, neuromuscular diseases is an umlsterm, Antibodies is an umlsterm, form is an umlsterm, Lambert - Eaton myasthenic syndrome is an umlsterm, neuromuscular diseases is an umlsterm, mitochondrial diseases is an umlsterm, diseases is an umlsterm, cranial nerves is an umlsterm, botulism is an umlsterm, congenital myasthenic syndromes is an umlsterm, differential diagnosis is an umlsterm
ZfuerHerzThoraxGefaesschirurgie.80120250.eng.abstr_task0
Sentence: The typical clinical features of myasthenia gravis are weakness and excessive fatiguability of striated muscles that increases during the course of the day or after strenous exercise . Ocular muscle involvement with ptosis ( in 50% ) and diplopia ( in 25% ) are the most common initial signs . The disease can progress to bulbar muscles and to all other striated muscles ( generalized myasthenia ) . The muscle fatiguability and a fluctuating course can mislead to a diagnosis of neurasthenia . Since the treatment of myasthenia gravis is directed at the pathogenetic mechanisms of the disease an early diagnosis is of great significance for the course of the disease . Also , a false positive diagnosis of myasthenia has to be avoided because of the potentially hazardous side effects of the therapy . The mainstay of the diagnosis is the history and a subtle clinical examination with tests of excessive muscle fatiguability . The injection of edrophonium ( Tensilon ) , the electrodiagnostic testing after repitive stimulation ( decrement test ) and the testing for serum antibodies against acetylcholin receptors have to be performed to secure the diagnosis of myasthenia . The edrophonium test and the decrement test can yield false positive results in other neuromuscular diseases . Antibodies are present in 50% of ocular myasthenia and in 80-90% of the generalized form . The Lambert-Eaton myasthenic syndrome , other neuromuscular diseases , mitochondrial diseases , diseases of the cranial nerves , botulism and the rare congenital myasthenic syndromes have to be considered as differential diagnosis . Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: umlsterm
[ "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "I-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "I-umlsterm", "I-umlsterm", "O", "O", "B-umlsterm", "I-umlsterm", "O", "B-umlsterm", "I-umlsterm", "O", "B-umlsterm", "O", "O", "B-umlsterm", "I-umlsterm", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O" ]
The typical clinical features of myasthenia gravis are weakness and excessive fatiguability of striated muscles that increases during the course of the day or after strenous exercise . Ocular muscle involvement with ptosis ( in 50% ) and diplopia ( in 25% ) are the most common initial signs . The disease can progress to bulbar muscles and to all other striated muscles ( generalized myasthenia ) . The muscle fatiguability and a fluctuating course can mislead to a diagnosis of neurasthenia . Since the treatment of myasthenia gravis is directed at the pathogenetic mechanisms of the disease an early diagnosis is of great significance for the course of the disease . Also , a false positive diagnosis of myasthenia has to be avoided because of the potentially hazardous side effects of the therapy . The mainstay of the diagnosis is the history and a subtle clinical examination with tests of excessive muscle fatiguability . The injection of edrophonium ( Tensilon ) , the electrodiagnostic testing after repitive stimulation ( decrement test ) and the testing for serum antibodies against acetylcholin receptors have to be performed to secure the diagnosis of myasthenia . The edrophonium test and the decrement test can yield false positive results in other neuromuscular diseases . Antibodies are present in 50% of ocular myasthenia and in 80-90% of the generalized form . The Lambert-Eaton myasthenic syndrome , other neuromuscular diseases , mitochondrial diseases , diseases of the cranial nerves , botulism and the rare congenital myasthenic syndromes have to be considered as differential diagnosis .
[ "The", "typical", "clinical", "features", "of", "myasthenia", "gravis", "are", "weakness", "and", "excessive", "fatiguability", "of", "striated", "muscles", "that", "increases", "during", "the", "course", "of", "the", "day", "or", "after", "strenous", "exercise", ".", "Ocular", "muscle", "involvement", "with", "ptosis", "(", "in", "50", "%", ")", "and", "diplopia", "(", "in", "25", "%", ")", "are", "the", "most", "common", "initial", "signs", ".", "The", "disease", "can", "progress", "to", "bulbar", "muscles", "and", "to", "all", "other", "striated", "muscles", "(", "generalized", "myasthenia", ")", ".", "The", "muscle", "fatiguability", "and", "a", "fluctuating", "course", "can", "mislead", "to", "a", "diagnosis", "of", "neurasthenia", ".", "Since", "the", "treatment", "of", "myasthenia", "gravis", "is", "directed", "at", "the", "pathogenetic", "mechanisms", "of", "the", "disease", "an", "early", "diagnosis", "is", "of", "great", "significance", "for", "the", "course", "of", "the", "disease", ".", "Also", ",", "a", "false", "positive", "diagnosis", "of", "myasthenia", "has", "to", "be", "avoided", "because", "of", "the", "potentially", "hazardous", "side", "effects", "of", "the", "therapy", ".", "The", "mainstay", "of", "the", "diagnosis", "is", "the", "history", "and", "a", "subtle", "clinical", "examination", "with", "tests", "of", "excessive", "muscle", "fatiguability", ".", "The", "injection", "of", "edrophonium", "(", "Tensilon", ")", ",", "the", "electrodiagnostic", "testing", "after", "repitive", "stimulation", "(", "decrement", "test", ")", "and", "the", "testing", "for", "serum", "antibodies", "against", "acetylcholin", "receptors", "have", "to", "be", "performed", "to", "secure", "the", "diagnosis", "of", "myasthenia", ".", "The", "edrophonium", "test", "and", "the", "decrement", "test", "can", "yield", "false", "positive", "results", "in", "other", "neuromuscular", "diseases", ".", "Antibodies", "are", "present", "in", "50", "%", "of", "ocular", "myasthenia", "and", "in", "80", "-", "90", "%", "of", "the", "generalized", "form", ".", "The", "Lambert", "-", "Eaton", "myasthenic", "syndrome", ",", "other", "neuromuscular", "diseases", ",", "mitochondrial", "diseases", ",", "diseases", "of", "the", "cranial", "nerves", ",", "botulism", "and", "the", "rare", "congenital", "myasthenic", "syndromes", "have", "to", "be", "considered", "as", "differential", "diagnosis", "." ]
[ "umlsterm" ]
myasthenia gravis is an umlsterm, weakness is an umlsterm, striated muscles is an umlsterm, exercise is an umlsterm, Ocular muscle is an umlsterm, ptosis is an umlsterm, diplopia is an umlsterm, signs is an umlsterm, disease is an umlsterm, muscles is an umlsterm, striated muscles is an umlsterm, muscle is an umlsterm, diagnosis is an umlsterm, neurasthenia is an umlsterm, treatment is an umlsterm, myasthenia gravis is an umlsterm, disease is an umlsterm, diagnosis is an umlsterm, disease is an umlsterm, diagnosis is an umlsterm, side effects is an umlsterm, therapy is an umlsterm, diagnosis is an umlsterm, history is an umlsterm, clinical examination is an umlsterm, tests is an umlsterm, muscle is an umlsterm, injection is an umlsterm, edrophonium is an umlsterm, Tensilon is an umlsterm, testing is an umlsterm, test is an umlsterm, testing is an umlsterm, antibodies is an umlsterm, diagnosis is an umlsterm, edrophonium is an umlsterm, test is an umlsterm, test is an umlsterm, neuromuscular diseases is an umlsterm, Antibodies is an umlsterm, form is an umlsterm, Lambert - Eaton myasthenic syndrome is an umlsterm, neuromuscular diseases is an umlsterm, mitochondrial diseases is an umlsterm, diseases is an umlsterm, cranial nerves is an umlsterm, botulism is an umlsterm, congenital myasthenic syndromes is an umlsterm, differential diagnosis is an umlsterm
ZfuerHerzThoraxGefaesschirurgie.80120250.eng.abstr_task1
Sentence: The typical clinical features of myasthenia gravis are weakness and excessive fatiguability of striated muscles that increases during the course of the day or after strenous exercise . Ocular muscle involvement with ptosis ( in 50% ) and diplopia ( in 25% ) are the most common initial signs . The disease can progress to bulbar muscles and to all other striated muscles ( generalized myasthenia ) . The muscle fatiguability and a fluctuating course can mislead to a diagnosis of neurasthenia . Since the treatment of myasthenia gravis is directed at the pathogenetic mechanisms of the disease an early diagnosis is of great significance for the course of the disease . Also , a false positive diagnosis of myasthenia has to be avoided because of the potentially hazardous side effects of the therapy . The mainstay of the diagnosis is the history and a subtle clinical examination with tests of excessive muscle fatiguability . The injection of edrophonium ( Tensilon ) , the electrodiagnostic testing after repitive stimulation ( decrement test ) and the testing for serum antibodies against acetylcholin receptors have to be performed to secure the diagnosis of myasthenia . The edrophonium test and the decrement test can yield false positive results in other neuromuscular diseases . Antibodies are present in 50% of ocular myasthenia and in 80-90% of the generalized form . The Lambert-Eaton myasthenic syndrome , other neuromuscular diseases , mitochondrial diseases , diseases of the cranial nerves , botulism and the rare congenital myasthenic syndromes have to be considered as differential diagnosis . Instructions: please typing these entity words according to sentence: myasthenia gravis, weakness, striated muscles, exercise, Ocular muscle, ptosis, diplopia, signs, disease, muscles, striated muscles, muscle, diagnosis, neurasthenia, treatment, myasthenia gravis, disease, diagnosis, disease, diagnosis, side effects, therapy, diagnosis, history, clinical examination, tests, muscle, injection, edrophonium, Tensilon, testing, test, testing, antibodies, diagnosis, edrophonium, test, test, neuromuscular diseases, Antibodies, form, Lambert - Eaton myasthenic syndrome, neuromuscular diseases, mitochondrial diseases, diseases, cranial nerves, botulism, congenital myasthenic syndromes, differential diagnosis Options: umlsterm
[ "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "I-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "I-umlsterm", "I-umlsterm", "O", "O", "B-umlsterm", "I-umlsterm", "O", "B-umlsterm", "I-umlsterm", "O", "B-umlsterm", "O", "O", "B-umlsterm", "I-umlsterm", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O" ]
The typical clinical features of myasthenia gravis are weakness and excessive fatiguability of striated muscles that increases during the course of the day or after strenous exercise . Ocular muscle involvement with ptosis ( in 50% ) and diplopia ( in 25% ) are the most common initial signs . The disease can progress to bulbar muscles and to all other striated muscles ( generalized myasthenia ) . The muscle fatiguability and a fluctuating course can mislead to a diagnosis of neurasthenia . Since the treatment of myasthenia gravis is directed at the pathogenetic mechanisms of the disease an early diagnosis is of great significance for the course of the disease . Also , a false positive diagnosis of myasthenia has to be avoided because of the potentially hazardous side effects of the therapy . The mainstay of the diagnosis is the history and a subtle clinical examination with tests of excessive muscle fatiguability . The injection of edrophonium ( Tensilon ) , the electrodiagnostic testing after repitive stimulation ( decrement test ) and the testing for serum antibodies against acetylcholin receptors have to be performed to secure the diagnosis of myasthenia . The edrophonium test and the decrement test can yield false positive results in other neuromuscular diseases . Antibodies are present in 50% of ocular myasthenia and in 80-90% of the generalized form . The Lambert-Eaton myasthenic syndrome , other neuromuscular diseases , mitochondrial diseases , diseases of the cranial nerves , botulism and the rare congenital myasthenic syndromes have to be considered as differential diagnosis .
[ "The", "typical", "clinical", "features", "of", "myasthenia", "gravis", "are", "weakness", "and", "excessive", "fatiguability", "of", "striated", "muscles", "that", "increases", "during", "the", "course", "of", "the", "day", "or", "after", "strenous", "exercise", ".", "Ocular", "muscle", "involvement", "with", "ptosis", "(", "in", "50", "%", ")", "and", "diplopia", "(", "in", "25", "%", ")", "are", "the", "most", "common", "initial", "signs", ".", "The", "disease", "can", "progress", "to", "bulbar", "muscles", "and", "to", "all", "other", "striated", "muscles", "(", "generalized", "myasthenia", ")", ".", "The", "muscle", "fatiguability", "and", "a", "fluctuating", "course", "can", "mislead", "to", "a", "diagnosis", "of", "neurasthenia", ".", "Since", "the", "treatment", "of", "myasthenia", "gravis", "is", "directed", "at", "the", "pathogenetic", "mechanisms", "of", "the", "disease", "an", "early", "diagnosis", "is", "of", "great", "significance", "for", "the", "course", "of", "the", "disease", ".", "Also", ",", "a", "false", "positive", "diagnosis", "of", "myasthenia", "has", "to", "be", "avoided", "because", "of", "the", "potentially", "hazardous", "side", "effects", "of", "the", "therapy", ".", "The", "mainstay", "of", "the", "diagnosis", "is", "the", "history", "and", "a", "subtle", "clinical", "examination", "with", "tests", "of", "excessive", "muscle", "fatiguability", ".", "The", "injection", "of", "edrophonium", "(", "Tensilon", ")", ",", "the", "electrodiagnostic", "testing", "after", "repitive", "stimulation", "(", "decrement", "test", ")", "and", "the", "testing", "for", "serum", "antibodies", "against", "acetylcholin", "receptors", "have", "to", "be", "performed", "to", "secure", "the", "diagnosis", "of", "myasthenia", ".", "The", "edrophonium", "test", "and", "the", "decrement", "test", "can", "yield", "false", "positive", "results", "in", "other", "neuromuscular", "diseases", ".", "Antibodies", "are", "present", "in", "50", "%", "of", "ocular", "myasthenia", "and", "in", "80", "-", "90", "%", "of", "the", "generalized", "form", ".", "The", "Lambert", "-", "Eaton", "myasthenic", "syndrome", ",", "other", "neuromuscular", "diseases", ",", "mitochondrial", "diseases", ",", "diseases", "of", "the", "cranial", "nerves", ",", "botulism", "and", "the", "rare", "congenital", "myasthenic", "syndromes", "have", "to", "be", "considered", "as", "differential", "diagnosis", "." ]
[ "umlsterm" ]
myasthenia gravis, weakness, striated muscles, exercise, Ocular muscle, ptosis, diplopia, signs, disease, muscles, striated muscles, muscle, diagnosis, neurasthenia, treatment, myasthenia gravis, disease, diagnosis, disease, diagnosis, side effects, therapy, diagnosis, history, clinical examination, tests, muscle, injection, edrophonium, Tensilon, testing, test, testing, antibodies, diagnosis, edrophonium, test, test, neuromuscular diseases, Antibodies, form, Lambert - Eaton myasthenic syndrome, neuromuscular diseases, mitochondrial diseases, diseases, cranial nerves, botulism, congenital myasthenic syndromes, differential diagnosis
ZfuerHerzThoraxGefaesschirurgie.80120250.eng.abstr_task2
Sentence: The typical clinical features of myasthenia gravis are weakness and excessive fatiguability of striated muscles that increases during the course of the day or after strenous exercise . Ocular muscle involvement with ptosis ( in 50% ) and diplopia ( in 25% ) are the most common initial signs . The disease can progress to bulbar muscles and to all other striated muscles ( generalized myasthenia ) . The muscle fatiguability and a fluctuating course can mislead to a diagnosis of neurasthenia . Since the treatment of myasthenia gravis is directed at the pathogenetic mechanisms of the disease an early diagnosis is of great significance for the course of the disease . Also , a false positive diagnosis of myasthenia has to be avoided because of the potentially hazardous side effects of the therapy . The mainstay of the diagnosis is the history and a subtle clinical examination with tests of excessive muscle fatiguability . The injection of edrophonium ( Tensilon ) , the electrodiagnostic testing after repitive stimulation ( decrement test ) and the testing for serum antibodies against acetylcholin receptors have to be performed to secure the diagnosis of myasthenia . The edrophonium test and the decrement test can yield false positive results in other neuromuscular diseases . Antibodies are present in 50% of ocular myasthenia and in 80-90% of the generalized form . The Lambert-Eaton myasthenic syndrome , other neuromuscular diseases , mitochondrial diseases , diseases of the cranial nerves , botulism and the rare congenital myasthenic syndromes have to be considered as differential diagnosis . Instructions: please extract entity words from the input sentence
[ "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "I-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "I-umlsterm", "I-umlsterm", "O", "O", "B-umlsterm", "I-umlsterm", "O", "B-umlsterm", "I-umlsterm", "O", "B-umlsterm", "O", "O", "B-umlsterm", "I-umlsterm", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O" ]
The typical clinical features of myasthenia gravis are weakness and excessive fatiguability of striated muscles that increases during the course of the day or after strenous exercise . Ocular muscle involvement with ptosis ( in 50% ) and diplopia ( in 25% ) are the most common initial signs . The disease can progress to bulbar muscles and to all other striated muscles ( generalized myasthenia ) . The muscle fatiguability and a fluctuating course can mislead to a diagnosis of neurasthenia . Since the treatment of myasthenia gravis is directed at the pathogenetic mechanisms of the disease an early diagnosis is of great significance for the course of the disease . Also , a false positive diagnosis of myasthenia has to be avoided because of the potentially hazardous side effects of the therapy . The mainstay of the diagnosis is the history and a subtle clinical examination with tests of excessive muscle fatiguability . The injection of edrophonium ( Tensilon ) , the electrodiagnostic testing after repitive stimulation ( decrement test ) and the testing for serum antibodies against acetylcholin receptors have to be performed to secure the diagnosis of myasthenia . The edrophonium test and the decrement test can yield false positive results in other neuromuscular diseases . Antibodies are present in 50% of ocular myasthenia and in 80-90% of the generalized form . The Lambert-Eaton myasthenic syndrome , other neuromuscular diseases , mitochondrial diseases , diseases of the cranial nerves , botulism and the rare congenital myasthenic syndromes have to be considered as differential diagnosis .
[ "The", "typical", "clinical", "features", "of", "myasthenia", "gravis", "are", "weakness", "and", "excessive", "fatiguability", "of", "striated", "muscles", "that", "increases", "during", "the", "course", "of", "the", "day", "or", "after", "strenous", "exercise", ".", "Ocular", "muscle", "involvement", "with", "ptosis", "(", "in", "50", "%", ")", "and", "diplopia", "(", "in", "25", "%", ")", "are", "the", "most", "common", "initial", "signs", ".", "The", "disease", "can", "progress", "to", "bulbar", "muscles", "and", "to", "all", "other", "striated", "muscles", "(", "generalized", "myasthenia", ")", ".", "The", "muscle", "fatiguability", "and", "a", "fluctuating", "course", "can", "mislead", "to", "a", "diagnosis", "of", "neurasthenia", ".", "Since", "the", "treatment", "of", "myasthenia", "gravis", "is", "directed", "at", "the", "pathogenetic", "mechanisms", "of", "the", "disease", "an", "early", "diagnosis", "is", "of", "great", "significance", "for", "the", "course", "of", "the", "disease", ".", "Also", ",", "a", "false", "positive", "diagnosis", "of", "myasthenia", "has", "to", "be", "avoided", "because", "of", "the", "potentially", "hazardous", "side", "effects", "of", "the", "therapy", ".", "The", "mainstay", "of", "the", "diagnosis", "is", "the", "history", "and", "a", "subtle", "clinical", "examination", "with", "tests", "of", "excessive", "muscle", "fatiguability", ".", "The", "injection", "of", "edrophonium", "(", "Tensilon", ")", ",", "the", "electrodiagnostic", "testing", "after", "repitive", "stimulation", "(", "decrement", "test", ")", "and", "the", "testing", "for", "serum", "antibodies", "against", "acetylcholin", "receptors", "have", "to", "be", "performed", "to", "secure", "the", "diagnosis", "of", "myasthenia", ".", "The", "edrophonium", "test", "and", "the", "decrement", "test", "can", "yield", "false", "positive", "results", "in", "other", "neuromuscular", "diseases", ".", "Antibodies", "are", "present", "in", "50", "%", "of", "ocular", "myasthenia", "and", "in", "80", "-", "90", "%", "of", "the", "generalized", "form", ".", "The", "Lambert", "-", "Eaton", "myasthenic", "syndrome", ",", "other", "neuromuscular", "diseases", ",", "mitochondrial", "diseases", ",", "diseases", "of", "the", "cranial", "nerves", ",", "botulism", "and", "the", "rare", "congenital", "myasthenic", "syndromes", "have", "to", "be", "considered", "as", "differential", "diagnosis", "." ]
[ "umlsterm" ]
transcriptional activator is a protein_family_or_group, NF - kappa B is a protein_molecule, I kappa B - alpha is a protein_molecule
82476_task0
Sentence: Mutual regulation of the transcriptional activator NF-kappa B and its inhibitor, I kappa B-alpha. Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: protein_family_or_group, protein_molecule
[ "O", "O", "O", "O", "B-protein_family_or_group", "I-protein_family_or_group", "B-protein_molecule", "I-protein_molecule", "I-protein_molecule", "I-protein_molecule", "O", "O", "O", "O", "B-protein_molecule", "I-protein_molecule", "I-protein_molecule", "I-protein_molecule", "I-protein_molecule", "O" ]
Mutual regulation of the transcriptional activator NF-kappa B and its inhibitor, I kappa B-alpha.
[ "Mutual", "regulation", "of", "the", "transcriptional", "activator", "NF", "-", "kappa", "B", "and", "its", "inhibitor", ",", "I", "kappa", "B", "-", "alpha", "." ]
[ "protein_complex", "other_organic_compound", "protein_molecule", "protein_family_or_group", "RNA_molecule", "cell_type", "protein_subunit" ]
transcriptional activator is a protein_family_or_group, NF - kappa B is a protein_molecule, I kappa B - alpha is a protein_molecule
82476_task1
Sentence: Mutual regulation of the transcriptional activator NF-kappa B and its inhibitor, I kappa B-alpha. Instructions: please typing these entity words according to sentence: transcriptional activator, NF - kappa B, I kappa B - alpha Options: protein_family_or_group, protein_molecule
[ "O", "O", "O", "O", "B-protein_family_or_group", "I-protein_family_or_group", "B-protein_molecule", "I-protein_molecule", "I-protein_molecule", "I-protein_molecule", "O", "O", "O", "O", "B-protein_molecule", "I-protein_molecule", "I-protein_molecule", "I-protein_molecule", "I-protein_molecule", "O" ]
Mutual regulation of the transcriptional activator NF-kappa B and its inhibitor, I kappa B-alpha.
[ "Mutual", "regulation", "of", "the", "transcriptional", "activator", "NF", "-", "kappa", "B", "and", "its", "inhibitor", ",", "I", "kappa", "B", "-", "alpha", "." ]
[ "protein_complex", "other_organic_compound", "protein_molecule", "protein_family_or_group", "RNA_molecule", "cell_type", "protein_subunit" ]
transcriptional activator, NF - kappa B, I kappa B - alpha
82476_task2
Sentence: Mutual regulation of the transcriptional activator NF-kappa B and its inhibitor, I kappa B-alpha. Instructions: please extract entity words from the input sentence
[ "O", "O", "O", "O", "B-protein_family_or_group", "I-protein_family_or_group", "B-protein_molecule", "I-protein_molecule", "I-protein_molecule", "I-protein_molecule", "O", "O", "O", "O", "B-protein_molecule", "I-protein_molecule", "I-protein_molecule", "I-protein_molecule", "I-protein_molecule", "O" ]
Mutual regulation of the transcriptional activator NF-kappa B and its inhibitor, I kappa B-alpha.
[ "Mutual", "regulation", "of", "the", "transcriptional", "activator", "NF", "-", "kappa", "B", "and", "its", "inhibitor", ",", "I", "kappa", "B", "-", "alpha", "." ]
[ "protein_complex", "other_organic_compound", "protein_molecule", "protein_family_or_group", "RNA_molecule", "cell_type", "protein_subunit" ]
Human cytomegalovirus is a virus, human monocytes is a cell_type, gene expression is an other_organic_compound
46295_task0
Sentence: Human cytomegalovirus binding to human monocytes induces immunoregulatory gene expression. Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: other_organic_compound, cell_type, virus
[ "B-virus", "I-virus", "O", "O", "B-cell_type", "I-cell_type", "O", "O", "B-other_organic_compound", "I-other_organic_compound", "O" ]
Human cytomegalovirus binding to human monocytes induces immunoregulatory gene expression.
[ "Human", "cytomegalovirus", "binding", "to", "human", "monocytes", "induces", "immunoregulatory", "gene", "expression", "." ]
[ "other_name", "cell_type", "virus", "protein_complex", "protein_family_or_group", "protein_molecule", "DNA_domain_or_region", "other_organic_compound", "DNA_family_or_group" ]
Human cytomegalovirus is a virus, human monocytes is a cell_type, gene expression is an other_organic_compound
46295_task1
Sentence: Human cytomegalovirus binding to human monocytes induces immunoregulatory gene expression. Instructions: please typing these entity words according to sentence: Human cytomegalovirus, human monocytes, gene expression Options: other_organic_compound, cell_type, virus
[ "B-virus", "I-virus", "O", "O", "B-cell_type", "I-cell_type", "O", "O", "B-other_organic_compound", "I-other_organic_compound", "O" ]
Human cytomegalovirus binding to human monocytes induces immunoregulatory gene expression.
[ "Human", "cytomegalovirus", "binding", "to", "human", "monocytes", "induces", "immunoregulatory", "gene", "expression", "." ]
[ "other_name", "cell_type", "virus", "protein_complex", "protein_family_or_group", "protein_molecule", "DNA_domain_or_region", "other_organic_compound", "DNA_family_or_group" ]
Human cytomegalovirus, human monocytes, gene expression
46295_task2
Sentence: Human cytomegalovirus binding to human monocytes induces immunoregulatory gene expression. Instructions: please extract entity words from the input sentence
[ "B-virus", "I-virus", "O", "O", "B-cell_type", "I-cell_type", "O", "O", "B-other_organic_compound", "I-other_organic_compound", "O" ]
Human cytomegalovirus binding to human monocytes induces immunoregulatory gene expression.
[ "Human", "cytomegalovirus", "binding", "to", "human", "monocytes", "induces", "immunoregulatory", "gene", "expression", "." ]
[ "other_name", "cell_type", "virus", "protein_complex", "protein_family_or_group", "protein_molecule", "DNA_domain_or_region", "other_organic_compound", "DNA_family_or_group" ]
adjuvant hormone therapy is a Intervention_Pharmacological, breast cancer is a Participant_Condition, evaluate is a Outcome_Other, efficacy is a Outcome_Physical, tamoxifen is a Intervention_Pharmacological, diethylstilbestrol is a Intervention_Pharmacological, orimethen amino glutethymide is a Intervention_Pharmacological, Tamoxifen is a Intervention_Pharmacological, 176 is a Participant_Sample-size, patients with T1 - 2N0M0 tumors . is a Participant_Condition, Five - year recurrence - free survival is a Outcome_Mortality, Untoward side - effect incidence is a Outcome_Adverse-effects, much higher is a Outcome_Physical, 5-year survival and recurrence - free survival . is a Outcome_Mortality
87269_task0
Sentence: [ Effectiveness of adjuvant hormone therapy in breast cancer ] . A third series of randomized tests was undertaken to evaluate the efficacy of postoperative adjuvant hormone therapy ( tamoxifen , diethylstilbestrol , orimethen amino glutethymide ) in breast cancer patients . Tamoxifen was studied in 176 patients with T1-2N0M0 tumors . Five-year recurrence-free survival was registered in 85.2 % of menopausal patients treated with tamoxifen versus 71.1 % in control ( P < 0.05 ) . Five-year recurrence-free survival in menopausal females with breast tumors , stage IIb , was 71.1 % among those treated with diethylstilbestrol and as low as 57.4 % in the tamoxifen group ( P < 0.05 ) . Untoward side-effect incidence was much higher in the diethylstilbestrol group ( 30.4 % ) as compared with tamoxifen ( 3.5 % ) . No significant difference was found for the relationship between orimethen and tamoxifen treatment with respect to 5-year survival and recurrence-free survival . Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: Intervention_Pharmacological, Outcome_Adverse-effects, Participant_Condition, Outcome_Mortality, Outcome_Physical, Participant_Sample-size, Outcome_Other
[ "O", "O", "O", "B-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "O", "B-Participant_Condition", "I-Participant_Condition", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Other", "O", "B-Outcome_Physical", "O", "O", "O", "O", "O", "O", "B-Intervention_Pharmacological", "O", "B-Intervention_Pharmacological", "O", "B-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "O", "O", "O", "O", "O", "O", "B-Intervention_Pharmacological", "O", "O", "O", "B-Participant_Sample-size", "B-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "B-Outcome_Mortality", "I-Outcome_Mortality", "I-Outcome_Mortality", "I-Outcome_Mortality", "I-Outcome_Mortality", "I-Outcome_Mortality", "I-Outcome_Mortality", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Adverse-effects", "I-Outcome_Adverse-effects", "I-Outcome_Adverse-effects", "I-Outcome_Adverse-effects", "I-Outcome_Adverse-effects", "O", "B-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Mortality", "I-Outcome_Mortality", "I-Outcome_Mortality", "I-Outcome_Mortality", "I-Outcome_Mortality", "I-Outcome_Mortality", "I-Outcome_Mortality", "I-Outcome_Mortality" ]
[ Effectiveness of adjuvant hormone therapy in breast cancer ] . A third series of randomized tests was undertaken to evaluate the efficacy of postoperative adjuvant hormone therapy ( tamoxifen , diethylstilbestrol , orimethen amino glutethymide ) in breast cancer patients . Tamoxifen was studied in 176 patients with T1-2N0M0 tumors . Five-year recurrence-free survival was registered in 85.2 % of menopausal patients treated with tamoxifen versus 71.1 % in control ( P < 0.05 ) . Five-year recurrence-free survival in menopausal females with breast tumors , stage IIb , was 71.1 % among those treated with diethylstilbestrol and as low as 57.4 % in the tamoxifen group ( P < 0.05 ) . Untoward side-effect incidence was much higher in the diethylstilbestrol group ( 30.4 % ) as compared with tamoxifen ( 3.5 % ) . No significant difference was found for the relationship between orimethen and tamoxifen treatment with respect to 5-year survival and recurrence-free survival .
[ "[", "Effectiveness", "of", "adjuvant", "hormone", "therapy", "in", "breast", "cancer", "]", ".", "A", "third", "series", "of", "randomized", "tests", "was", "undertaken", "to", "evaluate", "the", "efficacy", "of", "postoperative", "adjuvant", "hormone", "therapy", "(", "tamoxifen", ",", "diethylstilbestrol", ",", "orimethen", "amino", "glutethymide", ")", "in", "breast", "cancer", "patients", ".", "Tamoxifen", "was", "studied", "in", "176", "patients", "with", "T1", "-", "2N0M0", "tumors", ".", "Five", "-", "year", "recurrence", "-", "free", "survival", "was", "registered", "in", "85.2", "%", "of", "menopausal", "patients", "treated", "with", "tamoxifen", "versus", "71.1", "%", "in", "control", "(", "P", "<", "0.05", ")", ".", "Five", "-", "year", "recurrence", "-", "free", "survival", "in", "menopausal", "females", "with", "breast", "tumors", ",", "stage", "IIb", ",", "was", "71.1", "%", "among", "those", "treated", "with", "diethylstilbestrol", "and", "as", "low", "as", "57.4", "%", "in", "the", "tamoxifen", "group", "(", "P", "<", "0.05", ")", ".", "Untoward", "side", "-", "effect", "incidence", "was", "much", "higher", "in", "the", "diethylstilbestrol", "group", "(", "30.4", "%", ")", "as", "compared", "with", "tamoxifen", "(", "3.5", "%", ")", ".", "No", "significant", "difference", "was", "found", "for", "the", "relationship", "between", "orimethen", "and", "tamoxifen", "treatment", "with", "respect", "to", "5-year", "survival", "and", "recurrence", "-", "free", "survival", "." ]
[ "Outcome_Mortality", "Participant_Condition", "Outcome_Adverse-effects", "Intervention_Pharmacological", "Outcome_Physical", "Outcome_Other", "Participant_Sample-size" ]
adjuvant hormone therapy is a Intervention_Pharmacological, breast cancer is a Participant_Condition, evaluate is a Outcome_Other, efficacy is a Outcome_Physical, tamoxifen is a Intervention_Pharmacological, diethylstilbestrol is a Intervention_Pharmacological, orimethen amino glutethymide is a Intervention_Pharmacological, Tamoxifen is a Intervention_Pharmacological, 176 is a Participant_Sample-size, patients with T1 - 2N0M0 tumors . is a Participant_Condition, Five - year recurrence - free survival is a Outcome_Mortality, Untoward side - effect incidence is a Outcome_Adverse-effects, much higher is a Outcome_Physical, 5-year survival and recurrence - free survival . is a Outcome_Mortality
87269_task1
Sentence: [ Effectiveness of adjuvant hormone therapy in breast cancer ] . A third series of randomized tests was undertaken to evaluate the efficacy of postoperative adjuvant hormone therapy ( tamoxifen , diethylstilbestrol , orimethen amino glutethymide ) in breast cancer patients . Tamoxifen was studied in 176 patients with T1-2N0M0 tumors . Five-year recurrence-free survival was registered in 85.2 % of menopausal patients treated with tamoxifen versus 71.1 % in control ( P < 0.05 ) . Five-year recurrence-free survival in menopausal females with breast tumors , stage IIb , was 71.1 % among those treated with diethylstilbestrol and as low as 57.4 % in the tamoxifen group ( P < 0.05 ) . Untoward side-effect incidence was much higher in the diethylstilbestrol group ( 30.4 % ) as compared with tamoxifen ( 3.5 % ) . No significant difference was found for the relationship between orimethen and tamoxifen treatment with respect to 5-year survival and recurrence-free survival . Instructions: please typing these entity words according to sentence: adjuvant hormone therapy, breast cancer, evaluate, efficacy, tamoxifen, diethylstilbestrol, orimethen amino glutethymide, Tamoxifen, 176, patients with T1 - 2N0M0 tumors ., Five - year recurrence - free survival, Untoward side - effect incidence, much higher, 5-year survival and recurrence - free survival . Options: Intervention_Pharmacological, Outcome_Adverse-effects, Participant_Condition, Outcome_Mortality, Outcome_Physical, Participant_Sample-size, Outcome_Other
[ "O", "O", "O", "B-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "O", "B-Participant_Condition", "I-Participant_Condition", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Other", "O", "B-Outcome_Physical", "O", "O", "O", "O", "O", "O", "B-Intervention_Pharmacological", "O", "B-Intervention_Pharmacological", "O", "B-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "O", "O", "O", "O", "O", "O", "B-Intervention_Pharmacological", "O", "O", "O", "B-Participant_Sample-size", "B-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "B-Outcome_Mortality", "I-Outcome_Mortality", "I-Outcome_Mortality", "I-Outcome_Mortality", "I-Outcome_Mortality", "I-Outcome_Mortality", "I-Outcome_Mortality", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Adverse-effects", "I-Outcome_Adverse-effects", "I-Outcome_Adverse-effects", "I-Outcome_Adverse-effects", "I-Outcome_Adverse-effects", "O", "B-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Mortality", "I-Outcome_Mortality", "I-Outcome_Mortality", "I-Outcome_Mortality", "I-Outcome_Mortality", "I-Outcome_Mortality", "I-Outcome_Mortality", "I-Outcome_Mortality" ]
[ Effectiveness of adjuvant hormone therapy in breast cancer ] . A third series of randomized tests was undertaken to evaluate the efficacy of postoperative adjuvant hormone therapy ( tamoxifen , diethylstilbestrol , orimethen amino glutethymide ) in breast cancer patients . Tamoxifen was studied in 176 patients with T1-2N0M0 tumors . Five-year recurrence-free survival was registered in 85.2 % of menopausal patients treated with tamoxifen versus 71.1 % in control ( P < 0.05 ) . Five-year recurrence-free survival in menopausal females with breast tumors , stage IIb , was 71.1 % among those treated with diethylstilbestrol and as low as 57.4 % in the tamoxifen group ( P < 0.05 ) . Untoward side-effect incidence was much higher in the diethylstilbestrol group ( 30.4 % ) as compared with tamoxifen ( 3.5 % ) . No significant difference was found for the relationship between orimethen and tamoxifen treatment with respect to 5-year survival and recurrence-free survival .
[ "[", "Effectiveness", "of", "adjuvant", "hormone", "therapy", "in", "breast", "cancer", "]", ".", "A", "third", "series", "of", "randomized", "tests", "was", "undertaken", "to", "evaluate", "the", "efficacy", "of", "postoperative", "adjuvant", "hormone", "therapy", "(", "tamoxifen", ",", "diethylstilbestrol", ",", "orimethen", "amino", "glutethymide", ")", "in", "breast", "cancer", "patients", ".", "Tamoxifen", "was", "studied", "in", "176", "patients", "with", "T1", "-", "2N0M0", "tumors", ".", "Five", "-", "year", "recurrence", "-", "free", "survival", "was", "registered", "in", "85.2", "%", "of", "menopausal", "patients", "treated", "with", "tamoxifen", "versus", "71.1", "%", "in", "control", "(", "P", "<", "0.05", ")", ".", "Five", "-", "year", "recurrence", "-", "free", "survival", "in", "menopausal", "females", "with", "breast", "tumors", ",", "stage", "IIb", ",", "was", "71.1", "%", "among", "those", "treated", "with", "diethylstilbestrol", "and", "as", "low", "as", "57.4", "%", "in", "the", "tamoxifen", "group", "(", "P", "<", "0.05", ")", ".", "Untoward", "side", "-", "effect", "incidence", "was", "much", "higher", "in", "the", "diethylstilbestrol", "group", "(", "30.4", "%", ")", "as", "compared", "with", "tamoxifen", "(", "3.5", "%", ")", ".", "No", "significant", "difference", "was", "found", "for", "the", "relationship", "between", "orimethen", "and", "tamoxifen", "treatment", "with", "respect", "to", "5-year", "survival", "and", "recurrence", "-", "free", "survival", "." ]
[ "Outcome_Mortality", "Participant_Condition", "Outcome_Adverse-effects", "Intervention_Pharmacological", "Outcome_Physical", "Outcome_Other", "Participant_Sample-size" ]
adjuvant hormone therapy, breast cancer, evaluate, efficacy, tamoxifen, diethylstilbestrol, orimethen amino glutethymide, Tamoxifen, 176, patients with T1 - 2N0M0 tumors ., Five - year recurrence - free survival, Untoward side - effect incidence, much higher, 5-year survival and recurrence - free survival .
87269_task2
Sentence: [ Effectiveness of adjuvant hormone therapy in breast cancer ] . A third series of randomized tests was undertaken to evaluate the efficacy of postoperative adjuvant hormone therapy ( tamoxifen , diethylstilbestrol , orimethen amino glutethymide ) in breast cancer patients . Tamoxifen was studied in 176 patients with T1-2N0M0 tumors . Five-year recurrence-free survival was registered in 85.2 % of menopausal patients treated with tamoxifen versus 71.1 % in control ( P < 0.05 ) . Five-year recurrence-free survival in menopausal females with breast tumors , stage IIb , was 71.1 % among those treated with diethylstilbestrol and as low as 57.4 % in the tamoxifen group ( P < 0.05 ) . Untoward side-effect incidence was much higher in the diethylstilbestrol group ( 30.4 % ) as compared with tamoxifen ( 3.5 % ) . No significant difference was found for the relationship between orimethen and tamoxifen treatment with respect to 5-year survival and recurrence-free survival . Instructions: please extract entity words from the input sentence
[ "O", "O", "O", "B-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "O", "B-Participant_Condition", "I-Participant_Condition", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Other", "O", "B-Outcome_Physical", "O", "O", "O", "O", "O", "O", "B-Intervention_Pharmacological", "O", "B-Intervention_Pharmacological", "O", "B-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "O", "O", "O", "O", "O", "O", "B-Intervention_Pharmacological", "O", "O", "O", "B-Participant_Sample-size", "B-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "B-Outcome_Mortality", "I-Outcome_Mortality", "I-Outcome_Mortality", "I-Outcome_Mortality", "I-Outcome_Mortality", "I-Outcome_Mortality", "I-Outcome_Mortality", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Adverse-effects", "I-Outcome_Adverse-effects", "I-Outcome_Adverse-effects", "I-Outcome_Adverse-effects", "I-Outcome_Adverse-effects", "O", "B-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Mortality", "I-Outcome_Mortality", "I-Outcome_Mortality", "I-Outcome_Mortality", "I-Outcome_Mortality", "I-Outcome_Mortality", "I-Outcome_Mortality", "I-Outcome_Mortality" ]
[ Effectiveness of adjuvant hormone therapy in breast cancer ] . A third series of randomized tests was undertaken to evaluate the efficacy of postoperative adjuvant hormone therapy ( tamoxifen , diethylstilbestrol , orimethen amino glutethymide ) in breast cancer patients . Tamoxifen was studied in 176 patients with T1-2N0M0 tumors . Five-year recurrence-free survival was registered in 85.2 % of menopausal patients treated with tamoxifen versus 71.1 % in control ( P < 0.05 ) . Five-year recurrence-free survival in menopausal females with breast tumors , stage IIb , was 71.1 % among those treated with diethylstilbestrol and as low as 57.4 % in the tamoxifen group ( P < 0.05 ) . Untoward side-effect incidence was much higher in the diethylstilbestrol group ( 30.4 % ) as compared with tamoxifen ( 3.5 % ) . No significant difference was found for the relationship between orimethen and tamoxifen treatment with respect to 5-year survival and recurrence-free survival .
[ "[", "Effectiveness", "of", "adjuvant", "hormone", "therapy", "in", "breast", "cancer", "]", ".", "A", "third", "series", "of", "randomized", "tests", "was", "undertaken", "to", "evaluate", "the", "efficacy", "of", "postoperative", "adjuvant", "hormone", "therapy", "(", "tamoxifen", ",", "diethylstilbestrol", ",", "orimethen", "amino", "glutethymide", ")", "in", "breast", "cancer", "patients", ".", "Tamoxifen", "was", "studied", "in", "176", "patients", "with", "T1", "-", "2N0M0", "tumors", ".", "Five", "-", "year", "recurrence", "-", "free", "survival", "was", "registered", "in", "85.2", "%", "of", "menopausal", "patients", "treated", "with", "tamoxifen", "versus", "71.1", "%", "in", "control", "(", "P", "<", "0.05", ")", ".", "Five", "-", "year", "recurrence", "-", "free", "survival", "in", "menopausal", "females", "with", "breast", "tumors", ",", "stage", "IIb", ",", "was", "71.1", "%", "among", "those", "treated", "with", "diethylstilbestrol", "and", "as", "low", "as", "57.4", "%", "in", "the", "tamoxifen", "group", "(", "P", "<", "0.05", ")", ".", "Untoward", "side", "-", "effect", "incidence", "was", "much", "higher", "in", "the", "diethylstilbestrol", "group", "(", "30.4", "%", ")", "as", "compared", "with", "tamoxifen", "(", "3.5", "%", ")", ".", "No", "significant", "difference", "was", "found", "for", "the", "relationship", "between", "orimethen", "and", "tamoxifen", "treatment", "with", "respect", "to", "5-year", "survival", "and", "recurrence", "-", "free", "survival", "." ]
[ "Outcome_Mortality", "Participant_Condition", "Outcome_Adverse-effects", "Intervention_Pharmacological", "Outcome_Physical", "Outcome_Other", "Participant_Sample-size" ]
Cardiogenic shock is an umlsterm, cause of death is an umlsterm, patients is an umlsterm, myocardial infarction is an umlsterm, infarction is an umlsterm, development is an umlsterm, cardiogenic shock is an umlsterm, risk factors is an umlsterm, identification is an umlsterm, patients is an umlsterm, risk is an umlsterm, artery is an umlsterm, PTCA is an umlsterm, cardiogenic shock is an umlsterm, patients is an umlsterm, Patients is an umlsterm, cardiogenic shock is an umlsterm, diagnostic is an umlsterm, PTCA is an umlsterm, patients is an umlsterm, shock is an umlsterm, ischemia is an umlsterm, counterpulsation is an umlsterm, reperfusion is an umlsterm, thrombolytic therapy is an umlsterm, patients is an umlsterm, cardiogenic shock is an umlsterm, surgery is an umlsterm, patients is an umlsterm, complications is an umlsterm, mitral regurgitation is an umlsterm, rupture is an umlsterm, devices is an umlsterm, patients is an umlsterm, shock is an umlsterm, cardiac transplantation is an umlsterm
IntensiveMedizin.80350535.eng.abstr_task0
Sentence: Cardiogenic shock is the leading cause of death in patients hospitalized with acute myocardial infarction . The typical delay from the onset of acute infarction to the development of cardiogenic shock and well defined risk factors allow for an early identification of patients at risk . Immediate restoration of coronary artery patency by thrombolysis or PTCA can prevent cardiogenic shock in a number of these patients . Patients presenting with frank cardiogenic shock should be approached with diagnostic vigor in an attempt to identify a treatable lesion . Several non-randomized studies suggest that PTCA is superior to thrombolysis in patients with shock and ongoing ischemia . However , aortic counterpulsation may enhance reperfusion rates achieved by thrombolytic therapy in patients with cardiogenic shock . Early surgery is required in patients with shock due to mechanical complications , such as acute mitral regurgitation or rupture of the ventricular septum . Ventricular assist devices can be used in selected patients with refractory shock as a bridge to cardiac transplantation . Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: umlsterm
[ "B-umlsterm", "I-umlsterm", "O", "O", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "B-umlsterm", "O", "B-umlsterm", "I-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O" ]
Cardiogenic shock is the leading cause of death in patients hospitalized with acute myocardial infarction . The typical delay from the onset of acute infarction to the development of cardiogenic shock and well defined risk factors allow for an early identification of patients at risk . Immediate restoration of coronary artery patency by thrombolysis or PTCA can prevent cardiogenic shock in a number of these patients . Patients presenting with frank cardiogenic shock should be approached with diagnostic vigor in an attempt to identify a treatable lesion . Several non-randomized studies suggest that PTCA is superior to thrombolysis in patients with shock and ongoing ischemia . However , aortic counterpulsation may enhance reperfusion rates achieved by thrombolytic therapy in patients with cardiogenic shock . Early surgery is required in patients with shock due to mechanical complications , such as acute mitral regurgitation or rupture of the ventricular septum . Ventricular assist devices can be used in selected patients with refractory shock as a bridge to cardiac transplantation .
[ "Cardiogenic", "shock", "is", "the", "leading", "cause", "of", "death", "in", "patients", "hospitalized", "with", "acute", "myocardial", "infarction", ".", "The", "typical", "delay", "from", "the", "onset", "of", "acute", "infarction", "to", "the", "development", "of", "cardiogenic", "shock", "and", "well", "defined", "risk", "factors", "allow", "for", "an", "early", "identification", "of", "patients", "at", "risk", ".", "Immediate", "restoration", "of", "coronary", "artery", "patency", "by", "thrombolysis", "or", "PTCA", "can", "prevent", "cardiogenic", "shock", "in", "a", "number", "of", "these", "patients", ".", "Patients", "presenting", "with", "frank", "cardiogenic", "shock", "should", "be", "approached", "with", "diagnostic", "vigor", "in", "an", "attempt", "to", "identify", "a", "treatable", "lesion", ".", "Several", "non", "-", "randomized", "studies", "suggest", "that", "PTCA", "is", "superior", "to", "thrombolysis", "in", "patients", "with", "shock", "and", "ongoing", "ischemia", ".", "However", ",", "aortic", "counterpulsation", "may", "enhance", "reperfusion", "rates", "achieved", "by", "thrombolytic", "therapy", "in", "patients", "with", "cardiogenic", "shock", ".", "Early", "surgery", "is", "required", "in", "patients", "with", "shock", "due", "to", "mechanical", "complications", ",", "such", "as", "acute", "mitral", "regurgitation", "or", "rupture", "of", "the", "ventricular", "septum", ".", "Ventricular", "assist", "devices", "can", "be", "used", "in", "selected", "patients", "with", "refractory", "shock", "as", "a", "bridge", "to", "cardiac", "transplantation", "." ]
[ "umlsterm" ]
Cardiogenic shock is an umlsterm, cause of death is an umlsterm, patients is an umlsterm, myocardial infarction is an umlsterm, infarction is an umlsterm, development is an umlsterm, cardiogenic shock is an umlsterm, risk factors is an umlsterm, identification is an umlsterm, patients is an umlsterm, risk is an umlsterm, artery is an umlsterm, PTCA is an umlsterm, cardiogenic shock is an umlsterm, patients is an umlsterm, Patients is an umlsterm, cardiogenic shock is an umlsterm, diagnostic is an umlsterm, PTCA is an umlsterm, patients is an umlsterm, shock is an umlsterm, ischemia is an umlsterm, counterpulsation is an umlsterm, reperfusion is an umlsterm, thrombolytic therapy is an umlsterm, patients is an umlsterm, cardiogenic shock is an umlsterm, surgery is an umlsterm, patients is an umlsterm, complications is an umlsterm, mitral regurgitation is an umlsterm, rupture is an umlsterm, devices is an umlsterm, patients is an umlsterm, shock is an umlsterm, cardiac transplantation is an umlsterm
IntensiveMedizin.80350535.eng.abstr_task1
Sentence: Cardiogenic shock is the leading cause of death in patients hospitalized with acute myocardial infarction . The typical delay from the onset of acute infarction to the development of cardiogenic shock and well defined risk factors allow for an early identification of patients at risk . Immediate restoration of coronary artery patency by thrombolysis or PTCA can prevent cardiogenic shock in a number of these patients . Patients presenting with frank cardiogenic shock should be approached with diagnostic vigor in an attempt to identify a treatable lesion . Several non-randomized studies suggest that PTCA is superior to thrombolysis in patients with shock and ongoing ischemia . However , aortic counterpulsation may enhance reperfusion rates achieved by thrombolytic therapy in patients with cardiogenic shock . Early surgery is required in patients with shock due to mechanical complications , such as acute mitral regurgitation or rupture of the ventricular septum . Ventricular assist devices can be used in selected patients with refractory shock as a bridge to cardiac transplantation . Instructions: please typing these entity words according to sentence: Cardiogenic shock, cause of death, patients, myocardial infarction, infarction, development, cardiogenic shock, risk factors, identification, patients, risk, artery, PTCA, cardiogenic shock, patients, Patients, cardiogenic shock, diagnostic, PTCA, patients, shock, ischemia, counterpulsation, reperfusion, thrombolytic therapy, patients, cardiogenic shock, surgery, patients, complications, mitral regurgitation, rupture, devices, patients, shock, cardiac transplantation Options: umlsterm
[ "B-umlsterm", "I-umlsterm", "O", "O", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "B-umlsterm", "O", "B-umlsterm", "I-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O" ]
Cardiogenic shock is the leading cause of death in patients hospitalized with acute myocardial infarction . The typical delay from the onset of acute infarction to the development of cardiogenic shock and well defined risk factors allow for an early identification of patients at risk . Immediate restoration of coronary artery patency by thrombolysis or PTCA can prevent cardiogenic shock in a number of these patients . Patients presenting with frank cardiogenic shock should be approached with diagnostic vigor in an attempt to identify a treatable lesion . Several non-randomized studies suggest that PTCA is superior to thrombolysis in patients with shock and ongoing ischemia . However , aortic counterpulsation may enhance reperfusion rates achieved by thrombolytic therapy in patients with cardiogenic shock . Early surgery is required in patients with shock due to mechanical complications , such as acute mitral regurgitation or rupture of the ventricular septum . Ventricular assist devices can be used in selected patients with refractory shock as a bridge to cardiac transplantation .
[ "Cardiogenic", "shock", "is", "the", "leading", "cause", "of", "death", "in", "patients", "hospitalized", "with", "acute", "myocardial", "infarction", ".", "The", "typical", "delay", "from", "the", "onset", "of", "acute", "infarction", "to", "the", "development", "of", "cardiogenic", "shock", "and", "well", "defined", "risk", "factors", "allow", "for", "an", "early", "identification", "of", "patients", "at", "risk", ".", "Immediate", "restoration", "of", "coronary", "artery", "patency", "by", "thrombolysis", "or", "PTCA", "can", "prevent", "cardiogenic", "shock", "in", "a", "number", "of", "these", "patients", ".", "Patients", "presenting", "with", "frank", "cardiogenic", "shock", "should", "be", "approached", "with", "diagnostic", "vigor", "in", "an", "attempt", "to", "identify", "a", "treatable", "lesion", ".", "Several", "non", "-", "randomized", "studies", "suggest", "that", "PTCA", "is", "superior", "to", "thrombolysis", "in", "patients", "with", "shock", "and", "ongoing", "ischemia", ".", "However", ",", "aortic", "counterpulsation", "may", "enhance", "reperfusion", "rates", "achieved", "by", "thrombolytic", "therapy", "in", "patients", "with", "cardiogenic", "shock", ".", "Early", "surgery", "is", "required", "in", "patients", "with", "shock", "due", "to", "mechanical", "complications", ",", "such", "as", "acute", "mitral", "regurgitation", "or", "rupture", "of", "the", "ventricular", "septum", ".", "Ventricular", "assist", "devices", "can", "be", "used", "in", "selected", "patients", "with", "refractory", "shock", "as", "a", "bridge", "to", "cardiac", "transplantation", "." ]
[ "umlsterm" ]
Cardiogenic shock, cause of death, patients, myocardial infarction, infarction, development, cardiogenic shock, risk factors, identification, patients, risk, artery, PTCA, cardiogenic shock, patients, Patients, cardiogenic shock, diagnostic, PTCA, patients, shock, ischemia, counterpulsation, reperfusion, thrombolytic therapy, patients, cardiogenic shock, surgery, patients, complications, mitral regurgitation, rupture, devices, patients, shock, cardiac transplantation
IntensiveMedizin.80350535.eng.abstr_task2
Sentence: Cardiogenic shock is the leading cause of death in patients hospitalized with acute myocardial infarction . The typical delay from the onset of acute infarction to the development of cardiogenic shock and well defined risk factors allow for an early identification of patients at risk . Immediate restoration of coronary artery patency by thrombolysis or PTCA can prevent cardiogenic shock in a number of these patients . Patients presenting with frank cardiogenic shock should be approached with diagnostic vigor in an attempt to identify a treatable lesion . Several non-randomized studies suggest that PTCA is superior to thrombolysis in patients with shock and ongoing ischemia . However , aortic counterpulsation may enhance reperfusion rates achieved by thrombolytic therapy in patients with cardiogenic shock . Early surgery is required in patients with shock due to mechanical complications , such as acute mitral regurgitation or rupture of the ventricular septum . Ventricular assist devices can be used in selected patients with refractory shock as a bridge to cardiac transplantation . Instructions: please extract entity words from the input sentence
[ "B-umlsterm", "I-umlsterm", "O", "O", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "B-umlsterm", "O", "B-umlsterm", "I-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O" ]
Cardiogenic shock is the leading cause of death in patients hospitalized with acute myocardial infarction . The typical delay from the onset of acute infarction to the development of cardiogenic shock and well defined risk factors allow for an early identification of patients at risk . Immediate restoration of coronary artery patency by thrombolysis or PTCA can prevent cardiogenic shock in a number of these patients . Patients presenting with frank cardiogenic shock should be approached with diagnostic vigor in an attempt to identify a treatable lesion . Several non-randomized studies suggest that PTCA is superior to thrombolysis in patients with shock and ongoing ischemia . However , aortic counterpulsation may enhance reperfusion rates achieved by thrombolytic therapy in patients with cardiogenic shock . Early surgery is required in patients with shock due to mechanical complications , such as acute mitral regurgitation or rupture of the ventricular septum . Ventricular assist devices can be used in selected patients with refractory shock as a bridge to cardiac transplantation .
[ "Cardiogenic", "shock", "is", "the", "leading", "cause", "of", "death", "in", "patients", "hospitalized", "with", "acute", "myocardial", "infarction", ".", "The", "typical", "delay", "from", "the", "onset", "of", "acute", "infarction", "to", "the", "development", "of", "cardiogenic", "shock", "and", "well", "defined", "risk", "factors", "allow", "for", "an", "early", "identification", "of", "patients", "at", "risk", ".", "Immediate", "restoration", "of", "coronary", "artery", "patency", "by", "thrombolysis", "or", "PTCA", "can", "prevent", "cardiogenic", "shock", "in", "a", "number", "of", "these", "patients", ".", "Patients", "presenting", "with", "frank", "cardiogenic", "shock", "should", "be", "approached", "with", "diagnostic", "vigor", "in", "an", "attempt", "to", "identify", "a", "treatable", "lesion", ".", "Several", "non", "-", "randomized", "studies", "suggest", "that", "PTCA", "is", "superior", "to", "thrombolysis", "in", "patients", "with", "shock", "and", "ongoing", "ischemia", ".", "However", ",", "aortic", "counterpulsation", "may", "enhance", "reperfusion", "rates", "achieved", "by", "thrombolytic", "therapy", "in", "patients", "with", "cardiogenic", "shock", ".", "Early", "surgery", "is", "required", "in", "patients", "with", "shock", "due", "to", "mechanical", "complications", ",", "such", "as", "acute", "mitral", "regurgitation", "or", "rupture", "of", "the", "ventricular", "septum", ".", "Ventricular", "assist", "devices", "can", "be", "used", "in", "selected", "patients", "with", "refractory", "shock", "as", "a", "bridge", "to", "cardiac", "transplantation", "." ]
[ "umlsterm" ]
Aussenbandruptur is an umlsterm, Sprunggelenk is an umlsterm, Erstruptur is an umlsterm, Aussenbandruptur is an umlsterm, Rupturrezidiven is an umlsterm, Therapie is an umlsterm, Erstrupturen is an umlsterm, Rupturrezidive is an umlsterm, Therapieform is an umlsterm, Verletzung is an umlsterm, Zeit is an umlsterm, Unfallchirurgischen is an umlsterm, Hochschule is an umlsterm, Patienten is an umlsterm, Rezidiv is an umlsterm, Bandruptur is an umlsterm, Behandlung is an umlsterm, Verletzung is an umlsterm, Patienten is an umlsterm, Behandlung is an umlsterm, Aussenbandverletzung is an umlsterm, radiologische is an umlsterm, Patienten is an umlsterm, Wundinfektionen is an umlsterm, Komplikationen is an umlsterm, Patienten is an umlsterm, radiologisch is an umlsterm, Gelenkstabilitaet is an umlsterm, Patienten is an umlsterm, Trend is an umlsterm, Patienten is an umlsterm, radiologische is an umlsterm, Trend is an umlsterm, Gelenke is an umlsterm, Bandapparat is an umlsterm, Sprunggelenks is an umlsterm, Behandlung is an umlsterm
DerUnfallchirurg.91020023.ger.abstr_task0
Sentence: Bisherige Untersuchungen zum Thema " Aussenbandruptur am oberen Sprunggelenk " beschaeftigten sich mit der frischen Erstruptur , seltener mit einer wiederholten Aussenbandruptur , jedoch bisher nicht prospektiv-randomisiert mit Rupturrezidiven . Diese Studie sollte pruefen , ob sich die guten Ergebnisse der konservativ-funktionellen Therapie von frischen Erstrupturen auf Rupturrezidive uebertragen lassen und welche Therapieform die optimale in Abhaengigkeit von der Versorgung der vorangegangenen Verletzung ( en ) darstellt . In der Zeit von Dezember 1986 bis November 1989 wurden an der Unfallchirurgischen Klinik der Medizinischen Hochschule Hannover 109 Patienten mit dem Rezidiv einer fibularen Bandruptur prospektiv erfasst und in Abhaengigkeit der Behandlung der vorangegangenen Verletzung in Second-stage- oder Reruptur eingeteilt . Diese wurden randomisiert operativ-funktionell oder konservativ-funktionell behandelt . Von diesen konnten 100 Patienten ( 92 % ) mit einem Durchschnittsalter von 24 ( 11-49 ) Jahren zum Zeitpunkt ein Jahr nach Behandlung der erneuten Aussenbandverletzung nachuntersucht werden . Die Nachuntersuchung umfasste subjektive Angaben zu Beschwerden , einen klinisch-objektiven Untersuchungsbefund sowie eine radiologische Untersuchung mit gehaltenen Aufnahmen . Als Bewertungsmassstab fuer das Gesamtergebnis der Untersuchung wurde ein +/- 70-Punkte-Score verwendet . Im Kollektiv der operierten Patienten ( n = 50 ) wurden 2 revisionsbeduerftige Wundinfektionen beobachtet , es traten keine weiteren Komplikationen ein . Im Gesamtscore erzielten die operativ-funktionell behandelten Patienten mit Second-stage-Ruptur ( Gruppe A ) und Reruptur ( Gruppe C ) ein signifikant besseres ( p 0,05 ) Ergebnis als das jeweilige Vergleichskollektiv . Die radiologisch ermittelte Gelenkstabilitaet der operierten Patienten mit Second-stage-Ruptur ( Gruppe A ) war signifikant groesser ( p 0,001 ) als im Vergleichskollektiv . Darueber hinaus zeigte das subjektive und klinisch-objektive Ergebnis einen Trend ( p 0,09 und p 0,07 ) zugunsten besserer Resultate . Das subjektive Nachuntersuchungsergebnis der operierten Patienten nach Reruptur ( Gruppe C ) war signifikant besser ( p 0,05 ) als das des konservativ-funktionell behandelten Vergleichskollektivs . Das klinisch-objektive Ergebnis unterschied sich nicht , das radiologische Ergebnis zeigte jedoch einen Trend ( p 0,07 ) zugunsten stabilerer Gelenke in der Gruppe C. Aufgrund dieser Ergebnisse wird bei Second-stage- und bei Rerupturen am fibularen Bandapparat des oberen Sprunggelenks ( OSG ) die operative Behandlung empfohlen . Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: umlsterm
[ "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O" ]
Bisherige Untersuchungen zum Thema " Aussenbandruptur am oberen Sprunggelenk " beschaeftigten sich mit der frischen Erstruptur , seltener mit einer wiederholten Aussenbandruptur , jedoch bisher nicht prospektiv-randomisiert mit Rupturrezidiven . Diese Studie sollte pruefen , ob sich die guten Ergebnisse der konservativ-funktionellen Therapie von frischen Erstrupturen auf Rupturrezidive uebertragen lassen und welche Therapieform die optimale in Abhaengigkeit von der Versorgung der vorangegangenen Verletzung ( en ) darstellt . In der Zeit von Dezember 1986 bis November 1989 wurden an der Unfallchirurgischen Klinik der Medizinischen Hochschule Hannover 109 Patienten mit dem Rezidiv einer fibularen Bandruptur prospektiv erfasst und in Abhaengigkeit der Behandlung der vorangegangenen Verletzung in Second-stage- oder Reruptur eingeteilt . Diese wurden randomisiert operativ-funktionell oder konservativ-funktionell behandelt . Von diesen konnten 100 Patienten ( 92 % ) mit einem Durchschnittsalter von 24 ( 11-49 ) Jahren zum Zeitpunkt ein Jahr nach Behandlung der erneuten Aussenbandverletzung nachuntersucht werden . Die Nachuntersuchung umfasste subjektive Angaben zu Beschwerden , einen klinisch-objektiven Untersuchungsbefund sowie eine radiologische Untersuchung mit gehaltenen Aufnahmen . Als Bewertungsmassstab fuer das Gesamtergebnis der Untersuchung wurde ein +/- 70-Punkte-Score verwendet . Im Kollektiv der operierten Patienten ( n = 50 ) wurden 2 revisionsbeduerftige Wundinfektionen beobachtet , es traten keine weiteren Komplikationen ein . Im Gesamtscore erzielten die operativ-funktionell behandelten Patienten mit Second-stage-Ruptur ( Gruppe A ) und Reruptur ( Gruppe C ) ein signifikant besseres ( p 0,05 ) Ergebnis als das jeweilige Vergleichskollektiv . Die radiologisch ermittelte Gelenkstabilitaet der operierten Patienten mit Second-stage-Ruptur ( Gruppe A ) war signifikant groesser ( p 0,001 ) als im Vergleichskollektiv . Darueber hinaus zeigte das subjektive und klinisch-objektive Ergebnis einen Trend ( p 0,09 und p 0,07 ) zugunsten besserer Resultate . Das subjektive Nachuntersuchungsergebnis der operierten Patienten nach Reruptur ( Gruppe C ) war signifikant besser ( p 0,05 ) als das des konservativ-funktionell behandelten Vergleichskollektivs . Das klinisch-objektive Ergebnis unterschied sich nicht , das radiologische Ergebnis zeigte jedoch einen Trend ( p 0,07 ) zugunsten stabilerer Gelenke in der Gruppe C. Aufgrund dieser Ergebnisse wird bei Second-stage- und bei Rerupturen am fibularen Bandapparat des oberen Sprunggelenks ( OSG ) die operative Behandlung empfohlen .
[ "Bisherige", "Untersuchungen", "zum", "Thema", "\"", "Aussenbandruptur", "am", "oberen", "Sprunggelenk", "\"", "beschaeftigten", "sich", "mit", "der", "frischen", "Erstruptur", ",", "seltener", "mit", "einer", "wiederholten", "Aussenbandruptur", ",", "jedoch", "bisher", "nicht", "prospektiv", "-", "randomisiert", "mit", "Rupturrezidiven", ".", "Diese", "Studie", "sollte", "pruefen", ",", "ob", "sich", "die", "guten", "Ergebnisse", "der", "konservativ", "-", "funktionellen", "Therapie", "von", "frischen", "Erstrupturen", "auf", "Rupturrezidive", "uebertragen", "lassen", "und", "welche", "Therapieform", "die", "optimale", "in", "Abhaengigkeit", "von", "der", "Versorgung", "der", "vorangegangenen", "Verletzung", "(", "en", ")", "darstellt", ".", "In", "der", "Zeit", "von", "Dezember", "1986", "bis", "November", "1989", "wurden", "an", "der", "Unfallchirurgischen", "Klinik", "der", "Medizinischen", "Hochschule", "Hannover", "109", "Patienten", "mit", "dem", "Rezidiv", "einer", "fibularen", "Bandruptur", "prospektiv", "erfasst", "und", "in", "Abhaengigkeit", "der", "Behandlung", "der", "vorangegangenen", "Verletzung", "in", "Second", "-", "stage-", "oder", "Reruptur", "eingeteilt", ".", "Diese", "wurden", "randomisiert", "operativ", "-", "funktionell", "oder", "konservativ", "-", "funktionell", "behandelt", ".", "Von", "diesen", "konnten", "100", "Patienten", "(", "92", "%", ")", "mit", "einem", "Durchschnittsalter", "von", "24", "(", "11", "-", "49", ")", "Jahren", "zum", "Zeitpunkt", "ein", "Jahr", "nach", "Behandlung", "der", "erneuten", "Aussenbandverletzung", "nachuntersucht", "werden", ".", "Die", "Nachuntersuchung", "umfasste", "subjektive", "Angaben", "zu", "Beschwerden", ",", "einen", "klinisch", "-", "objektiven", "Untersuchungsbefund", "sowie", "eine", "radiologische", "Untersuchung", "mit", "gehaltenen", "Aufnahmen", ".", "Als", "Bewertungsmassstab", "fuer", "das", "Gesamtergebnis", "der", "Untersuchung", "wurde", "ein", "+", "/-", "70-Punkte", "-", "Score", "verwendet", ".", "Im", "Kollektiv", "der", "operierten", "Patienten", "(", "n", "=", "50", ")", "wurden", "2", "revisionsbeduerftige", "Wundinfektionen", "beobachtet", ",", "es", "traten", "keine", "weiteren", "Komplikationen", "ein", ".", "Im", "Gesamtscore", "erzielten", "die", "operativ", "-", "funktionell", "behandelten", "Patienten", "mit", "Second", "-", "stage", "-", "Ruptur", "(", "Gruppe", "A", ")", "und", "Reruptur", "(", "Gruppe", "C", ")", "ein", "signifikant", "besseres", "(", "p", "0,05", ")", "Ergebnis", "als", "das", "jeweilige", "Vergleichskollektiv", ".", "Die", "radiologisch", "ermittelte", "Gelenkstabilitaet", "der", "operierten", "Patienten", "mit", "Second", "-", "stage", "-", "Ruptur", "(", "Gruppe", "A", ")", "war", "signifikant", "groesser", "(", "p", "0,001", ")", "als", "im", "Vergleichskollektiv", ".", "Darueber", "hinaus", "zeigte", "das", "subjektive", "und", "klinisch", "-", "objektive", "Ergebnis", "einen", "Trend", "(", "p", "0,09", "und", "p", "0,07", ")", "zugunsten", "besserer", "Resultate", ".", "Das", "subjektive", "Nachuntersuchungsergebnis", "der", "operierten", "Patienten", "nach", "Reruptur", "(", "Gruppe", "C", ")", "war", "signifikant", "besser", "(", "p", "0,05", ")", "als", "das", "des", "konservativ", "-", "funktionell", "behandelten", "Vergleichskollektivs", ".", "Das", "klinisch", "-", "objektive", "Ergebnis", "unterschied", "sich", "nicht", ",", "das", "radiologische", "Ergebnis", "zeigte", "jedoch", "einen", "Trend", "(", "p", "0,07", ")", "zugunsten", "stabilerer", "Gelenke", "in", "der", "Gruppe", "C.", "Aufgrund", "dieser", "Ergebnisse", "wird", "bei", "Second", "-", "stage-", "und", "bei", "Rerupturen", "am", "fibularen", "Bandapparat", "des", "oberen", "Sprunggelenks", "(", "OSG", ")", "die", "operative", "Behandlung", "empfohlen", "." ]
[ "umlsterm" ]
Aussenbandruptur is an umlsterm, Sprunggelenk is an umlsterm, Erstruptur is an umlsterm, Aussenbandruptur is an umlsterm, Rupturrezidiven is an umlsterm, Therapie is an umlsterm, Erstrupturen is an umlsterm, Rupturrezidive is an umlsterm, Therapieform is an umlsterm, Verletzung is an umlsterm, Zeit is an umlsterm, Unfallchirurgischen is an umlsterm, Hochschule is an umlsterm, Patienten is an umlsterm, Rezidiv is an umlsterm, Bandruptur is an umlsterm, Behandlung is an umlsterm, Verletzung is an umlsterm, Patienten is an umlsterm, Behandlung is an umlsterm, Aussenbandverletzung is an umlsterm, radiologische is an umlsterm, Patienten is an umlsterm, Wundinfektionen is an umlsterm, Komplikationen is an umlsterm, Patienten is an umlsterm, radiologisch is an umlsterm, Gelenkstabilitaet is an umlsterm, Patienten is an umlsterm, Trend is an umlsterm, Patienten is an umlsterm, radiologische is an umlsterm, Trend is an umlsterm, Gelenke is an umlsterm, Bandapparat is an umlsterm, Sprunggelenks is an umlsterm, Behandlung is an umlsterm
DerUnfallchirurg.91020023.ger.abstr_task1
Sentence: Bisherige Untersuchungen zum Thema " Aussenbandruptur am oberen Sprunggelenk " beschaeftigten sich mit der frischen Erstruptur , seltener mit einer wiederholten Aussenbandruptur , jedoch bisher nicht prospektiv-randomisiert mit Rupturrezidiven . Diese Studie sollte pruefen , ob sich die guten Ergebnisse der konservativ-funktionellen Therapie von frischen Erstrupturen auf Rupturrezidive uebertragen lassen und welche Therapieform die optimale in Abhaengigkeit von der Versorgung der vorangegangenen Verletzung ( en ) darstellt . In der Zeit von Dezember 1986 bis November 1989 wurden an der Unfallchirurgischen Klinik der Medizinischen Hochschule Hannover 109 Patienten mit dem Rezidiv einer fibularen Bandruptur prospektiv erfasst und in Abhaengigkeit der Behandlung der vorangegangenen Verletzung in Second-stage- oder Reruptur eingeteilt . Diese wurden randomisiert operativ-funktionell oder konservativ-funktionell behandelt . Von diesen konnten 100 Patienten ( 92 % ) mit einem Durchschnittsalter von 24 ( 11-49 ) Jahren zum Zeitpunkt ein Jahr nach Behandlung der erneuten Aussenbandverletzung nachuntersucht werden . Die Nachuntersuchung umfasste subjektive Angaben zu Beschwerden , einen klinisch-objektiven Untersuchungsbefund sowie eine radiologische Untersuchung mit gehaltenen Aufnahmen . Als Bewertungsmassstab fuer das Gesamtergebnis der Untersuchung wurde ein +/- 70-Punkte-Score verwendet . Im Kollektiv der operierten Patienten ( n = 50 ) wurden 2 revisionsbeduerftige Wundinfektionen beobachtet , es traten keine weiteren Komplikationen ein . Im Gesamtscore erzielten die operativ-funktionell behandelten Patienten mit Second-stage-Ruptur ( Gruppe A ) und Reruptur ( Gruppe C ) ein signifikant besseres ( p 0,05 ) Ergebnis als das jeweilige Vergleichskollektiv . Die radiologisch ermittelte Gelenkstabilitaet der operierten Patienten mit Second-stage-Ruptur ( Gruppe A ) war signifikant groesser ( p 0,001 ) als im Vergleichskollektiv . Darueber hinaus zeigte das subjektive und klinisch-objektive Ergebnis einen Trend ( p 0,09 und p 0,07 ) zugunsten besserer Resultate . Das subjektive Nachuntersuchungsergebnis der operierten Patienten nach Reruptur ( Gruppe C ) war signifikant besser ( p 0,05 ) als das des konservativ-funktionell behandelten Vergleichskollektivs . Das klinisch-objektive Ergebnis unterschied sich nicht , das radiologische Ergebnis zeigte jedoch einen Trend ( p 0,07 ) zugunsten stabilerer Gelenke in der Gruppe C. Aufgrund dieser Ergebnisse wird bei Second-stage- und bei Rerupturen am fibularen Bandapparat des oberen Sprunggelenks ( OSG ) die operative Behandlung empfohlen . Instructions: please typing these entity words according to sentence: Aussenbandruptur, Sprunggelenk, Erstruptur, Aussenbandruptur, Rupturrezidiven, Therapie, Erstrupturen, Rupturrezidive, Therapieform, Verletzung, Zeit, Unfallchirurgischen, Hochschule, Patienten, Rezidiv, Bandruptur, Behandlung, Verletzung, Patienten, Behandlung, Aussenbandverletzung, radiologische, Patienten, Wundinfektionen, Komplikationen, Patienten, radiologisch, Gelenkstabilitaet, Patienten, Trend, Patienten, radiologische, Trend, Gelenke, Bandapparat, Sprunggelenks, Behandlung Options: umlsterm
[ "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O" ]
Bisherige Untersuchungen zum Thema " Aussenbandruptur am oberen Sprunggelenk " beschaeftigten sich mit der frischen Erstruptur , seltener mit einer wiederholten Aussenbandruptur , jedoch bisher nicht prospektiv-randomisiert mit Rupturrezidiven . Diese Studie sollte pruefen , ob sich die guten Ergebnisse der konservativ-funktionellen Therapie von frischen Erstrupturen auf Rupturrezidive uebertragen lassen und welche Therapieform die optimale in Abhaengigkeit von der Versorgung der vorangegangenen Verletzung ( en ) darstellt . In der Zeit von Dezember 1986 bis November 1989 wurden an der Unfallchirurgischen Klinik der Medizinischen Hochschule Hannover 109 Patienten mit dem Rezidiv einer fibularen Bandruptur prospektiv erfasst und in Abhaengigkeit der Behandlung der vorangegangenen Verletzung in Second-stage- oder Reruptur eingeteilt . Diese wurden randomisiert operativ-funktionell oder konservativ-funktionell behandelt . Von diesen konnten 100 Patienten ( 92 % ) mit einem Durchschnittsalter von 24 ( 11-49 ) Jahren zum Zeitpunkt ein Jahr nach Behandlung der erneuten Aussenbandverletzung nachuntersucht werden . Die Nachuntersuchung umfasste subjektive Angaben zu Beschwerden , einen klinisch-objektiven Untersuchungsbefund sowie eine radiologische Untersuchung mit gehaltenen Aufnahmen . Als Bewertungsmassstab fuer das Gesamtergebnis der Untersuchung wurde ein +/- 70-Punkte-Score verwendet . Im Kollektiv der operierten Patienten ( n = 50 ) wurden 2 revisionsbeduerftige Wundinfektionen beobachtet , es traten keine weiteren Komplikationen ein . Im Gesamtscore erzielten die operativ-funktionell behandelten Patienten mit Second-stage-Ruptur ( Gruppe A ) und Reruptur ( Gruppe C ) ein signifikant besseres ( p 0,05 ) Ergebnis als das jeweilige Vergleichskollektiv . Die radiologisch ermittelte Gelenkstabilitaet der operierten Patienten mit Second-stage-Ruptur ( Gruppe A ) war signifikant groesser ( p 0,001 ) als im Vergleichskollektiv . Darueber hinaus zeigte das subjektive und klinisch-objektive Ergebnis einen Trend ( p 0,09 und p 0,07 ) zugunsten besserer Resultate . Das subjektive Nachuntersuchungsergebnis der operierten Patienten nach Reruptur ( Gruppe C ) war signifikant besser ( p 0,05 ) als das des konservativ-funktionell behandelten Vergleichskollektivs . Das klinisch-objektive Ergebnis unterschied sich nicht , das radiologische Ergebnis zeigte jedoch einen Trend ( p 0,07 ) zugunsten stabilerer Gelenke in der Gruppe C. Aufgrund dieser Ergebnisse wird bei Second-stage- und bei Rerupturen am fibularen Bandapparat des oberen Sprunggelenks ( OSG ) die operative Behandlung empfohlen .
[ "Bisherige", "Untersuchungen", "zum", "Thema", "\"", "Aussenbandruptur", "am", "oberen", "Sprunggelenk", "\"", "beschaeftigten", "sich", "mit", "der", "frischen", "Erstruptur", ",", "seltener", "mit", "einer", "wiederholten", "Aussenbandruptur", ",", "jedoch", "bisher", "nicht", "prospektiv", "-", "randomisiert", "mit", "Rupturrezidiven", ".", "Diese", "Studie", "sollte", "pruefen", ",", "ob", "sich", "die", "guten", "Ergebnisse", "der", "konservativ", "-", "funktionellen", "Therapie", "von", "frischen", "Erstrupturen", "auf", "Rupturrezidive", "uebertragen", "lassen", "und", "welche", "Therapieform", "die", "optimale", "in", "Abhaengigkeit", "von", "der", "Versorgung", "der", "vorangegangenen", "Verletzung", "(", "en", ")", "darstellt", ".", "In", "der", "Zeit", "von", "Dezember", "1986", "bis", "November", "1989", "wurden", "an", "der", "Unfallchirurgischen", "Klinik", "der", "Medizinischen", "Hochschule", "Hannover", "109", "Patienten", "mit", "dem", "Rezidiv", "einer", "fibularen", "Bandruptur", "prospektiv", "erfasst", "und", "in", "Abhaengigkeit", "der", "Behandlung", "der", "vorangegangenen", "Verletzung", "in", "Second", "-", "stage-", "oder", "Reruptur", "eingeteilt", ".", "Diese", "wurden", "randomisiert", "operativ", "-", "funktionell", "oder", "konservativ", "-", "funktionell", "behandelt", ".", "Von", "diesen", "konnten", "100", "Patienten", "(", "92", "%", ")", "mit", "einem", "Durchschnittsalter", "von", "24", "(", "11", "-", "49", ")", "Jahren", "zum", "Zeitpunkt", "ein", "Jahr", "nach", "Behandlung", "der", "erneuten", "Aussenbandverletzung", "nachuntersucht", "werden", ".", "Die", "Nachuntersuchung", "umfasste", "subjektive", "Angaben", "zu", "Beschwerden", ",", "einen", "klinisch", "-", "objektiven", "Untersuchungsbefund", "sowie", "eine", "radiologische", "Untersuchung", "mit", "gehaltenen", "Aufnahmen", ".", "Als", "Bewertungsmassstab", "fuer", "das", "Gesamtergebnis", "der", "Untersuchung", "wurde", "ein", "+", "/-", "70-Punkte", "-", "Score", "verwendet", ".", "Im", "Kollektiv", "der", "operierten", "Patienten", "(", "n", "=", "50", ")", "wurden", "2", "revisionsbeduerftige", "Wundinfektionen", "beobachtet", ",", "es", "traten", "keine", "weiteren", "Komplikationen", "ein", ".", "Im", "Gesamtscore", "erzielten", "die", "operativ", "-", "funktionell", "behandelten", "Patienten", "mit", "Second", "-", "stage", "-", "Ruptur", "(", "Gruppe", "A", ")", "und", "Reruptur", "(", "Gruppe", "C", ")", "ein", "signifikant", "besseres", "(", "p", "0,05", ")", "Ergebnis", "als", "das", "jeweilige", "Vergleichskollektiv", ".", "Die", "radiologisch", "ermittelte", "Gelenkstabilitaet", "der", "operierten", "Patienten", "mit", "Second", "-", "stage", "-", "Ruptur", "(", "Gruppe", "A", ")", "war", "signifikant", "groesser", "(", "p", "0,001", ")", "als", "im", "Vergleichskollektiv", ".", "Darueber", "hinaus", "zeigte", "das", "subjektive", "und", "klinisch", "-", "objektive", "Ergebnis", "einen", "Trend", "(", "p", "0,09", "und", "p", "0,07", ")", "zugunsten", "besserer", "Resultate", ".", "Das", "subjektive", "Nachuntersuchungsergebnis", "der", "operierten", "Patienten", "nach", "Reruptur", "(", "Gruppe", "C", ")", "war", "signifikant", "besser", "(", "p", "0,05", ")", "als", "das", "des", "konservativ", "-", "funktionell", "behandelten", "Vergleichskollektivs", ".", "Das", "klinisch", "-", "objektive", "Ergebnis", "unterschied", "sich", "nicht", ",", "das", "radiologische", "Ergebnis", "zeigte", "jedoch", "einen", "Trend", "(", "p", "0,07", ")", "zugunsten", "stabilerer", "Gelenke", "in", "der", "Gruppe", "C.", "Aufgrund", "dieser", "Ergebnisse", "wird", "bei", "Second", "-", "stage-", "und", "bei", "Rerupturen", "am", "fibularen", "Bandapparat", "des", "oberen", "Sprunggelenks", "(", "OSG", ")", "die", "operative", "Behandlung", "empfohlen", "." ]
[ "umlsterm" ]
Aussenbandruptur, Sprunggelenk, Erstruptur, Aussenbandruptur, Rupturrezidiven, Therapie, Erstrupturen, Rupturrezidive, Therapieform, Verletzung, Zeit, Unfallchirurgischen, Hochschule, Patienten, Rezidiv, Bandruptur, Behandlung, Verletzung, Patienten, Behandlung, Aussenbandverletzung, radiologische, Patienten, Wundinfektionen, Komplikationen, Patienten, radiologisch, Gelenkstabilitaet, Patienten, Trend, Patienten, radiologische, Trend, Gelenke, Bandapparat, Sprunggelenks, Behandlung
DerUnfallchirurg.91020023.ger.abstr_task2
Sentence: Bisherige Untersuchungen zum Thema " Aussenbandruptur am oberen Sprunggelenk " beschaeftigten sich mit der frischen Erstruptur , seltener mit einer wiederholten Aussenbandruptur , jedoch bisher nicht prospektiv-randomisiert mit Rupturrezidiven . Diese Studie sollte pruefen , ob sich die guten Ergebnisse der konservativ-funktionellen Therapie von frischen Erstrupturen auf Rupturrezidive uebertragen lassen und welche Therapieform die optimale in Abhaengigkeit von der Versorgung der vorangegangenen Verletzung ( en ) darstellt . In der Zeit von Dezember 1986 bis November 1989 wurden an der Unfallchirurgischen Klinik der Medizinischen Hochschule Hannover 109 Patienten mit dem Rezidiv einer fibularen Bandruptur prospektiv erfasst und in Abhaengigkeit der Behandlung der vorangegangenen Verletzung in Second-stage- oder Reruptur eingeteilt . Diese wurden randomisiert operativ-funktionell oder konservativ-funktionell behandelt . Von diesen konnten 100 Patienten ( 92 % ) mit einem Durchschnittsalter von 24 ( 11-49 ) Jahren zum Zeitpunkt ein Jahr nach Behandlung der erneuten Aussenbandverletzung nachuntersucht werden . Die Nachuntersuchung umfasste subjektive Angaben zu Beschwerden , einen klinisch-objektiven Untersuchungsbefund sowie eine radiologische Untersuchung mit gehaltenen Aufnahmen . Als Bewertungsmassstab fuer das Gesamtergebnis der Untersuchung wurde ein +/- 70-Punkte-Score verwendet . Im Kollektiv der operierten Patienten ( n = 50 ) wurden 2 revisionsbeduerftige Wundinfektionen beobachtet , es traten keine weiteren Komplikationen ein . Im Gesamtscore erzielten die operativ-funktionell behandelten Patienten mit Second-stage-Ruptur ( Gruppe A ) und Reruptur ( Gruppe C ) ein signifikant besseres ( p 0,05 ) Ergebnis als das jeweilige Vergleichskollektiv . Die radiologisch ermittelte Gelenkstabilitaet der operierten Patienten mit Second-stage-Ruptur ( Gruppe A ) war signifikant groesser ( p 0,001 ) als im Vergleichskollektiv . Darueber hinaus zeigte das subjektive und klinisch-objektive Ergebnis einen Trend ( p 0,09 und p 0,07 ) zugunsten besserer Resultate . Das subjektive Nachuntersuchungsergebnis der operierten Patienten nach Reruptur ( Gruppe C ) war signifikant besser ( p 0,05 ) als das des konservativ-funktionell behandelten Vergleichskollektivs . Das klinisch-objektive Ergebnis unterschied sich nicht , das radiologische Ergebnis zeigte jedoch einen Trend ( p 0,07 ) zugunsten stabilerer Gelenke in der Gruppe C. Aufgrund dieser Ergebnisse wird bei Second-stage- und bei Rerupturen am fibularen Bandapparat des oberen Sprunggelenks ( OSG ) die operative Behandlung empfohlen . Instructions: please extract entity words from the input sentence
[ "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O" ]
Bisherige Untersuchungen zum Thema " Aussenbandruptur am oberen Sprunggelenk " beschaeftigten sich mit der frischen Erstruptur , seltener mit einer wiederholten Aussenbandruptur , jedoch bisher nicht prospektiv-randomisiert mit Rupturrezidiven . Diese Studie sollte pruefen , ob sich die guten Ergebnisse der konservativ-funktionellen Therapie von frischen Erstrupturen auf Rupturrezidive uebertragen lassen und welche Therapieform die optimale in Abhaengigkeit von der Versorgung der vorangegangenen Verletzung ( en ) darstellt . In der Zeit von Dezember 1986 bis November 1989 wurden an der Unfallchirurgischen Klinik der Medizinischen Hochschule Hannover 109 Patienten mit dem Rezidiv einer fibularen Bandruptur prospektiv erfasst und in Abhaengigkeit der Behandlung der vorangegangenen Verletzung in Second-stage- oder Reruptur eingeteilt . Diese wurden randomisiert operativ-funktionell oder konservativ-funktionell behandelt . Von diesen konnten 100 Patienten ( 92 % ) mit einem Durchschnittsalter von 24 ( 11-49 ) Jahren zum Zeitpunkt ein Jahr nach Behandlung der erneuten Aussenbandverletzung nachuntersucht werden . Die Nachuntersuchung umfasste subjektive Angaben zu Beschwerden , einen klinisch-objektiven Untersuchungsbefund sowie eine radiologische Untersuchung mit gehaltenen Aufnahmen . Als Bewertungsmassstab fuer das Gesamtergebnis der Untersuchung wurde ein +/- 70-Punkte-Score verwendet . Im Kollektiv der operierten Patienten ( n = 50 ) wurden 2 revisionsbeduerftige Wundinfektionen beobachtet , es traten keine weiteren Komplikationen ein . Im Gesamtscore erzielten die operativ-funktionell behandelten Patienten mit Second-stage-Ruptur ( Gruppe A ) und Reruptur ( Gruppe C ) ein signifikant besseres ( p 0,05 ) Ergebnis als das jeweilige Vergleichskollektiv . Die radiologisch ermittelte Gelenkstabilitaet der operierten Patienten mit Second-stage-Ruptur ( Gruppe A ) war signifikant groesser ( p 0,001 ) als im Vergleichskollektiv . Darueber hinaus zeigte das subjektive und klinisch-objektive Ergebnis einen Trend ( p 0,09 und p 0,07 ) zugunsten besserer Resultate . Das subjektive Nachuntersuchungsergebnis der operierten Patienten nach Reruptur ( Gruppe C ) war signifikant besser ( p 0,05 ) als das des konservativ-funktionell behandelten Vergleichskollektivs . Das klinisch-objektive Ergebnis unterschied sich nicht , das radiologische Ergebnis zeigte jedoch einen Trend ( p 0,07 ) zugunsten stabilerer Gelenke in der Gruppe C. Aufgrund dieser Ergebnisse wird bei Second-stage- und bei Rerupturen am fibularen Bandapparat des oberen Sprunggelenks ( OSG ) die operative Behandlung empfohlen .
[ "Bisherige", "Untersuchungen", "zum", "Thema", "\"", "Aussenbandruptur", "am", "oberen", "Sprunggelenk", "\"", "beschaeftigten", "sich", "mit", "der", "frischen", "Erstruptur", ",", "seltener", "mit", "einer", "wiederholten", "Aussenbandruptur", ",", "jedoch", "bisher", "nicht", "prospektiv", "-", "randomisiert", "mit", "Rupturrezidiven", ".", "Diese", "Studie", "sollte", "pruefen", ",", "ob", "sich", "die", "guten", "Ergebnisse", "der", "konservativ", "-", "funktionellen", "Therapie", "von", "frischen", "Erstrupturen", "auf", "Rupturrezidive", "uebertragen", "lassen", "und", "welche", "Therapieform", "die", "optimale", "in", "Abhaengigkeit", "von", "der", "Versorgung", "der", "vorangegangenen", "Verletzung", "(", "en", ")", "darstellt", ".", "In", "der", "Zeit", "von", "Dezember", "1986", "bis", "November", "1989", "wurden", "an", "der", "Unfallchirurgischen", "Klinik", "der", "Medizinischen", "Hochschule", "Hannover", "109", "Patienten", "mit", "dem", "Rezidiv", "einer", "fibularen", "Bandruptur", "prospektiv", "erfasst", "und", "in", "Abhaengigkeit", "der", "Behandlung", "der", "vorangegangenen", "Verletzung", "in", "Second", "-", "stage-", "oder", "Reruptur", "eingeteilt", ".", "Diese", "wurden", "randomisiert", "operativ", "-", "funktionell", "oder", "konservativ", "-", "funktionell", "behandelt", ".", "Von", "diesen", "konnten", "100", "Patienten", "(", "92", "%", ")", "mit", "einem", "Durchschnittsalter", "von", "24", "(", "11", "-", "49", ")", "Jahren", "zum", "Zeitpunkt", "ein", "Jahr", "nach", "Behandlung", "der", "erneuten", "Aussenbandverletzung", "nachuntersucht", "werden", ".", "Die", "Nachuntersuchung", "umfasste", "subjektive", "Angaben", "zu", "Beschwerden", ",", "einen", "klinisch", "-", "objektiven", "Untersuchungsbefund", "sowie", "eine", "radiologische", "Untersuchung", "mit", "gehaltenen", "Aufnahmen", ".", "Als", "Bewertungsmassstab", "fuer", "das", "Gesamtergebnis", "der", "Untersuchung", "wurde", "ein", "+", "/-", "70-Punkte", "-", "Score", "verwendet", ".", "Im", "Kollektiv", "der", "operierten", "Patienten", "(", "n", "=", "50", ")", "wurden", "2", "revisionsbeduerftige", "Wundinfektionen", "beobachtet", ",", "es", "traten", "keine", "weiteren", "Komplikationen", "ein", ".", "Im", "Gesamtscore", "erzielten", "die", "operativ", "-", "funktionell", "behandelten", "Patienten", "mit", "Second", "-", "stage", "-", "Ruptur", "(", "Gruppe", "A", ")", "und", "Reruptur", "(", "Gruppe", "C", ")", "ein", "signifikant", "besseres", "(", "p", "0,05", ")", "Ergebnis", "als", "das", "jeweilige", "Vergleichskollektiv", ".", "Die", "radiologisch", "ermittelte", "Gelenkstabilitaet", "der", "operierten", "Patienten", "mit", "Second", "-", "stage", "-", "Ruptur", "(", "Gruppe", "A", ")", "war", "signifikant", "groesser", "(", "p", "0,001", ")", "als", "im", "Vergleichskollektiv", ".", "Darueber", "hinaus", "zeigte", "das", "subjektive", "und", "klinisch", "-", "objektive", "Ergebnis", "einen", "Trend", "(", "p", "0,09", "und", "p", "0,07", ")", "zugunsten", "besserer", "Resultate", ".", "Das", "subjektive", "Nachuntersuchungsergebnis", "der", "operierten", "Patienten", "nach", "Reruptur", "(", "Gruppe", "C", ")", "war", "signifikant", "besser", "(", "p", "0,05", ")", "als", "das", "des", "konservativ", "-", "funktionell", "behandelten", "Vergleichskollektivs", ".", "Das", "klinisch", "-", "objektive", "Ergebnis", "unterschied", "sich", "nicht", ",", "das", "radiologische", "Ergebnis", "zeigte", "jedoch", "einen", "Trend", "(", "p", "0,07", ")", "zugunsten", "stabilerer", "Gelenke", "in", "der", "Gruppe", "C.", "Aufgrund", "dieser", "Ergebnisse", "wird", "bei", "Second", "-", "stage-", "und", "bei", "Rerupturen", "am", "fibularen", "Bandapparat", "des", "oberen", "Sprunggelenks", "(", "OSG", ")", "die", "operative", "Behandlung", "empfohlen", "." ]
[ "umlsterm" ]
Financial and quality - of - life burden is a Intervention_Educational, dysfunctional uterine bleeding among women agreeing to obtain surgical treatment . is a Participant_Condition, financial and quality - of - life burden is a Intervention_Other, baseline data on DUB symptoms and aspects of the financial and quality - of - life burden is a Intervention_Educational, out - of - pocket pharmaceutical expenditures is a Outcome_Other, excess expenditures on pads or tampons is a Outcome_Other, the value of time missed from paid work and home management activities is a Outcome_Other, health utility is a Outcome_Other, Pelvic pain and cramps is a Outcome_Pain, activity limitations is a Outcome_Pain, tiredness is a Outcome_Physical, lower health utility is a Outcome_Other, Excess pharmaceutical and pad and tampon costs is a Outcome_Other, paid work and home management loss costs is a Outcome_Other, Effective surgical treatment is a Outcome_Other, financial and quality - of - life effects is a Intervention_Other
38456_task0
Sentence: Financial and quality-of-life burden of dysfunctional uterine bleeding among women agreeing to obtain surgical treatment . PURPOSE In this study , we sought to 1 ) describe elements of the financial and quality-of-life burden of dysfunctional uterine bleeding ( DUB ) from the perspective of women who agreed to obtain surgical treatment ; 2 ) explore associations between DUB symptom characteristics and the financial and quality-of-life burden ; 3 ) estimate the annual dollar value of the financial burden ; and 4 ) estimate the most that could be spent on surgery to eliminate DUB symptoms for which medical treatment has been unsuccessful that would result in a $ 50,000/quality-adjusted life-year incremental cost-effectiveness ratio . METHODS We collected baseline data on DUB symptoms and aspects of the financial and quality-of-life burden for 237 women agreeing to surgery for DUB in a randomized trial comparing hysterectomy with endometrial ablation . Measures included out-of-pocket pharmaceutical expenditures , excess expenditures on pads or tampons , the value of time missed from paid work and home management activities , and health utility . We used chi2 and t tests to assess the statistical significance of associations between DUB characteristics and the financial and quality-of-life burden . The annual financial burden was estimated . RESULTS Pelvic pain and cramps were associated with activity limitations and tiredness was associated with a lower health utility . Excess pharmaceutical and pad and tampon costs were $ 333 per patient per year ( 95 % confidence interval [ CI ] , $ 263- $ 403 ) . Excess paid work and home management loss costs were $ 2,291 per patient per year ( 95 % CI , $ 1847- $ 2752 ) . Effective surgical treatment costing $ 40,000 would be cost-effective compared with unsuccessful medical treatment . CONCLUSION The financial and quality-of-life effects of DUB represent a substantial burden . Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: Participant_Condition, Intervention_Educational, Intervention_Other, Outcome_Pain, Outcome_Physical, Outcome_Other
[ "B-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "O", "B-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Other", "I-Intervention_Other", "I-Intervention_Other", "I-Intervention_Other", "I-Intervention_Other", "I-Intervention_Other", "I-Intervention_Other", "I-Intervention_Other", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "O", "B-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "O", "B-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "O", "O", "B-Outcome_Other", "I-Outcome_Other", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Pain", "I-Outcome_Pain", "I-Outcome_Pain", "I-Outcome_Pain", "O", "O", "O", "B-Outcome_Pain", "I-Outcome_Pain", "O", "B-Outcome_Physical", "O", "O", "O", "O", "B-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "O", "B-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Other", "I-Intervention_Other", "I-Intervention_Other", "I-Intervention_Other", "I-Intervention_Other", "I-Intervention_Other", "I-Intervention_Other", "I-Intervention_Other", "O", "O", "O", "O", "O", "O", "O" ]
Financial and quality-of-life burden of dysfunctional uterine bleeding among women agreeing to obtain surgical treatment . PURPOSE In this study , we sought to 1 ) describe elements of the financial and quality-of-life burden of dysfunctional uterine bleeding ( DUB ) from the perspective of women who agreed to obtain surgical treatment ; 2 ) explore associations between DUB symptom characteristics and the financial and quality-of-life burden ; 3 ) estimate the annual dollar value of the financial burden ; and 4 ) estimate the most that could be spent on surgery to eliminate DUB symptoms for which medical treatment has been unsuccessful that would result in a $ 50,000/quality-adjusted life-year incremental cost-effectiveness ratio . METHODS We collected baseline data on DUB symptoms and aspects of the financial and quality-of-life burden for 237 women agreeing to surgery for DUB in a randomized trial comparing hysterectomy with endometrial ablation . Measures included out-of-pocket pharmaceutical expenditures , excess expenditures on pads or tampons , the value of time missed from paid work and home management activities , and health utility . We used chi2 and t tests to assess the statistical significance of associations between DUB characteristics and the financial and quality-of-life burden . The annual financial burden was estimated . RESULTS Pelvic pain and cramps were associated with activity limitations and tiredness was associated with a lower health utility . Excess pharmaceutical and pad and tampon costs were $ 333 per patient per year ( 95 % confidence interval [ CI ] , $ 263- $ 403 ) . Excess paid work and home management loss costs were $ 2,291 per patient per year ( 95 % CI , $ 1847- $ 2752 ) . Effective surgical treatment costing $ 40,000 would be cost-effective compared with unsuccessful medical treatment . CONCLUSION The financial and quality-of-life effects of DUB represent a substantial burden .
[ "Financial", "and", "quality", "-", "of", "-", "life", "burden", "of", "dysfunctional", "uterine", "bleeding", "among", "women", "agreeing", "to", "obtain", "surgical", "treatment", ".", "PURPOSE", "In", "this", "study", ",", "we", "sought", "to", "1", ")", "describe", "elements", "of", "the", "financial", "and", "quality", "-", "of", "-", "life", "burden", "of", "dysfunctional", "uterine", "bleeding", "(", "DUB", ")", "from", "the", "perspective", "of", "women", "who", "agreed", "to", "obtain", "surgical", "treatment", ";", "2", ")", "explore", "associations", "between", "DUB", "symptom", "characteristics", "and", "the", "financial", "and", "quality", "-", "of", "-", "life", "burden", ";", "3", ")", "estimate", "the", "annual", "dollar", "value", "of", "the", "financial", "burden", ";", "and", "4", ")", "estimate", "the", "most", "that", "could", "be", "spent", "on", "surgery", "to", "eliminate", "DUB", "symptoms", "for", "which", "medical", "treatment", "has", "been", "unsuccessful", "that", "would", "result", "in", "a", "$", "50,000", "/", "quality", "-", "adjusted", "life", "-", "year", "incremental", "cost", "-", "effectiveness", "ratio", ".", "METHODS", "We", "collected", "baseline", "data", "on", "DUB", "symptoms", "and", "aspects", "of", "the", "financial", "and", "quality", "-", "of", "-", "life", "burden", "for", "237", "women", "agreeing", "to", "surgery", "for", "DUB", "in", "a", "randomized", "trial", "comparing", "hysterectomy", "with", "endometrial", "ablation", ".", "Measures", "included", "out", "-", "of", "-", "pocket", "pharmaceutical", "expenditures", ",", "excess", "expenditures", "on", "pads", "or", "tampons", ",", "the", "value", "of", "time", "missed", "from", "paid", "work", "and", "home", "management", "activities", ",", "and", "health", "utility", ".", "We", "used", "chi2", "and", "t", "tests", "to", "assess", "the", "statistical", "significance", "of", "associations", "between", "DUB", "characteristics", "and", "the", "financial", "and", "quality", "-", "of", "-", "life", "burden", ".", "The", "annual", "financial", "burden", "was", "estimated", ".", "RESULTS", "Pelvic", "pain", "and", "cramps", "were", "associated", "with", "activity", "limitations", "and", "tiredness", "was", "associated", "with", "a", "lower", "health", "utility", ".", "Excess", "pharmaceutical", "and", "pad", "and", "tampon", "costs", "were", "$", "333", "per", "patient", "per", "year", "(", "95", "%", "confidence", "interval", "[", "CI", "]", ",", "$", "263-", "$", "403", ")", ".", "Excess", "paid", "work", "and", "home", "management", "loss", "costs", "were", "$", "2,291", "per", "patient", "per", "year", "(", "95", "%", "CI", ",", "$", "1847-", "$", "2752", ")", ".", "Effective", "surgical", "treatment", "costing", "$", "40,000", "would", "be", "cost", "-", "effective", "compared", "with", "unsuccessful", "medical", "treatment", ".", "CONCLUSION", "The", "financial", "and", "quality", "-", "of", "-", "life", "effects", "of", "DUB", "represent", "a", "substantial", "burden", "." ]
[ "Intervention_Educational", "Participant_Condition", "Outcome_Other", "Intervention_Other", "Outcome_Pain", "Outcome_Physical" ]
Financial and quality - of - life burden is a Intervention_Educational, dysfunctional uterine bleeding among women agreeing to obtain surgical treatment . is a Participant_Condition, financial and quality - of - life burden is a Intervention_Other, baseline data on DUB symptoms and aspects of the financial and quality - of - life burden is a Intervention_Educational, out - of - pocket pharmaceutical expenditures is a Outcome_Other, excess expenditures on pads or tampons is a Outcome_Other, the value of time missed from paid work and home management activities is a Outcome_Other, health utility is a Outcome_Other, Pelvic pain and cramps is a Outcome_Pain, activity limitations is a Outcome_Pain, tiredness is a Outcome_Physical, lower health utility is a Outcome_Other, Excess pharmaceutical and pad and tampon costs is a Outcome_Other, paid work and home management loss costs is a Outcome_Other, Effective surgical treatment is a Outcome_Other, financial and quality - of - life effects is a Intervention_Other
38456_task1
Sentence: Financial and quality-of-life burden of dysfunctional uterine bleeding among women agreeing to obtain surgical treatment . PURPOSE In this study , we sought to 1 ) describe elements of the financial and quality-of-life burden of dysfunctional uterine bleeding ( DUB ) from the perspective of women who agreed to obtain surgical treatment ; 2 ) explore associations between DUB symptom characteristics and the financial and quality-of-life burden ; 3 ) estimate the annual dollar value of the financial burden ; and 4 ) estimate the most that could be spent on surgery to eliminate DUB symptoms for which medical treatment has been unsuccessful that would result in a $ 50,000/quality-adjusted life-year incremental cost-effectiveness ratio . METHODS We collected baseline data on DUB symptoms and aspects of the financial and quality-of-life burden for 237 women agreeing to surgery for DUB in a randomized trial comparing hysterectomy with endometrial ablation . Measures included out-of-pocket pharmaceutical expenditures , excess expenditures on pads or tampons , the value of time missed from paid work and home management activities , and health utility . We used chi2 and t tests to assess the statistical significance of associations between DUB characteristics and the financial and quality-of-life burden . The annual financial burden was estimated . RESULTS Pelvic pain and cramps were associated with activity limitations and tiredness was associated with a lower health utility . Excess pharmaceutical and pad and tampon costs were $ 333 per patient per year ( 95 % confidence interval [ CI ] , $ 263- $ 403 ) . Excess paid work and home management loss costs were $ 2,291 per patient per year ( 95 % CI , $ 1847- $ 2752 ) . Effective surgical treatment costing $ 40,000 would be cost-effective compared with unsuccessful medical treatment . CONCLUSION The financial and quality-of-life effects of DUB represent a substantial burden . Instructions: please typing these entity words according to sentence: Financial and quality - of - life burden, dysfunctional uterine bleeding among women agreeing to obtain surgical treatment ., financial and quality - of - life burden, baseline data on DUB symptoms and aspects of the financial and quality - of - life burden, out - of - pocket pharmaceutical expenditures, excess expenditures on pads or tampons, the value of time missed from paid work and home management activities, health utility, Pelvic pain and cramps, activity limitations, tiredness, lower health utility, Excess pharmaceutical and pad and tampon costs, paid work and home management loss costs, Effective surgical treatment, financial and quality - of - life effects Options: Participant_Condition, Intervention_Educational, Intervention_Other, Outcome_Pain, Outcome_Physical, Outcome_Other
[ "B-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "O", "B-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Other", "I-Intervention_Other", "I-Intervention_Other", "I-Intervention_Other", "I-Intervention_Other", "I-Intervention_Other", "I-Intervention_Other", "I-Intervention_Other", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "O", "B-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "O", "B-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "O", "O", "B-Outcome_Other", "I-Outcome_Other", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Pain", "I-Outcome_Pain", "I-Outcome_Pain", "I-Outcome_Pain", "O", "O", "O", "B-Outcome_Pain", "I-Outcome_Pain", "O", "B-Outcome_Physical", "O", "O", "O", "O", "B-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "O", "B-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Other", "I-Intervention_Other", "I-Intervention_Other", "I-Intervention_Other", "I-Intervention_Other", "I-Intervention_Other", "I-Intervention_Other", "I-Intervention_Other", "O", "O", "O", "O", "O", "O", "O" ]
Financial and quality-of-life burden of dysfunctional uterine bleeding among women agreeing to obtain surgical treatment . PURPOSE In this study , we sought to 1 ) describe elements of the financial and quality-of-life burden of dysfunctional uterine bleeding ( DUB ) from the perspective of women who agreed to obtain surgical treatment ; 2 ) explore associations between DUB symptom characteristics and the financial and quality-of-life burden ; 3 ) estimate the annual dollar value of the financial burden ; and 4 ) estimate the most that could be spent on surgery to eliminate DUB symptoms for which medical treatment has been unsuccessful that would result in a $ 50,000/quality-adjusted life-year incremental cost-effectiveness ratio . METHODS We collected baseline data on DUB symptoms and aspects of the financial and quality-of-life burden for 237 women agreeing to surgery for DUB in a randomized trial comparing hysterectomy with endometrial ablation . Measures included out-of-pocket pharmaceutical expenditures , excess expenditures on pads or tampons , the value of time missed from paid work and home management activities , and health utility . We used chi2 and t tests to assess the statistical significance of associations between DUB characteristics and the financial and quality-of-life burden . The annual financial burden was estimated . RESULTS Pelvic pain and cramps were associated with activity limitations and tiredness was associated with a lower health utility . Excess pharmaceutical and pad and tampon costs were $ 333 per patient per year ( 95 % confidence interval [ CI ] , $ 263- $ 403 ) . Excess paid work and home management loss costs were $ 2,291 per patient per year ( 95 % CI , $ 1847- $ 2752 ) . Effective surgical treatment costing $ 40,000 would be cost-effective compared with unsuccessful medical treatment . CONCLUSION The financial and quality-of-life effects of DUB represent a substantial burden .
[ "Financial", "and", "quality", "-", "of", "-", "life", "burden", "of", "dysfunctional", "uterine", "bleeding", "among", "women", "agreeing", "to", "obtain", "surgical", "treatment", ".", "PURPOSE", "In", "this", "study", ",", "we", "sought", "to", "1", ")", "describe", "elements", "of", "the", "financial", "and", "quality", "-", "of", "-", "life", "burden", "of", "dysfunctional", "uterine", "bleeding", "(", "DUB", ")", "from", "the", "perspective", "of", "women", "who", "agreed", "to", "obtain", "surgical", "treatment", ";", "2", ")", "explore", "associations", "between", "DUB", "symptom", "characteristics", "and", "the", "financial", "and", "quality", "-", "of", "-", "life", "burden", ";", "3", ")", "estimate", "the", "annual", "dollar", "value", "of", "the", "financial", "burden", ";", "and", "4", ")", "estimate", "the", "most", "that", "could", "be", "spent", "on", "surgery", "to", "eliminate", "DUB", "symptoms", "for", "which", "medical", "treatment", "has", "been", "unsuccessful", "that", "would", "result", "in", "a", "$", "50,000", "/", "quality", "-", "adjusted", "life", "-", "year", "incremental", "cost", "-", "effectiveness", "ratio", ".", "METHODS", "We", "collected", "baseline", "data", "on", "DUB", "symptoms", "and", "aspects", "of", "the", "financial", "and", "quality", "-", "of", "-", "life", "burden", "for", "237", "women", "agreeing", "to", "surgery", "for", "DUB", "in", "a", "randomized", "trial", "comparing", "hysterectomy", "with", "endometrial", "ablation", ".", "Measures", "included", "out", "-", "of", "-", "pocket", "pharmaceutical", "expenditures", ",", "excess", "expenditures", "on", "pads", "or", "tampons", ",", "the", "value", "of", "time", "missed", "from", "paid", "work", "and", "home", "management", "activities", ",", "and", "health", "utility", ".", "We", "used", "chi2", "and", "t", "tests", "to", "assess", "the", "statistical", "significance", "of", "associations", "between", "DUB", "characteristics", "and", "the", "financial", "and", "quality", "-", "of", "-", "life", "burden", ".", "The", "annual", "financial", "burden", "was", "estimated", ".", "RESULTS", "Pelvic", "pain", "and", "cramps", "were", "associated", "with", "activity", "limitations", "and", "tiredness", "was", "associated", "with", "a", "lower", "health", "utility", ".", "Excess", "pharmaceutical", "and", "pad", "and", "tampon", "costs", "were", "$", "333", "per", "patient", "per", "year", "(", "95", "%", "confidence", "interval", "[", "CI", "]", ",", "$", "263-", "$", "403", ")", ".", "Excess", "paid", "work", "and", "home", "management", "loss", "costs", "were", "$", "2,291", "per", "patient", "per", "year", "(", "95", "%", "CI", ",", "$", "1847-", "$", "2752", ")", ".", "Effective", "surgical", "treatment", "costing", "$", "40,000", "would", "be", "cost", "-", "effective", "compared", "with", "unsuccessful", "medical", "treatment", ".", "CONCLUSION", "The", "financial", "and", "quality", "-", "of", "-", "life", "effects", "of", "DUB", "represent", "a", "substantial", "burden", "." ]
[ "Intervention_Educational", "Participant_Condition", "Outcome_Other", "Intervention_Other", "Outcome_Pain", "Outcome_Physical" ]
Financial and quality - of - life burden, dysfunctional uterine bleeding among women agreeing to obtain surgical treatment ., financial and quality - of - life burden, baseline data on DUB symptoms and aspects of the financial and quality - of - life burden, out - of - pocket pharmaceutical expenditures, excess expenditures on pads or tampons, the value of time missed from paid work and home management activities, health utility, Pelvic pain and cramps, activity limitations, tiredness, lower health utility, Excess pharmaceutical and pad and tampon costs, paid work and home management loss costs, Effective surgical treatment, financial and quality - of - life effects
38456_task2
Sentence: Financial and quality-of-life burden of dysfunctional uterine bleeding among women agreeing to obtain surgical treatment . PURPOSE In this study , we sought to 1 ) describe elements of the financial and quality-of-life burden of dysfunctional uterine bleeding ( DUB ) from the perspective of women who agreed to obtain surgical treatment ; 2 ) explore associations between DUB symptom characteristics and the financial and quality-of-life burden ; 3 ) estimate the annual dollar value of the financial burden ; and 4 ) estimate the most that could be spent on surgery to eliminate DUB symptoms for which medical treatment has been unsuccessful that would result in a $ 50,000/quality-adjusted life-year incremental cost-effectiveness ratio . METHODS We collected baseline data on DUB symptoms and aspects of the financial and quality-of-life burden for 237 women agreeing to surgery for DUB in a randomized trial comparing hysterectomy with endometrial ablation . Measures included out-of-pocket pharmaceutical expenditures , excess expenditures on pads or tampons , the value of time missed from paid work and home management activities , and health utility . We used chi2 and t tests to assess the statistical significance of associations between DUB characteristics and the financial and quality-of-life burden . The annual financial burden was estimated . RESULTS Pelvic pain and cramps were associated with activity limitations and tiredness was associated with a lower health utility . Excess pharmaceutical and pad and tampon costs were $ 333 per patient per year ( 95 % confidence interval [ CI ] , $ 263- $ 403 ) . Excess paid work and home management loss costs were $ 2,291 per patient per year ( 95 % CI , $ 1847- $ 2752 ) . Effective surgical treatment costing $ 40,000 would be cost-effective compared with unsuccessful medical treatment . CONCLUSION The financial and quality-of-life effects of DUB represent a substantial burden . Instructions: please extract entity words from the input sentence
[ "B-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "O", "B-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Other", "I-Intervention_Other", "I-Intervention_Other", "I-Intervention_Other", "I-Intervention_Other", "I-Intervention_Other", "I-Intervention_Other", "I-Intervention_Other", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "O", "B-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "O", "B-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "O", "O", "B-Outcome_Other", "I-Outcome_Other", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Pain", "I-Outcome_Pain", "I-Outcome_Pain", "I-Outcome_Pain", "O", "O", "O", "B-Outcome_Pain", "I-Outcome_Pain", "O", "B-Outcome_Physical", "O", "O", "O", "O", "B-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "O", "B-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Other", "I-Intervention_Other", "I-Intervention_Other", "I-Intervention_Other", "I-Intervention_Other", "I-Intervention_Other", "I-Intervention_Other", "I-Intervention_Other", "O", "O", "O", "O", "O", "O", "O" ]
Financial and quality-of-life burden of dysfunctional uterine bleeding among women agreeing to obtain surgical treatment . PURPOSE In this study , we sought to 1 ) describe elements of the financial and quality-of-life burden of dysfunctional uterine bleeding ( DUB ) from the perspective of women who agreed to obtain surgical treatment ; 2 ) explore associations between DUB symptom characteristics and the financial and quality-of-life burden ; 3 ) estimate the annual dollar value of the financial burden ; and 4 ) estimate the most that could be spent on surgery to eliminate DUB symptoms for which medical treatment has been unsuccessful that would result in a $ 50,000/quality-adjusted life-year incremental cost-effectiveness ratio . METHODS We collected baseline data on DUB symptoms and aspects of the financial and quality-of-life burden for 237 women agreeing to surgery for DUB in a randomized trial comparing hysterectomy with endometrial ablation . Measures included out-of-pocket pharmaceutical expenditures , excess expenditures on pads or tampons , the value of time missed from paid work and home management activities , and health utility . We used chi2 and t tests to assess the statistical significance of associations between DUB characteristics and the financial and quality-of-life burden . The annual financial burden was estimated . RESULTS Pelvic pain and cramps were associated with activity limitations and tiredness was associated with a lower health utility . Excess pharmaceutical and pad and tampon costs were $ 333 per patient per year ( 95 % confidence interval [ CI ] , $ 263- $ 403 ) . Excess paid work and home management loss costs were $ 2,291 per patient per year ( 95 % CI , $ 1847- $ 2752 ) . Effective surgical treatment costing $ 40,000 would be cost-effective compared with unsuccessful medical treatment . CONCLUSION The financial and quality-of-life effects of DUB represent a substantial burden .
[ "Financial", "and", "quality", "-", "of", "-", "life", "burden", "of", "dysfunctional", "uterine", "bleeding", "among", "women", "agreeing", "to", "obtain", "surgical", "treatment", ".", "PURPOSE", "In", "this", "study", ",", "we", "sought", "to", "1", ")", "describe", "elements", "of", "the", "financial", "and", "quality", "-", "of", "-", "life", "burden", "of", "dysfunctional", "uterine", "bleeding", "(", "DUB", ")", "from", "the", "perspective", "of", "women", "who", "agreed", "to", "obtain", "surgical", "treatment", ";", "2", ")", "explore", "associations", "between", "DUB", "symptom", "characteristics", "and", "the", "financial", "and", "quality", "-", "of", "-", "life", "burden", ";", "3", ")", "estimate", "the", "annual", "dollar", "value", "of", "the", "financial", "burden", ";", "and", "4", ")", "estimate", "the", "most", "that", "could", "be", "spent", "on", "surgery", "to", "eliminate", "DUB", "symptoms", "for", "which", "medical", "treatment", "has", "been", "unsuccessful", "that", "would", "result", "in", "a", "$", "50,000", "/", "quality", "-", "adjusted", "life", "-", "year", "incremental", "cost", "-", "effectiveness", "ratio", ".", "METHODS", "We", "collected", "baseline", "data", "on", "DUB", "symptoms", "and", "aspects", "of", "the", "financial", "and", "quality", "-", "of", "-", "life", "burden", "for", "237", "women", "agreeing", "to", "surgery", "for", "DUB", "in", "a", "randomized", "trial", "comparing", "hysterectomy", "with", "endometrial", "ablation", ".", "Measures", "included", "out", "-", "of", "-", "pocket", "pharmaceutical", "expenditures", ",", "excess", "expenditures", "on", "pads", "or", "tampons", ",", "the", "value", "of", "time", "missed", "from", "paid", "work", "and", "home", "management", "activities", ",", "and", "health", "utility", ".", "We", "used", "chi2", "and", "t", "tests", "to", "assess", "the", "statistical", "significance", "of", "associations", "between", "DUB", "characteristics", "and", "the", "financial", "and", "quality", "-", "of", "-", "life", "burden", ".", "The", "annual", "financial", "burden", "was", "estimated", ".", "RESULTS", "Pelvic", "pain", "and", "cramps", "were", "associated", "with", "activity", "limitations", "and", "tiredness", "was", "associated", "with", "a", "lower", "health", "utility", ".", "Excess", "pharmaceutical", "and", "pad", "and", "tampon", "costs", "were", "$", "333", "per", "patient", "per", "year", "(", "95", "%", "confidence", "interval", "[", "CI", "]", ",", "$", "263-", "$", "403", ")", ".", "Excess", "paid", "work", "and", "home", "management", "loss", "costs", "were", "$", "2,291", "per", "patient", "per", "year", "(", "95", "%", "CI", ",", "$", "1847-", "$", "2752", ")", ".", "Effective", "surgical", "treatment", "costing", "$", "40,000", "would", "be", "cost", "-", "effective", "compared", "with", "unsuccessful", "medical", "treatment", ".", "CONCLUSION", "The", "financial", "and", "quality", "-", "of", "-", "life", "effects", "of", "DUB", "represent", "a", "substantial", "burden", "." ]
[ "Intervention_Educational", "Participant_Condition", "Outcome_Other", "Intervention_Other", "Outcome_Pain", "Outcome_Physical" ]
Grb2-binding proteins is a protein_family_or_group, human platelets is a cell_type, Fc gamma RIIA cross - linking is an other_name
22188_task0
Sentence: Characterization of Grb2-binding proteins in human platelets activated by Fc gamma RIIA cross-linking. Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: cell_type, protein_family_or_group, other_name
[ "O", "O", "B-protein_family_or_group", "I-protein_family_or_group", "O", "B-cell_type", "I-cell_type", "O", "O", "B-other_name", "I-other_name", "I-other_name", "I-other_name", "I-other_name", "I-other_name", "O" ]
Characterization of Grb2-binding proteins in human platelets activated by Fc gamma RIIA cross-linking.
[ "Characterization", "of", "Grb2-binding", "proteins", "in", "human", "platelets", "activated", "by", "Fc", "gamma", "RIIA", "cross", "-", "linking", "." ]
[ "protein_molecule", "other_name", "cell_line", "protein_family_or_group", "(AND protein_domain_or_region protein_domain_or_region)", "cell_type", "protein_domain_or_region", "amino_acid_monomer", "protein_complex", "" ]
Grb2-binding proteins is a protein_family_or_group, human platelets is a cell_type, Fc gamma RIIA cross - linking is an other_name
22188_task1
Sentence: Characterization of Grb2-binding proteins in human platelets activated by Fc gamma RIIA cross-linking. Instructions: please typing these entity words according to sentence: Grb2-binding proteins, human platelets, Fc gamma RIIA cross - linking Options: cell_type, protein_family_or_group, other_name
[ "O", "O", "B-protein_family_or_group", "I-protein_family_or_group", "O", "B-cell_type", "I-cell_type", "O", "O", "B-other_name", "I-other_name", "I-other_name", "I-other_name", "I-other_name", "I-other_name", "O" ]
Characterization of Grb2-binding proteins in human platelets activated by Fc gamma RIIA cross-linking.
[ "Characterization", "of", "Grb2-binding", "proteins", "in", "human", "platelets", "activated", "by", "Fc", "gamma", "RIIA", "cross", "-", "linking", "." ]
[ "protein_molecule", "other_name", "cell_line", "protein_family_or_group", "(AND protein_domain_or_region protein_domain_or_region)", "cell_type", "protein_domain_or_region", "amino_acid_monomer", "protein_complex", "" ]
Grb2-binding proteins, human platelets, Fc gamma RIIA cross - linking
22188_task2
Sentence: Characterization of Grb2-binding proteins in human platelets activated by Fc gamma RIIA cross-linking. Instructions: please extract entity words from the input sentence
[ "O", "O", "B-protein_family_or_group", "I-protein_family_or_group", "O", "B-cell_type", "I-cell_type", "O", "O", "B-other_name", "I-other_name", "I-other_name", "I-other_name", "I-other_name", "I-other_name", "O" ]
Characterization of Grb2-binding proteins in human platelets activated by Fc gamma RIIA cross-linking.
[ "Characterization", "of", "Grb2-binding", "proteins", "in", "human", "platelets", "activated", "by", "Fc", "gamma", "RIIA", "cross", "-", "linking", "." ]
[ "protein_molecule", "other_name", "cell_line", "protein_family_or_group", "(AND protein_domain_or_region protein_domain_or_region)", "cell_type", "protein_domain_or_region", "amino_acid_monomer", "protein_complex", "" ]
Patienten is an umlsterm, koronaren Herzkrankheit is an umlsterm
ZfuerHerzThoraxGefaesschirurgie.90130001.ger.abstr_task0
Sentence: Patienten mit einer operationswuerdigen koronaren Herzkrankheit haben in einem geringen Prozentsatz auch eine klinisch relevante Carotisstenose . Es ist die Frage , inwieweit die simultane peripher- und koronarchirurgische Revaskularisation das postoperative Ergebnis nach kardiochirurgischen Eingriffen beeinflusst . Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: umlsterm
[ "B-umlsterm", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]
Patienten mit einer operationswuerdigen koronaren Herzkrankheit haben in einem geringen Prozentsatz auch eine klinisch relevante Carotisstenose . Es ist die Frage , inwieweit die simultane peripher- und koronarchirurgische Revaskularisation das postoperative Ergebnis nach kardiochirurgischen Eingriffen beeinflusst .
[ "Patienten", "mit", "einer", "operationswuerdigen", "koronaren", "Herzkrankheit", "haben", "in", "einem", "geringen", "Prozentsatz", "auch", "eine", "klinisch", "relevante", "Carotisstenose", ".", "Es", "ist", "die", "Frage", ",", "inwieweit", "die", "simultane", "peripher-", "und", "koronarchirurgische", "Revaskularisation", "das", "postoperative", "Ergebnis", "nach", "kardiochirurgischen", "Eingriffen", "beeinflusst", "." ]
[ "umlsterm" ]
Patienten is an umlsterm, koronaren Herzkrankheit is an umlsterm
ZfuerHerzThoraxGefaesschirurgie.90130001.ger.abstr_task1
Sentence: Patienten mit einer operationswuerdigen koronaren Herzkrankheit haben in einem geringen Prozentsatz auch eine klinisch relevante Carotisstenose . Es ist die Frage , inwieweit die simultane peripher- und koronarchirurgische Revaskularisation das postoperative Ergebnis nach kardiochirurgischen Eingriffen beeinflusst . Instructions: please typing these entity words according to sentence: Patienten, koronaren Herzkrankheit Options: umlsterm
[ "B-umlsterm", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]
Patienten mit einer operationswuerdigen koronaren Herzkrankheit haben in einem geringen Prozentsatz auch eine klinisch relevante Carotisstenose . Es ist die Frage , inwieweit die simultane peripher- und koronarchirurgische Revaskularisation das postoperative Ergebnis nach kardiochirurgischen Eingriffen beeinflusst .
[ "Patienten", "mit", "einer", "operationswuerdigen", "koronaren", "Herzkrankheit", "haben", "in", "einem", "geringen", "Prozentsatz", "auch", "eine", "klinisch", "relevante", "Carotisstenose", ".", "Es", "ist", "die", "Frage", ",", "inwieweit", "die", "simultane", "peripher-", "und", "koronarchirurgische", "Revaskularisation", "das", "postoperative", "Ergebnis", "nach", "kardiochirurgischen", "Eingriffen", "beeinflusst", "." ]
[ "umlsterm" ]
Patienten, koronaren Herzkrankheit
ZfuerHerzThoraxGefaesschirurgie.90130001.ger.abstr_task2
Sentence: Patienten mit einer operationswuerdigen koronaren Herzkrankheit haben in einem geringen Prozentsatz auch eine klinisch relevante Carotisstenose . Es ist die Frage , inwieweit die simultane peripher- und koronarchirurgische Revaskularisation das postoperative Ergebnis nach kardiochirurgischen Eingriffen beeinflusst . Instructions: please extract entity words from the input sentence
[ "B-umlsterm", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]
Patienten mit einer operationswuerdigen koronaren Herzkrankheit haben in einem geringen Prozentsatz auch eine klinisch relevante Carotisstenose . Es ist die Frage , inwieweit die simultane peripher- und koronarchirurgische Revaskularisation das postoperative Ergebnis nach kardiochirurgischen Eingriffen beeinflusst .
[ "Patienten", "mit", "einer", "operationswuerdigen", "koronaren", "Herzkrankheit", "haben", "in", "einem", "geringen", "Prozentsatz", "auch", "eine", "klinisch", "relevante", "Carotisstenose", ".", "Es", "ist", "die", "Frage", ",", "inwieweit", "die", "simultane", "peripher-", "und", "koronarchirurgische", "Revaskularisation", "das", "postoperative", "Ergebnis", "nach", "kardiochirurgischen", "Eingriffen", "beeinflusst", "." ]
[ "umlsterm" ]
mild cognitive impairment : is a Participant_Condition, cognitive rehabilitation intervention is a Intervention_Pharmacological, amnestic mild cognitive impairment ( MCI ) is a Participant_Condition, memory loss . is a Outcome_Mental, calendar / notebook rehabilitation intervention is a Intervention_Physical, memory support system ( MSS ) is a Intervention_Educational, amnestic MCI . is a Participant_Condition, Forty is a Participant_Sample-size, single domain amnestic MCI is a Participant_Condition, activities of daily living , and emotional impact is a Outcome_Mental, Functional ability is a Outcome_Mental, memory self - efficacy is a Outcome_Mental, mood is a Outcome_Mental, caregiver burden is a Outcome_Mental, Memory support system training is a Intervention_Educational
55325_task0
Sentence: The memory support system for mild cognitive impairment : randomized trial of a cognitive rehabilitation intervention . OBJECTIVE Individuals with amnestic mild cognitive impairment ( MCI ) have few empirically based treatment options for combating their memory loss . This study sought to examine the efficacy of a calendar/notebook rehabilitation intervention , the memory support system ( MSS ) , for individuals with amnestic MCI . METHODS Forty individuals with single domain amnestic MCI and their program partners were randomized to receive the MSS , either with training or without ( controls ) . Measures of adherence , activities of daily living , and emotional impact were completed at the first and last intervention sessions and again at 8 weeks and 6 months post intervention . RESULTS Training in use of a notebook/calendar system significantly improved adherence over those who received the calendars but no training . Functional ability and memory self-efficacy significantly improved for those who received MSS training . Change in functional ability remained significantly better in the intervention group than in the control group out to 8-week follow-up . Care partners in the intervention group demonstrated improved mood by 8-week and 6-month follow-ups , whereas control care partners reported worse caregiver burden by 6-month follow-up . CONCLUSIONS Memory support system training resulted in improvement in activities of daily living and sense of memory self-efficacy for individuals with MCI . Although activities of daily living benefits were maintained out to 8 weeks post intervention , future inclusion of booster sessions may help extend the therapeutic effect out even further . Improved mood of care partners of trained individuals and worsening sense of caregiver burden over time for partners of untrained individuals further support the efficacy of the MSS for MCI . Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: Intervention_Pharmacological, Intervention_Physical, Participant_Condition, Intervention_Educational, Participant_Sample-size, Outcome_Mental
[ "O", "O", "O", "O", "O", "B-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "O", "O", "O", "O", "B-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "O", "O", "O", "O", "B-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Physical", "I-Intervention_Physical", "I-Intervention_Physical", "I-Intervention_Physical", "I-Intervention_Physical", "O", "O", "B-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "O", "O", "O", "O", "B-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "O", "B-Participant_Sample-size", "O", "O", "B-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Mental", "I-Outcome_Mental", "O", "B-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Mental", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Mental", "I-Outcome_Mental", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]
The memory support system for mild cognitive impairment : randomized trial of a cognitive rehabilitation intervention . OBJECTIVE Individuals with amnestic mild cognitive impairment ( MCI ) have few empirically based treatment options for combating their memory loss . This study sought to examine the efficacy of a calendar/notebook rehabilitation intervention , the memory support system ( MSS ) , for individuals with amnestic MCI . METHODS Forty individuals with single domain amnestic MCI and their program partners were randomized to receive the MSS , either with training or without ( controls ) . Measures of adherence , activities of daily living , and emotional impact were completed at the first and last intervention sessions and again at 8 weeks and 6 months post intervention . RESULTS Training in use of a notebook/calendar system significantly improved adherence over those who received the calendars but no training . Functional ability and memory self-efficacy significantly improved for those who received MSS training . Change in functional ability remained significantly better in the intervention group than in the control group out to 8-week follow-up . Care partners in the intervention group demonstrated improved mood by 8-week and 6-month follow-ups , whereas control care partners reported worse caregiver burden by 6-month follow-up . CONCLUSIONS Memory support system training resulted in improvement in activities of daily living and sense of memory self-efficacy for individuals with MCI . Although activities of daily living benefits were maintained out to 8 weeks post intervention , future inclusion of booster sessions may help extend the therapeutic effect out even further . Improved mood of care partners of trained individuals and worsening sense of caregiver burden over time for partners of untrained individuals further support the efficacy of the MSS for MCI .
[ "The", "memory", "support", "system", "for", "mild", "cognitive", "impairment", ":", "randomized", "trial", "of", "a", "cognitive", "rehabilitation", "intervention", ".", "OBJECTIVE", "Individuals", "with", "amnestic", "mild", "cognitive", "impairment", "(", "MCI", ")", "have", "few", "empirically", "based", "treatment", "options", "for", "combating", "their", "memory", "loss", ".", "This", "study", "sought", "to", "examine", "the", "efficacy", "of", "a", "calendar", "/", "notebook", "rehabilitation", "intervention", ",", "the", "memory", "support", "system", "(", "MSS", ")", ",", "for", "individuals", "with", "amnestic", "MCI", ".", "METHODS", "Forty", "individuals", "with", "single", "domain", "amnestic", "MCI", "and", "their", "program", "partners", "were", "randomized", "to", "receive", "the", "MSS", ",", "either", "with", "training", "or", "without", "(", "controls", ")", ".", "Measures", "of", "adherence", ",", "activities", "of", "daily", "living", ",", "and", "emotional", "impact", "were", "completed", "at", "the", "first", "and", "last", "intervention", "sessions", "and", "again", "at", "8", "weeks", "and", "6", "months", "post", "intervention", ".", "RESULTS", "Training", "in", "use", "of", "a", "notebook", "/", "calendar", "system", "significantly", "improved", "adherence", "over", "those", "who", "received", "the", "calendars", "but", "no", "training", ".", "Functional", "ability", "and", "memory", "self", "-", "efficacy", "significantly", "improved", "for", "those", "who", "received", "MSS", "training", ".", "Change", "in", "functional", "ability", "remained", "significantly", "better", "in", "the", "intervention", "group", "than", "in", "the", "control", "group", "out", "to", "8-week", "follow", "-", "up", ".", "Care", "partners", "in", "the", "intervention", "group", "demonstrated", "improved", "mood", "by", "8-week", "and", "6-month", "follow", "-", "ups", ",", "whereas", "control", "care", "partners", "reported", "worse", "caregiver", "burden", "by", "6-month", "follow", "-", "up", ".", "CONCLUSIONS", "Memory", "support", "system", "training", "resulted", "in", "improvement", "in", "activities", "of", "daily", "living", "and", "sense", "of", "memory", "self", "-", "efficacy", "for", "individuals", "with", "MCI", ".", "Although", "activities", "of", "daily", "living", "benefits", "were", "maintained", "out", "to", "8", "weeks", "post", "intervention", ",", "future", "inclusion", "of", "booster", "sessions", "may", "help", "extend", "the", "therapeutic", "effect", "out", "even", "further", ".", "Improved", "mood", "of", "care", "partners", "of", "trained", "individuals", "and", "worsening", "sense", "of", "caregiver", "burden", "over", "time", "for", "partners", "of", "untrained", "individuals", "further", "support", "the", "efficacy", "of", "the", "MSS", "for", "MCI", "." ]
[ "Outcome_Mental", "Intervention_Physical", "Participant_Condition", "Intervention_Pharmacological", "Intervention_Educational", "Participant_Sample-size" ]
mild cognitive impairment : is a Participant_Condition, cognitive rehabilitation intervention is a Intervention_Pharmacological, amnestic mild cognitive impairment ( MCI ) is a Participant_Condition, memory loss . is a Outcome_Mental, calendar / notebook rehabilitation intervention is a Intervention_Physical, memory support system ( MSS ) is a Intervention_Educational, amnestic MCI . is a Participant_Condition, Forty is a Participant_Sample-size, single domain amnestic MCI is a Participant_Condition, activities of daily living , and emotional impact is a Outcome_Mental, Functional ability is a Outcome_Mental, memory self - efficacy is a Outcome_Mental, mood is a Outcome_Mental, caregiver burden is a Outcome_Mental, Memory support system training is a Intervention_Educational
55325_task1
Sentence: The memory support system for mild cognitive impairment : randomized trial of a cognitive rehabilitation intervention . OBJECTIVE Individuals with amnestic mild cognitive impairment ( MCI ) have few empirically based treatment options for combating their memory loss . This study sought to examine the efficacy of a calendar/notebook rehabilitation intervention , the memory support system ( MSS ) , for individuals with amnestic MCI . METHODS Forty individuals with single domain amnestic MCI and their program partners were randomized to receive the MSS , either with training or without ( controls ) . Measures of adherence , activities of daily living , and emotional impact were completed at the first and last intervention sessions and again at 8 weeks and 6 months post intervention . RESULTS Training in use of a notebook/calendar system significantly improved adherence over those who received the calendars but no training . Functional ability and memory self-efficacy significantly improved for those who received MSS training . Change in functional ability remained significantly better in the intervention group than in the control group out to 8-week follow-up . Care partners in the intervention group demonstrated improved mood by 8-week and 6-month follow-ups , whereas control care partners reported worse caregiver burden by 6-month follow-up . CONCLUSIONS Memory support system training resulted in improvement in activities of daily living and sense of memory self-efficacy for individuals with MCI . Although activities of daily living benefits were maintained out to 8 weeks post intervention , future inclusion of booster sessions may help extend the therapeutic effect out even further . Improved mood of care partners of trained individuals and worsening sense of caregiver burden over time for partners of untrained individuals further support the efficacy of the MSS for MCI . Instructions: please typing these entity words according to sentence: mild cognitive impairment :, cognitive rehabilitation intervention, amnestic mild cognitive impairment ( MCI ), memory loss ., calendar / notebook rehabilitation intervention, memory support system ( MSS ), amnestic MCI ., Forty, single domain amnestic MCI, activities of daily living , and emotional impact, Functional ability, memory self - efficacy, mood, caregiver burden, Memory support system training Options: Intervention_Pharmacological, Intervention_Physical, Participant_Condition, Intervention_Educational, Participant_Sample-size, Outcome_Mental
[ "O", "O", "O", "O", "O", "B-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "O", "O", "O", "O", "B-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "O", "O", "O", "O", "B-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Physical", "I-Intervention_Physical", "I-Intervention_Physical", "I-Intervention_Physical", "I-Intervention_Physical", "O", "O", "B-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "O", "O", "O", "O", "B-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "O", "B-Participant_Sample-size", "O", "O", "B-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Mental", "I-Outcome_Mental", "O", "B-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Mental", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Mental", "I-Outcome_Mental", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]
The memory support system for mild cognitive impairment : randomized trial of a cognitive rehabilitation intervention . OBJECTIVE Individuals with amnestic mild cognitive impairment ( MCI ) have few empirically based treatment options for combating their memory loss . This study sought to examine the efficacy of a calendar/notebook rehabilitation intervention , the memory support system ( MSS ) , for individuals with amnestic MCI . METHODS Forty individuals with single domain amnestic MCI and their program partners were randomized to receive the MSS , either with training or without ( controls ) . Measures of adherence , activities of daily living , and emotional impact were completed at the first and last intervention sessions and again at 8 weeks and 6 months post intervention . RESULTS Training in use of a notebook/calendar system significantly improved adherence over those who received the calendars but no training . Functional ability and memory self-efficacy significantly improved for those who received MSS training . Change in functional ability remained significantly better in the intervention group than in the control group out to 8-week follow-up . Care partners in the intervention group demonstrated improved mood by 8-week and 6-month follow-ups , whereas control care partners reported worse caregiver burden by 6-month follow-up . CONCLUSIONS Memory support system training resulted in improvement in activities of daily living and sense of memory self-efficacy for individuals with MCI . Although activities of daily living benefits were maintained out to 8 weeks post intervention , future inclusion of booster sessions may help extend the therapeutic effect out even further . Improved mood of care partners of trained individuals and worsening sense of caregiver burden over time for partners of untrained individuals further support the efficacy of the MSS for MCI .
[ "The", "memory", "support", "system", "for", "mild", "cognitive", "impairment", ":", "randomized", "trial", "of", "a", "cognitive", "rehabilitation", "intervention", ".", "OBJECTIVE", "Individuals", "with", "amnestic", "mild", "cognitive", "impairment", "(", "MCI", ")", "have", "few", "empirically", "based", "treatment", "options", "for", "combating", "their", "memory", "loss", ".", "This", "study", "sought", "to", "examine", "the", "efficacy", "of", "a", "calendar", "/", "notebook", "rehabilitation", "intervention", ",", "the", "memory", "support", "system", "(", "MSS", ")", ",", "for", "individuals", "with", "amnestic", "MCI", ".", "METHODS", "Forty", "individuals", "with", "single", "domain", "amnestic", "MCI", "and", "their", "program", "partners", "were", "randomized", "to", "receive", "the", "MSS", ",", "either", "with", "training", "or", "without", "(", "controls", ")", ".", "Measures", "of", "adherence", ",", "activities", "of", "daily", "living", ",", "and", "emotional", "impact", "were", "completed", "at", "the", "first", "and", "last", "intervention", "sessions", "and", "again", "at", "8", "weeks", "and", "6", "months", "post", "intervention", ".", "RESULTS", "Training", "in", "use", "of", "a", "notebook", "/", "calendar", "system", "significantly", "improved", "adherence", "over", "those", "who", "received", "the", "calendars", "but", "no", "training", ".", "Functional", "ability", "and", "memory", "self", "-", "efficacy", "significantly", "improved", "for", "those", "who", "received", "MSS", "training", ".", "Change", "in", "functional", "ability", "remained", "significantly", "better", "in", "the", "intervention", "group", "than", "in", "the", "control", "group", "out", "to", "8-week", "follow", "-", "up", ".", "Care", "partners", "in", "the", "intervention", "group", "demonstrated", "improved", "mood", "by", "8-week", "and", "6-month", "follow", "-", "ups", ",", "whereas", "control", "care", "partners", "reported", "worse", "caregiver", "burden", "by", "6-month", "follow", "-", "up", ".", "CONCLUSIONS", "Memory", "support", "system", "training", "resulted", "in", "improvement", "in", "activities", "of", "daily", "living", "and", "sense", "of", "memory", "self", "-", "efficacy", "for", "individuals", "with", "MCI", ".", "Although", "activities", "of", "daily", "living", "benefits", "were", "maintained", "out", "to", "8", "weeks", "post", "intervention", ",", "future", "inclusion", "of", "booster", "sessions", "may", "help", "extend", "the", "therapeutic", "effect", "out", "even", "further", ".", "Improved", "mood", "of", "care", "partners", "of", "trained", "individuals", "and", "worsening", "sense", "of", "caregiver", "burden", "over", "time", "for", "partners", "of", "untrained", "individuals", "further", "support", "the", "efficacy", "of", "the", "MSS", "for", "MCI", "." ]
[ "Outcome_Mental", "Intervention_Physical", "Participant_Condition", "Intervention_Pharmacological", "Intervention_Educational", "Participant_Sample-size" ]
mild cognitive impairment :, cognitive rehabilitation intervention, amnestic mild cognitive impairment ( MCI ), memory loss ., calendar / notebook rehabilitation intervention, memory support system ( MSS ), amnestic MCI ., Forty, single domain amnestic MCI, activities of daily living , and emotional impact, Functional ability, memory self - efficacy, mood, caregiver burden, Memory support system training
55325_task2
Sentence: The memory support system for mild cognitive impairment : randomized trial of a cognitive rehabilitation intervention . OBJECTIVE Individuals with amnestic mild cognitive impairment ( MCI ) have few empirically based treatment options for combating their memory loss . This study sought to examine the efficacy of a calendar/notebook rehabilitation intervention , the memory support system ( MSS ) , for individuals with amnestic MCI . METHODS Forty individuals with single domain amnestic MCI and their program partners were randomized to receive the MSS , either with training or without ( controls ) . Measures of adherence , activities of daily living , and emotional impact were completed at the first and last intervention sessions and again at 8 weeks and 6 months post intervention . RESULTS Training in use of a notebook/calendar system significantly improved adherence over those who received the calendars but no training . Functional ability and memory self-efficacy significantly improved for those who received MSS training . Change in functional ability remained significantly better in the intervention group than in the control group out to 8-week follow-up . Care partners in the intervention group demonstrated improved mood by 8-week and 6-month follow-ups , whereas control care partners reported worse caregiver burden by 6-month follow-up . CONCLUSIONS Memory support system training resulted in improvement in activities of daily living and sense of memory self-efficacy for individuals with MCI . Although activities of daily living benefits were maintained out to 8 weeks post intervention , future inclusion of booster sessions may help extend the therapeutic effect out even further . Improved mood of care partners of trained individuals and worsening sense of caregiver burden over time for partners of untrained individuals further support the efficacy of the MSS for MCI . Instructions: please extract entity words from the input sentence
[ "O", "O", "O", "O", "O", "B-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "O", "O", "O", "O", "B-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "O", "O", "O", "O", "B-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Physical", "I-Intervention_Physical", "I-Intervention_Physical", "I-Intervention_Physical", "I-Intervention_Physical", "O", "O", "B-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "O", "O", "O", "O", "B-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "O", "B-Participant_Sample-size", "O", "O", "B-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Mental", "I-Outcome_Mental", "O", "B-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Mental", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Mental", "I-Outcome_Mental", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]
The memory support system for mild cognitive impairment : randomized trial of a cognitive rehabilitation intervention . OBJECTIVE Individuals with amnestic mild cognitive impairment ( MCI ) have few empirically based treatment options for combating their memory loss . This study sought to examine the efficacy of a calendar/notebook rehabilitation intervention , the memory support system ( MSS ) , for individuals with amnestic MCI . METHODS Forty individuals with single domain amnestic MCI and their program partners were randomized to receive the MSS , either with training or without ( controls ) . Measures of adherence , activities of daily living , and emotional impact were completed at the first and last intervention sessions and again at 8 weeks and 6 months post intervention . RESULTS Training in use of a notebook/calendar system significantly improved adherence over those who received the calendars but no training . Functional ability and memory self-efficacy significantly improved for those who received MSS training . Change in functional ability remained significantly better in the intervention group than in the control group out to 8-week follow-up . Care partners in the intervention group demonstrated improved mood by 8-week and 6-month follow-ups , whereas control care partners reported worse caregiver burden by 6-month follow-up . CONCLUSIONS Memory support system training resulted in improvement in activities of daily living and sense of memory self-efficacy for individuals with MCI . Although activities of daily living benefits were maintained out to 8 weeks post intervention , future inclusion of booster sessions may help extend the therapeutic effect out even further . Improved mood of care partners of trained individuals and worsening sense of caregiver burden over time for partners of untrained individuals further support the efficacy of the MSS for MCI .
[ "The", "memory", "support", "system", "for", "mild", "cognitive", "impairment", ":", "randomized", "trial", "of", "a", "cognitive", "rehabilitation", "intervention", ".", "OBJECTIVE", "Individuals", "with", "amnestic", "mild", "cognitive", "impairment", "(", "MCI", ")", "have", "few", "empirically", "based", "treatment", "options", "for", "combating", "their", "memory", "loss", ".", "This", "study", "sought", "to", "examine", "the", "efficacy", "of", "a", "calendar", "/", "notebook", "rehabilitation", "intervention", ",", "the", "memory", "support", "system", "(", "MSS", ")", ",", "for", "individuals", "with", "amnestic", "MCI", ".", "METHODS", "Forty", "individuals", "with", "single", "domain", "amnestic", "MCI", "and", "their", "program", "partners", "were", "randomized", "to", "receive", "the", "MSS", ",", "either", "with", "training", "or", "without", "(", "controls", ")", ".", "Measures", "of", "adherence", ",", "activities", "of", "daily", "living", ",", "and", "emotional", "impact", "were", "completed", "at", "the", "first", "and", "last", "intervention", "sessions", "and", "again", "at", "8", "weeks", "and", "6", "months", "post", "intervention", ".", "RESULTS", "Training", "in", "use", "of", "a", "notebook", "/", "calendar", "system", "significantly", "improved", "adherence", "over", "those", "who", "received", "the", "calendars", "but", "no", "training", ".", "Functional", "ability", "and", "memory", "self", "-", "efficacy", "significantly", "improved", "for", "those", "who", "received", "MSS", "training", ".", "Change", "in", "functional", "ability", "remained", "significantly", "better", "in", "the", "intervention", "group", "than", "in", "the", "control", "group", "out", "to", "8-week", "follow", "-", "up", ".", "Care", "partners", "in", "the", "intervention", "group", "demonstrated", "improved", "mood", "by", "8-week", "and", "6-month", "follow", "-", "ups", ",", "whereas", "control", "care", "partners", "reported", "worse", "caregiver", "burden", "by", "6-month", "follow", "-", "up", ".", "CONCLUSIONS", "Memory", "support", "system", "training", "resulted", "in", "improvement", "in", "activities", "of", "daily", "living", "and", "sense", "of", "memory", "self", "-", "efficacy", "for", "individuals", "with", "MCI", ".", "Although", "activities", "of", "daily", "living", "benefits", "were", "maintained", "out", "to", "8", "weeks", "post", "intervention", ",", "future", "inclusion", "of", "booster", "sessions", "may", "help", "extend", "the", "therapeutic", "effect", "out", "even", "further", ".", "Improved", "mood", "of", "care", "partners", "of", "trained", "individuals", "and", "worsening", "sense", "of", "caregiver", "burden", "over", "time", "for", "partners", "of", "untrained", "individuals", "further", "support", "the", "efficacy", "of", "the", "MSS", "for", "MCI", "." ]
[ "Outcome_Mental", "Intervention_Physical", "Participant_Condition", "Intervention_Pharmacological", "Intervention_Educational", "Participant_Sample-size" ]
ASF / SF2 is a protein, purine - rich element is a DNA, 3'UTR is a RNA, PKCI - r mRNA is a RNA
1.0alpha7.train.426_task0
Sentence: ASF/SF2 binds a purine-rich element positioned within the 3'UTR of the mature PKCI-r mRNA. Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: DNA, RNA, protein
[ "B-protein", "I-protein", "I-protein", "O", "O", "O", "B-DNA", "I-DNA", "I-DNA", "I-DNA", "O", "O", "O", "O", "B-RNA", "O", "O", "O", "O", "B-RNA", "I-RNA", "I-RNA", "I-RNA", "O" ]
ASF/SF2 binds a purine-rich element positioned within the 3'UTR of the mature PKCI-r mRNA.
[ "ASF", "/", "SF2", "binds", "a", " ", "purine", "-", "rich", "element", "positioned", "within", "the", " ", "3'UTR", "of", "the", "mature", " ", "PKCI", "-", "r", "mRNA", "." ]
[ "DNA", "RNA", "protein" ]
ASF / SF2 is a protein, purine - rich element is a DNA, 3'UTR is a RNA, PKCI - r mRNA is a RNA
1.0alpha7.train.426_task1
Sentence: ASF/SF2 binds a purine-rich element positioned within the 3'UTR of the mature PKCI-r mRNA. Instructions: please typing these entity words according to sentence: ASF / SF2, purine - rich element, 3'UTR, PKCI - r mRNA Options: DNA, RNA, protein
[ "B-protein", "I-protein", "I-protein", "O", "O", "O", "B-DNA", "I-DNA", "I-DNA", "I-DNA", "O", "O", "O", "O", "B-RNA", "O", "O", "O", "O", "B-RNA", "I-RNA", "I-RNA", "I-RNA", "O" ]
ASF/SF2 binds a purine-rich element positioned within the 3'UTR of the mature PKCI-r mRNA.
[ "ASF", "/", "SF2", "binds", "a", " ", "purine", "-", "rich", "element", "positioned", "within", "the", " ", "3'UTR", "of", "the", "mature", " ", "PKCI", "-", "r", "mRNA", "." ]
[ "DNA", "RNA", "protein" ]
ASF / SF2, purine - rich element, 3'UTR, PKCI - r mRNA
1.0alpha7.train.426_task2
Sentence: ASF/SF2 binds a purine-rich element positioned within the 3'UTR of the mature PKCI-r mRNA. Instructions: please extract entity words from the input sentence
[ "B-protein", "I-protein", "I-protein", "O", "O", "O", "B-DNA", "I-DNA", "I-DNA", "I-DNA", "O", "O", "O", "O", "B-RNA", "O", "O", "O", "O", "B-RNA", "I-RNA", "I-RNA", "I-RNA", "O" ]
ASF/SF2 binds a purine-rich element positioned within the 3'UTR of the mature PKCI-r mRNA.
[ "ASF", "/", "SF2", "binds", "a", " ", "purine", "-", "rich", "element", "positioned", "within", "the", " ", "3'UTR", "of", "the", "mature", " ", "PKCI", "-", "r", "mRNA", "." ]
[ "DNA", "RNA", "protein" ]
Male is a Person, female is a Person, aged is a Person, = 18 to = 65 years is a Value, General good health is a Condition, established by medical history is a Qualifier, physical examination is a Procedure, Written informed consent is a Observation, Females of childbearing potential is a Scope, agree to use an efficacious hormonal or barrier method of birth control during the study . Abstinence is a Scope, Available for all visits is a Observation, scheduled in this study is a Qualifier
NCT02121145_inc_task0
Sentence: Male or female subjects aged =18 to =65 years General good health as established by medical history and physical examination Written informed consent Females of childbearing potential must agree to use an efficacious hormonal or barrier method of birth control during the study. Abstinence is acceptable. Available for all visits scheduled in this study. Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: Condition, Qualifier, Value, Person, Observation, Procedure, Scope
[ "B-Person", "O", "B-Person", "O", "B-Person", "B-Value", "I-Value", "I-Value", "I-Value", "I-Value", "I-Value", "O", "B-Condition", "I-Condition", "I-Condition", "O", "B-Qualifier", "I-Qualifier", "I-Qualifier", "I-Qualifier", "O", "B-Procedure", "I-Procedure", "O", "B-Observation", "I-Observation", "I-Observation", "O", "B-Scope", "I-Scope", "I-Scope", "I-Scope", "O", "B-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "O", "O", "O", "O", "B-Observation", "I-Observation", "I-Observation", "I-Observation", "B-Qualifier", "I-Qualifier", "I-Qualifier", "I-Qualifier", "O", "O" ]
Male or female subjects aged =18 to =65 years General good health as established by medical history and physical examination Written informed consent Females of childbearing potential must agree to use an efficacious hormonal or barrier method of birth control during the study. Abstinence is acceptable. Available for all visits scheduled in this study.
[ "Male", "or", "female", "subjects", "aged", "=", "18", "to", "=", "65", "years", "\n", "General", "good", "health", "as", "established", "by", "medical", "history", "and", "physical", "examination", "\n", "Written", "informed", "consent", "\n", "Females", "of", "childbearing", "potential", "must", "agree", "to", "use", "an", "efficacious", "hormonal", "or", "barrier", "method", "of", "birth", "control", "during", "the", "study", ".", "Abstinence", "is", "acceptable", ".", "\n", "Available", "for", "all", "visits", "scheduled", "in", "this", "study", ".", "\n" ]
[ "Scope", "Qualifier", "Observation", "Procedure", "Condition", "Value", "Temporal", "Mood", "Person" ]
Male is a Person, female is a Person, aged is a Person, = 18 to = 65 years is a Value, General good health is a Condition, established by medical history is a Qualifier, physical examination is a Procedure, Written informed consent is a Observation, Females of childbearing potential is a Scope, agree to use an efficacious hormonal or barrier method of birth control during the study . Abstinence is a Scope, Available for all visits is a Observation, scheduled in this study is a Qualifier
NCT02121145_inc_task1
Sentence: Male or female subjects aged =18 to =65 years General good health as established by medical history and physical examination Written informed consent Females of childbearing potential must agree to use an efficacious hormonal or barrier method of birth control during the study. Abstinence is acceptable. Available for all visits scheduled in this study. Instructions: please typing these entity words according to sentence: Male, female, aged, = 18 to = 65 years, General good health, established by medical history, physical examination, Written informed consent, Females of childbearing potential, agree to use an efficacious hormonal or barrier method of birth control during the study . Abstinence, Available for all visits, scheduled in this study Options: Condition, Qualifier, Value, Person, Observation, Procedure, Scope
[ "B-Person", "O", "B-Person", "O", "B-Person", "B-Value", "I-Value", "I-Value", "I-Value", "I-Value", "I-Value", "O", "B-Condition", "I-Condition", "I-Condition", "O", "B-Qualifier", "I-Qualifier", "I-Qualifier", "I-Qualifier", "O", "B-Procedure", "I-Procedure", "O", "B-Observation", "I-Observation", "I-Observation", "O", "B-Scope", "I-Scope", "I-Scope", "I-Scope", "O", "B-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "O", "O", "O", "O", "B-Observation", "I-Observation", "I-Observation", "I-Observation", "B-Qualifier", "I-Qualifier", "I-Qualifier", "I-Qualifier", "O", "O" ]
Male or female subjects aged =18 to =65 years General good health as established by medical history and physical examination Written informed consent Females of childbearing potential must agree to use an efficacious hormonal or barrier method of birth control during the study. Abstinence is acceptable. Available for all visits scheduled in this study.
[ "Male", "or", "female", "subjects", "aged", "=", "18", "to", "=", "65", "years", "\n", "General", "good", "health", "as", "established", "by", "medical", "history", "and", "physical", "examination", "\n", "Written", "informed", "consent", "\n", "Females", "of", "childbearing", "potential", "must", "agree", "to", "use", "an", "efficacious", "hormonal", "or", "barrier", "method", "of", "birth", "control", "during", "the", "study", ".", "Abstinence", "is", "acceptable", ".", "\n", "Available", "for", "all", "visits", "scheduled", "in", "this", "study", ".", "\n" ]
[ "Scope", "Qualifier", "Observation", "Procedure", "Condition", "Value", "Temporal", "Mood", "Person" ]
Male, female, aged, = 18 to = 65 years, General good health, established by medical history, physical examination, Written informed consent, Females of childbearing potential, agree to use an efficacious hormonal or barrier method of birth control during the study . Abstinence, Available for all visits, scheduled in this study
NCT02121145_inc_task2
Sentence: Male or female subjects aged =18 to =65 years General good health as established by medical history and physical examination Written informed consent Females of childbearing potential must agree to use an efficacious hormonal or barrier method of birth control during the study. Abstinence is acceptable. Available for all visits scheduled in this study. Instructions: please extract entity words from the input sentence
[ "B-Person", "O", "B-Person", "O", "B-Person", "B-Value", "I-Value", "I-Value", "I-Value", "I-Value", "I-Value", "O", "B-Condition", "I-Condition", "I-Condition", "O", "B-Qualifier", "I-Qualifier", "I-Qualifier", "I-Qualifier", "O", "B-Procedure", "I-Procedure", "O", "B-Observation", "I-Observation", "I-Observation", "O", "B-Scope", "I-Scope", "I-Scope", "I-Scope", "O", "B-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "O", "O", "O", "O", "B-Observation", "I-Observation", "I-Observation", "I-Observation", "B-Qualifier", "I-Qualifier", "I-Qualifier", "I-Qualifier", "O", "O" ]
Male or female subjects aged =18 to =65 years General good health as established by medical history and physical examination Written informed consent Females of childbearing potential must agree to use an efficacious hormonal or barrier method of birth control during the study. Abstinence is acceptable. Available for all visits scheduled in this study.
[ "Male", "or", "female", "subjects", "aged", "=", "18", "to", "=", "65", "years", "\n", "General", "good", "health", "as", "established", "by", "medical", "history", "and", "physical", "examination", "\n", "Written", "informed", "consent", "\n", "Females", "of", "childbearing", "potential", "must", "agree", "to", "use", "an", "efficacious", "hormonal", "or", "barrier", "method", "of", "birth", "control", "during", "the", "study", ".", "Abstinence", "is", "acceptable", ".", "\n", "Available", "for", "all", "visits", "scheduled", "in", "this", "study", ".", "\n" ]
[ "Scope", "Qualifier", "Observation", "Procedure", "Condition", "Value", "Temporal", "Mood", "Person" ]
Val158Met is a ProteinMutation
401_task0
Sentence: Catechol-O-methyltransferase (COMT) gene variants: possible association of the Val158Met variant with opiate addiction in Hispanic women. Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: ProteinMutation
[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-ProteinMutation", "O", "O", "O", "O", "O", "O", "O", "O" ]
Catechol-O-methyltransferase (COMT) gene variants: possible association of the Val158Met variant with opiate addiction in Hispanic women.
[ "Catechol", "-", "O", "-", "methyltransferase", "(", "COMT", ")", "gene", "variants", ":", "possible", "association", "of", "the", "Val158Met", "variant", "with", "opiate", "addiction", "in", "Hispanic", "women", "." ]
[ "ProteinMutation", "DNAMutation" ]
Val158Met is a ProteinMutation
401_task1
Sentence: Catechol-O-methyltransferase (COMT) gene variants: possible association of the Val158Met variant with opiate addiction in Hispanic women. Instructions: please typing these entity words according to sentence: Val158Met Options: ProteinMutation
[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-ProteinMutation", "O", "O", "O", "O", "O", "O", "O", "O" ]
Catechol-O-methyltransferase (COMT) gene variants: possible association of the Val158Met variant with opiate addiction in Hispanic women.
[ "Catechol", "-", "O", "-", "methyltransferase", "(", "COMT", ")", "gene", "variants", ":", "possible", "association", "of", "the", "Val158Met", "variant", "with", "opiate", "addiction", "in", "Hispanic", "women", "." ]
[ "ProteinMutation", "DNAMutation" ]
Val158Met
401_task2
Sentence: Catechol-O-methyltransferase (COMT) gene variants: possible association of the Val158Met variant with opiate addiction in Hispanic women. Instructions: please extract entity words from the input sentence
[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-ProteinMutation", "O", "O", "O", "O", "O", "O", "O", "O" ]
Catechol-O-methyltransferase (COMT) gene variants: possible association of the Val158Met variant with opiate addiction in Hispanic women.
[ "Catechol", "-", "O", "-", "methyltransferase", "(", "COMT", ")", "gene", "variants", ":", "possible", "association", "of", "the", "Val158Met", "variant", "with", "opiate", "addiction", "in", "Hispanic", "women", "." ]
[ "ProteinMutation", "DNAMutation" ]
Behandlung is an umlsterm, Techniken is an umlsterm, Behandlung is an umlsterm
DerGynaekologe.00330113.ger.abstr_task0
Sentence: Die urologische Strategie in der operativen Behandlung des andrologischen Faktors in der sterilen Partnerschaft erfolgt nach standardisierten Kriterien unter Einschluss modernster operativer Techniken . Die Ueberpruefung der Operationsergebnisse , auch unter dem Aspekt der Qualititaetskontrolle , ist z . T. realisiert , wird jedoch in der Zukunft einen wesentlichen Beitrag zur Verbesserung operativer Strategien in der Behandlung des andrologischen Sterilitaetsfaktors leisten . Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: umlsterm
[ "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O" ]
Die urologische Strategie in der operativen Behandlung des andrologischen Faktors in der sterilen Partnerschaft erfolgt nach standardisierten Kriterien unter Einschluss modernster operativer Techniken . Die Ueberpruefung der Operationsergebnisse , auch unter dem Aspekt der Qualititaetskontrolle , ist z . T. realisiert , wird jedoch in der Zukunft einen wesentlichen Beitrag zur Verbesserung operativer Strategien in der Behandlung des andrologischen Sterilitaetsfaktors leisten .
[ "Die", "urologische", "Strategie", "in", "der", "operativen", "Behandlung", "des", "andrologischen", "Faktors", "in", "der", "sterilen", "Partnerschaft", "erfolgt", "nach", "standardisierten", "Kriterien", "unter", "Einschluss", "modernster", "operativer", "Techniken", ".", "Die", "Ueberpruefung", "der", "Operationsergebnisse", ",", "auch", "unter", "dem", "Aspekt", "der", "Qualititaetskontrolle", ",", "ist", "z", ".", "T.", "realisiert", ",", "wird", "jedoch", "in", "der", "Zukunft", "einen", "wesentlichen", "Beitrag", "zur", "Verbesserung", "operativer", "Strategien", "in", "der", "Behandlung", "des", "andrologischen", "Sterilitaetsfaktors", "leisten", "." ]
[ "umlsterm" ]
Behandlung is an umlsterm, Techniken is an umlsterm, Behandlung is an umlsterm
DerGynaekologe.00330113.ger.abstr_task1
Sentence: Die urologische Strategie in der operativen Behandlung des andrologischen Faktors in der sterilen Partnerschaft erfolgt nach standardisierten Kriterien unter Einschluss modernster operativer Techniken . Die Ueberpruefung der Operationsergebnisse , auch unter dem Aspekt der Qualititaetskontrolle , ist z . T. realisiert , wird jedoch in der Zukunft einen wesentlichen Beitrag zur Verbesserung operativer Strategien in der Behandlung des andrologischen Sterilitaetsfaktors leisten . Instructions: please typing these entity words according to sentence: Behandlung, Techniken, Behandlung Options: umlsterm
[ "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O" ]
Die urologische Strategie in der operativen Behandlung des andrologischen Faktors in der sterilen Partnerschaft erfolgt nach standardisierten Kriterien unter Einschluss modernster operativer Techniken . Die Ueberpruefung der Operationsergebnisse , auch unter dem Aspekt der Qualititaetskontrolle , ist z . T. realisiert , wird jedoch in der Zukunft einen wesentlichen Beitrag zur Verbesserung operativer Strategien in der Behandlung des andrologischen Sterilitaetsfaktors leisten .
[ "Die", "urologische", "Strategie", "in", "der", "operativen", "Behandlung", "des", "andrologischen", "Faktors", "in", "der", "sterilen", "Partnerschaft", "erfolgt", "nach", "standardisierten", "Kriterien", "unter", "Einschluss", "modernster", "operativer", "Techniken", ".", "Die", "Ueberpruefung", "der", "Operationsergebnisse", ",", "auch", "unter", "dem", "Aspekt", "der", "Qualititaetskontrolle", ",", "ist", "z", ".", "T.", "realisiert", ",", "wird", "jedoch", "in", "der", "Zukunft", "einen", "wesentlichen", "Beitrag", "zur", "Verbesserung", "operativer", "Strategien", "in", "der", "Behandlung", "des", "andrologischen", "Sterilitaetsfaktors", "leisten", "." ]
[ "umlsterm" ]
Behandlung, Techniken, Behandlung
DerGynaekologe.00330113.ger.abstr_task2
Sentence: Die urologische Strategie in der operativen Behandlung des andrologischen Faktors in der sterilen Partnerschaft erfolgt nach standardisierten Kriterien unter Einschluss modernster operativer Techniken . Die Ueberpruefung der Operationsergebnisse , auch unter dem Aspekt der Qualititaetskontrolle , ist z . T. realisiert , wird jedoch in der Zukunft einen wesentlichen Beitrag zur Verbesserung operativer Strategien in der Behandlung des andrologischen Sterilitaetsfaktors leisten . Instructions: please extract entity words from the input sentence
[ "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O" ]
Die urologische Strategie in der operativen Behandlung des andrologischen Faktors in der sterilen Partnerschaft erfolgt nach standardisierten Kriterien unter Einschluss modernster operativer Techniken . Die Ueberpruefung der Operationsergebnisse , auch unter dem Aspekt der Qualititaetskontrolle , ist z . T. realisiert , wird jedoch in der Zukunft einen wesentlichen Beitrag zur Verbesserung operativer Strategien in der Behandlung des andrologischen Sterilitaetsfaktors leisten .
[ "Die", "urologische", "Strategie", "in", "der", "operativen", "Behandlung", "des", "andrologischen", "Faktors", "in", "der", "sterilen", "Partnerschaft", "erfolgt", "nach", "standardisierten", "Kriterien", "unter", "Einschluss", "modernster", "operativer", "Techniken", ".", "Die", "Ueberpruefung", "der", "Operationsergebnisse", ",", "auch", "unter", "dem", "Aspekt", "der", "Qualititaetskontrolle", ",", "ist", "z", ".", "T.", "realisiert", ",", "wird", "jedoch", "in", "der", "Zukunft", "einen", "wesentlichen", "Beitrag", "zur", "Verbesserung", "operativer", "Strategien", "in", "der", "Behandlung", "des", "andrologischen", "Sterilitaetsfaktors", "leisten", "." ]
[ "umlsterm" ]
treatment is an umlsterm, fractures is an umlsterm, humerus is an umlsterm, risk of is an umlsterm, necrosis is an umlsterm, methods is an umlsterm, methods is an umlsterm, fracture is an umlsterm, risk of is an umlsterm, rotator cuff is an umlsterm, patients is an umlsterm, fractures is an umlsterm, humerus is an umlsterm, October is an umlsterm, polydioxanone is an umlsterm, fractures is an umlsterm, head is an umlsterm, necrosis is an umlsterm, patients is an umlsterm, necrosis is an umlsterm, time is an umlsterm, procedure is an umlsterm, shoulder is an umlsterm, function is an umlsterm
DerUnfallchirurg.71000349.eng.abstr_task0
Sentence: The operative treatment of dislocated fractures of the proximal humerus has been evolving in recent years . Replacement using endoprostheses often results in only moderate functional outcome , and with the high risk of aseptic necrosis with ORIF , new methods of minimally invasive stabilisation have been developed . These methods reduce the opening of the fracture site to a minimum and thereby limit the risk of iatrogenic damage to local vascularity and the rotator cuff . This study reviewed 18 patients operated on with minimal osteosynthesis for dislocated four-part fractures of the proximal humerus from March 1991 to October 1994. Only tension band wiring with resorbable cords from woven polydioxanone was applied . After an average follow-up of 26 months ( 20 - 37 months ) , 72% ( n = 13 ) of the four-part fractures were rated as good and very good results according to the Neer Score . In 16.7% , a complete head necrosis occurred , requiring a prosthetic replacement . Two patients with partial necrosis ( 11.1% ) had a good functional outcome . With regard to these results , we recommend head-preserving tension band wiring with resorbable cords and preservation of the articular surface . At the present time the procedure seems comparable with prosthetic replacement in respect of shoulder function . Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: umlsterm
[ "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O" ]
The operative treatment of dislocated fractures of the proximal humerus has been evolving in recent years . Replacement using endoprostheses often results in only moderate functional outcome , and with the high risk of aseptic necrosis with ORIF , new methods of minimally invasive stabilisation have been developed . These methods reduce the opening of the fracture site to a minimum and thereby limit the risk of iatrogenic damage to local vascularity and the rotator cuff . This study reviewed 18 patients operated on with minimal osteosynthesis for dislocated four-part fractures of the proximal humerus from March 1991 to October 1994. Only tension band wiring with resorbable cords from woven polydioxanone was applied . After an average follow-up of 26 months ( 20 - 37 months ) , 72% ( n = 13 ) of the four-part fractures were rated as good and very good results according to the Neer Score . In 16.7% , a complete head necrosis occurred , requiring a prosthetic replacement . Two patients with partial necrosis ( 11.1% ) had a good functional outcome . With regard to these results , we recommend head-preserving tension band wiring with resorbable cords and preservation of the articular surface . At the present time the procedure seems comparable with prosthetic replacement in respect of shoulder function .
[ "The", "operative", "treatment", "of", "dislocated", "fractures", "of", "the", "proximal", "humerus", "has", "been", "evolving", "in", "recent", "years", ".", "Replacement", "using", "endoprostheses", "often", "results", "in", "only", "moderate", "functional", "outcome", ",", "and", "with", "the", "high", "risk", "of", "aseptic", "necrosis", "with", "ORIF", ",", "new", "methods", "of", "minimally", "invasive", "stabilisation", "have", "been", "developed", ".", "These", "methods", "reduce", "the", "opening", "of", "the", "fracture", "site", "to", "a", "minimum", "and", "thereby", "limit", "the", "risk", "of", "iatrogenic", "damage", "to", "local", "vascularity", "and", "the", "rotator", "cuff", ".", "This", "study", "reviewed", "18", "patients", "operated", "on", "with", "minimal", "osteosynthesis", "for", "dislocated", "four", "-", "part", "fractures", "of", "the", "proximal", "humerus", "from", "March", "1991", "to", "October", "1994", ".", "Only", "tension", "band", "wiring", "with", "resorbable", "cords", "from", "woven", "polydioxanone", "was", "applied", ".", "After", "an", "average", "follow", "-", "up", "of", "26", "months", "(", "20", "-", "37", "months", ")", ",", "72", "%", "(", "n", "=", "13", ")", "of", "the", "four", "-", "part", "fractures", "were", "rated", "as", "good", "and", "very", "good", "results", "according", "to", "the", "Neer", "Score", ".", "In", "16.7", "%", ",", "a", "complete", "head", "necrosis", "occurred", ",", "requiring", "a", "prosthetic", "replacement", ".", "Two", "patients", "with", "partial", "necrosis", "(", "11.1", "%", ")", "had", "a", "good", "functional", "outcome", ".", "With", "regard", "to", "these", "results", ",", "we", "recommend", "head", "-", "preserving", "tension", "band", "wiring", "with", "resorbable", "cords", "and", "preservation", "of", "the", "articular", "surface", ".", "At", "the", "present", "time", "the", "procedure", "seems", "comparable", "with", "prosthetic", "replacement", "in", "respect", "of", "shoulder", "function", "." ]
[ "umlsterm" ]
treatment is an umlsterm, fractures is an umlsterm, humerus is an umlsterm, risk of is an umlsterm, necrosis is an umlsterm, methods is an umlsterm, methods is an umlsterm, fracture is an umlsterm, risk of is an umlsterm, rotator cuff is an umlsterm, patients is an umlsterm, fractures is an umlsterm, humerus is an umlsterm, October is an umlsterm, polydioxanone is an umlsterm, fractures is an umlsterm, head is an umlsterm, necrosis is an umlsterm, patients is an umlsterm, necrosis is an umlsterm, time is an umlsterm, procedure is an umlsterm, shoulder is an umlsterm, function is an umlsterm
DerUnfallchirurg.71000349.eng.abstr_task1
Sentence: The operative treatment of dislocated fractures of the proximal humerus has been evolving in recent years . Replacement using endoprostheses often results in only moderate functional outcome , and with the high risk of aseptic necrosis with ORIF , new methods of minimally invasive stabilisation have been developed . These methods reduce the opening of the fracture site to a minimum and thereby limit the risk of iatrogenic damage to local vascularity and the rotator cuff . This study reviewed 18 patients operated on with minimal osteosynthesis for dislocated four-part fractures of the proximal humerus from March 1991 to October 1994. Only tension band wiring with resorbable cords from woven polydioxanone was applied . After an average follow-up of 26 months ( 20 - 37 months ) , 72% ( n = 13 ) of the four-part fractures were rated as good and very good results according to the Neer Score . In 16.7% , a complete head necrosis occurred , requiring a prosthetic replacement . Two patients with partial necrosis ( 11.1% ) had a good functional outcome . With regard to these results , we recommend head-preserving tension band wiring with resorbable cords and preservation of the articular surface . At the present time the procedure seems comparable with prosthetic replacement in respect of shoulder function . Instructions: please typing these entity words according to sentence: treatment, fractures, humerus, risk of, necrosis, methods, methods, fracture, risk of, rotator cuff, patients, fractures, humerus, October, polydioxanone, fractures, head, necrosis, patients, necrosis, time, procedure, shoulder, function Options: umlsterm
[ "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O" ]
The operative treatment of dislocated fractures of the proximal humerus has been evolving in recent years . Replacement using endoprostheses often results in only moderate functional outcome , and with the high risk of aseptic necrosis with ORIF , new methods of minimally invasive stabilisation have been developed . These methods reduce the opening of the fracture site to a minimum and thereby limit the risk of iatrogenic damage to local vascularity and the rotator cuff . This study reviewed 18 patients operated on with minimal osteosynthesis for dislocated four-part fractures of the proximal humerus from March 1991 to October 1994. Only tension band wiring with resorbable cords from woven polydioxanone was applied . After an average follow-up of 26 months ( 20 - 37 months ) , 72% ( n = 13 ) of the four-part fractures were rated as good and very good results according to the Neer Score . In 16.7% , a complete head necrosis occurred , requiring a prosthetic replacement . Two patients with partial necrosis ( 11.1% ) had a good functional outcome . With regard to these results , we recommend head-preserving tension band wiring with resorbable cords and preservation of the articular surface . At the present time the procedure seems comparable with prosthetic replacement in respect of shoulder function .
[ "The", "operative", "treatment", "of", "dislocated", "fractures", "of", "the", "proximal", "humerus", "has", "been", "evolving", "in", "recent", "years", ".", "Replacement", "using", "endoprostheses", "often", "results", "in", "only", "moderate", "functional", "outcome", ",", "and", "with", "the", "high", "risk", "of", "aseptic", "necrosis", "with", "ORIF", ",", "new", "methods", "of", "minimally", "invasive", "stabilisation", "have", "been", "developed", ".", "These", "methods", "reduce", "the", "opening", "of", "the", "fracture", "site", "to", "a", "minimum", "and", "thereby", "limit", "the", "risk", "of", "iatrogenic", "damage", "to", "local", "vascularity", "and", "the", "rotator", "cuff", ".", "This", "study", "reviewed", "18", "patients", "operated", "on", "with", "minimal", "osteosynthesis", "for", "dislocated", "four", "-", "part", "fractures", "of", "the", "proximal", "humerus", "from", "March", "1991", "to", "October", "1994", ".", "Only", "tension", "band", "wiring", "with", "resorbable", "cords", "from", "woven", "polydioxanone", "was", "applied", ".", "After", "an", "average", "follow", "-", "up", "of", "26", "months", "(", "20", "-", "37", "months", ")", ",", "72", "%", "(", "n", "=", "13", ")", "of", "the", "four", "-", "part", "fractures", "were", "rated", "as", "good", "and", "very", "good", "results", "according", "to", "the", "Neer", "Score", ".", "In", "16.7", "%", ",", "a", "complete", "head", "necrosis", "occurred", ",", "requiring", "a", "prosthetic", "replacement", ".", "Two", "patients", "with", "partial", "necrosis", "(", "11.1", "%", ")", "had", "a", "good", "functional", "outcome", ".", "With", "regard", "to", "these", "results", ",", "we", "recommend", "head", "-", "preserving", "tension", "band", "wiring", "with", "resorbable", "cords", "and", "preservation", "of", "the", "articular", "surface", ".", "At", "the", "present", "time", "the", "procedure", "seems", "comparable", "with", "prosthetic", "replacement", "in", "respect", "of", "shoulder", "function", "." ]
[ "umlsterm" ]
treatment, fractures, humerus, risk of, necrosis, methods, methods, fracture, risk of, rotator cuff, patients, fractures, humerus, October, polydioxanone, fractures, head, necrosis, patients, necrosis, time, procedure, shoulder, function
DerUnfallchirurg.71000349.eng.abstr_task2
Sentence: The operative treatment of dislocated fractures of the proximal humerus has been evolving in recent years . Replacement using endoprostheses often results in only moderate functional outcome , and with the high risk of aseptic necrosis with ORIF , new methods of minimally invasive stabilisation have been developed . These methods reduce the opening of the fracture site to a minimum and thereby limit the risk of iatrogenic damage to local vascularity and the rotator cuff . This study reviewed 18 patients operated on with minimal osteosynthesis for dislocated four-part fractures of the proximal humerus from March 1991 to October 1994. Only tension band wiring with resorbable cords from woven polydioxanone was applied . After an average follow-up of 26 months ( 20 - 37 months ) , 72% ( n = 13 ) of the four-part fractures were rated as good and very good results according to the Neer Score . In 16.7% , a complete head necrosis occurred , requiring a prosthetic replacement . Two patients with partial necrosis ( 11.1% ) had a good functional outcome . With regard to these results , we recommend head-preserving tension band wiring with resorbable cords and preservation of the articular surface . At the present time the procedure seems comparable with prosthetic replacement in respect of shoulder function . Instructions: please extract entity words from the input sentence
[ "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O" ]
The operative treatment of dislocated fractures of the proximal humerus has been evolving in recent years . Replacement using endoprostheses often results in only moderate functional outcome , and with the high risk of aseptic necrosis with ORIF , new methods of minimally invasive stabilisation have been developed . These methods reduce the opening of the fracture site to a minimum and thereby limit the risk of iatrogenic damage to local vascularity and the rotator cuff . This study reviewed 18 patients operated on with minimal osteosynthesis for dislocated four-part fractures of the proximal humerus from March 1991 to October 1994. Only tension band wiring with resorbable cords from woven polydioxanone was applied . After an average follow-up of 26 months ( 20 - 37 months ) , 72% ( n = 13 ) of the four-part fractures were rated as good and very good results according to the Neer Score . In 16.7% , a complete head necrosis occurred , requiring a prosthetic replacement . Two patients with partial necrosis ( 11.1% ) had a good functional outcome . With regard to these results , we recommend head-preserving tension band wiring with resorbable cords and preservation of the articular surface . At the present time the procedure seems comparable with prosthetic replacement in respect of shoulder function .
[ "The", "operative", "treatment", "of", "dislocated", "fractures", "of", "the", "proximal", "humerus", "has", "been", "evolving", "in", "recent", "years", ".", "Replacement", "using", "endoprostheses", "often", "results", "in", "only", "moderate", "functional", "outcome", ",", "and", "with", "the", "high", "risk", "of", "aseptic", "necrosis", "with", "ORIF", ",", "new", "methods", "of", "minimally", "invasive", "stabilisation", "have", "been", "developed", ".", "These", "methods", "reduce", "the", "opening", "of", "the", "fracture", "site", "to", "a", "minimum", "and", "thereby", "limit", "the", "risk", "of", "iatrogenic", "damage", "to", "local", "vascularity", "and", "the", "rotator", "cuff", ".", "This", "study", "reviewed", "18", "patients", "operated", "on", "with", "minimal", "osteosynthesis", "for", "dislocated", "four", "-", "part", "fractures", "of", "the", "proximal", "humerus", "from", "March", "1991", "to", "October", "1994", ".", "Only", "tension", "band", "wiring", "with", "resorbable", "cords", "from", "woven", "polydioxanone", "was", "applied", ".", "After", "an", "average", "follow", "-", "up", "of", "26", "months", "(", "20", "-", "37", "months", ")", ",", "72", "%", "(", "n", "=", "13", ")", "of", "the", "four", "-", "part", "fractures", "were", "rated", "as", "good", "and", "very", "good", "results", "according", "to", "the", "Neer", "Score", ".", "In", "16.7", "%", ",", "a", "complete", "head", "necrosis", "occurred", ",", "requiring", "a", "prosthetic", "replacement", ".", "Two", "patients", "with", "partial", "necrosis", "(", "11.1", "%", ")", "had", "a", "good", "functional", "outcome", ".", "With", "regard", "to", "these", "results", ",", "we", "recommend", "head", "-", "preserving", "tension", "band", "wiring", "with", "resorbable", "cords", "and", "preservation", "of", "the", "articular", "surface", ".", "At", "the", "present", "time", "the", "procedure", "seems", "comparable", "with", "prosthetic", "replacement", "in", "respect", "of", "shoulder", "function", "." ]
[ "umlsterm" ]
group - B streptococci is a Participant_Condition, preterm labour is a Outcome_Physical, pregnant is a Participant_Condition, women is a Participant_Sex, 4122 is a Participant_Sample-size, 69 is a Participant_Sample-size, penicillin is a Intervention_Pharmacological, placebo is a Intervention_Control, primary rupture of the membranes is a Outcome_Physical, frequency of preterm labour is a Outcome_Physical
73995_task0
Sentence: Antibiotic elimination of group-B streptococci in urine in prevention of preterm labour . The presence of group-B streptococci in the urine of pregnant women seems to be associated with preterm labour . Urine samples from 4122 women at 27-31 weeks ' gestation were examined for bacteria . Group-B streptococci were found in the urine of 69 women . In a double-blind , controlled study these patients were given either penicillin ( 10 ( 6 ) IU three times daily for 6 days ; 37 patients ) or placebo ( 32 patients ) . The rates of primary rupture of the membranes ( 11 % v 53 % ; p less than 0.001 ) and preterm labour ( 5.4 % v 38 % ; p less than 0.002 ) were significantly lower in the penicillin group than in the placebo group . These results suggest that treatment and follow-up to prevent recolonisation in pregnant women with group-B streptococci in the urine may reduce the frequency of preterm labour in these patients . Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: Intervention_Pharmacological, Participant_Sex, Participant_Condition, Intervention_Control, Outcome_Physical, Participant_Sample-size
[ "O", "O", "O", "B-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Participant_Condition", "B-Participant_Sex", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Participant_Sample-size", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Participant_Sample-size", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Pharmacological", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Control", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O" ]
Antibiotic elimination of group-B streptococci in urine in prevention of preterm labour . The presence of group-B streptococci in the urine of pregnant women seems to be associated with preterm labour . Urine samples from 4122 women at 27-31 weeks ' gestation were examined for bacteria . Group-B streptococci were found in the urine of 69 women . In a double-blind , controlled study these patients were given either penicillin ( 10 ( 6 ) IU three times daily for 6 days ; 37 patients ) or placebo ( 32 patients ) . The rates of primary rupture of the membranes ( 11 % v 53 % ; p less than 0.001 ) and preterm labour ( 5.4 % v 38 % ; p less than 0.002 ) were significantly lower in the penicillin group than in the placebo group . These results suggest that treatment and follow-up to prevent recolonisation in pregnant women with group-B streptococci in the urine may reduce the frequency of preterm labour in these patients .
[ "Antibiotic", "elimination", "of", "group", "-", "B", "streptococci", "in", "urine", "in", "prevention", "of", "preterm", "labour", ".", "The", "presence", "of", "group", "-", "B", "streptococci", "in", "the", "urine", "of", "pregnant", "women", "seems", "to", "be", "associated", "with", "preterm", "labour", ".", "Urine", "samples", "from", "4122", "women", "at", "27", "-", "31", "weeks", "'", "gestation", "were", "examined", "for", "bacteria", ".", "Group", "-", "B", "streptococci", "were", "found", "in", "the", "urine", "of", "69", "women", ".", "In", "a", "double", "-", "blind", ",", "controlled", "study", "these", "patients", "were", "given", "either", "penicillin", "(", "10", "(", "6", ")", "IU", "three", "times", "daily", "for", "6", "days", ";", "37", "patients", ")", "or", "placebo", "(", "32", "patients", ")", ".", "The", "rates", "of", "primary", "rupture", "of", "the", "membranes", "(", "11", "%", "v", "53", "%", ";", "p", "less", "than", "0.001", ")", "and", "preterm", "labour", "(", "5.4", "%", "v", "38", "%", ";", "p", "less", "than", "0.002", ")", "were", "significantly", "lower", "in", "the", "penicillin", "group", "than", "in", "the", "placebo", "group", ".", "These", "results", "suggest", "that", "treatment", "and", "follow", "-", "up", "to", "prevent", "recolonisation", "in", "pregnant", "women", "with", "group", "-", "B", "streptococci", "in", "the", "urine", "may", "reduce", "the", "frequency", "of", "preterm", "labour", "in", "these", "patients", "." ]
[ "Outcome_Physical", "Participant_Condition", "Intervention_Pharmacological", "Intervention_Control", "Participant_Sex", "Participant_Sample-size" ]
group - B streptococci is a Participant_Condition, preterm labour is a Outcome_Physical, pregnant is a Participant_Condition, women is a Participant_Sex, 4122 is a Participant_Sample-size, 69 is a Participant_Sample-size, penicillin is a Intervention_Pharmacological, placebo is a Intervention_Control, primary rupture of the membranes is a Outcome_Physical, frequency of preterm labour is a Outcome_Physical
73995_task1
Sentence: Antibiotic elimination of group-B streptococci in urine in prevention of preterm labour . The presence of group-B streptococci in the urine of pregnant women seems to be associated with preterm labour . Urine samples from 4122 women at 27-31 weeks ' gestation were examined for bacteria . Group-B streptococci were found in the urine of 69 women . In a double-blind , controlled study these patients were given either penicillin ( 10 ( 6 ) IU three times daily for 6 days ; 37 patients ) or placebo ( 32 patients ) . The rates of primary rupture of the membranes ( 11 % v 53 % ; p less than 0.001 ) and preterm labour ( 5.4 % v 38 % ; p less than 0.002 ) were significantly lower in the penicillin group than in the placebo group . These results suggest that treatment and follow-up to prevent recolonisation in pregnant women with group-B streptococci in the urine may reduce the frequency of preterm labour in these patients . Instructions: please typing these entity words according to sentence: group - B streptococci, preterm labour, pregnant, women, 4122, 69, penicillin, placebo, primary rupture of the membranes, frequency of preterm labour Options: Intervention_Pharmacological, Participant_Sex, Participant_Condition, Intervention_Control, Outcome_Physical, Participant_Sample-size
[ "O", "O", "O", "B-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Participant_Condition", "B-Participant_Sex", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Participant_Sample-size", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Participant_Sample-size", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Pharmacological", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Control", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O" ]
Antibiotic elimination of group-B streptococci in urine in prevention of preterm labour . The presence of group-B streptococci in the urine of pregnant women seems to be associated with preterm labour . Urine samples from 4122 women at 27-31 weeks ' gestation were examined for bacteria . Group-B streptococci were found in the urine of 69 women . In a double-blind , controlled study these patients were given either penicillin ( 10 ( 6 ) IU three times daily for 6 days ; 37 patients ) or placebo ( 32 patients ) . The rates of primary rupture of the membranes ( 11 % v 53 % ; p less than 0.001 ) and preterm labour ( 5.4 % v 38 % ; p less than 0.002 ) were significantly lower in the penicillin group than in the placebo group . These results suggest that treatment and follow-up to prevent recolonisation in pregnant women with group-B streptococci in the urine may reduce the frequency of preterm labour in these patients .
[ "Antibiotic", "elimination", "of", "group", "-", "B", "streptococci", "in", "urine", "in", "prevention", "of", "preterm", "labour", ".", "The", "presence", "of", "group", "-", "B", "streptococci", "in", "the", "urine", "of", "pregnant", "women", "seems", "to", "be", "associated", "with", "preterm", "labour", ".", "Urine", "samples", "from", "4122", "women", "at", "27", "-", "31", "weeks", "'", "gestation", "were", "examined", "for", "bacteria", ".", "Group", "-", "B", "streptococci", "were", "found", "in", "the", "urine", "of", "69", "women", ".", "In", "a", "double", "-", "blind", ",", "controlled", "study", "these", "patients", "were", "given", "either", "penicillin", "(", "10", "(", "6", ")", "IU", "three", "times", "daily", "for", "6", "days", ";", "37", "patients", ")", "or", "placebo", "(", "32", "patients", ")", ".", "The", "rates", "of", "primary", "rupture", "of", "the", "membranes", "(", "11", "%", "v", "53", "%", ";", "p", "less", "than", "0.001", ")", "and", "preterm", "labour", "(", "5.4", "%", "v", "38", "%", ";", "p", "less", "than", "0.002", ")", "were", "significantly", "lower", "in", "the", "penicillin", "group", "than", "in", "the", "placebo", "group", ".", "These", "results", "suggest", "that", "treatment", "and", "follow", "-", "up", "to", "prevent", "recolonisation", "in", "pregnant", "women", "with", "group", "-", "B", "streptococci", "in", "the", "urine", "may", "reduce", "the", "frequency", "of", "preterm", "labour", "in", "these", "patients", "." ]
[ "Outcome_Physical", "Participant_Condition", "Intervention_Pharmacological", "Intervention_Control", "Participant_Sex", "Participant_Sample-size" ]
group - B streptococci, preterm labour, pregnant, women, 4122, 69, penicillin, placebo, primary rupture of the membranes, frequency of preterm labour
73995_task2
Sentence: Antibiotic elimination of group-B streptococci in urine in prevention of preterm labour . The presence of group-B streptococci in the urine of pregnant women seems to be associated with preterm labour . Urine samples from 4122 women at 27-31 weeks ' gestation were examined for bacteria . Group-B streptococci were found in the urine of 69 women . In a double-blind , controlled study these patients were given either penicillin ( 10 ( 6 ) IU three times daily for 6 days ; 37 patients ) or placebo ( 32 patients ) . The rates of primary rupture of the membranes ( 11 % v 53 % ; p less than 0.001 ) and preterm labour ( 5.4 % v 38 % ; p less than 0.002 ) were significantly lower in the penicillin group than in the placebo group . These results suggest that treatment and follow-up to prevent recolonisation in pregnant women with group-B streptococci in the urine may reduce the frequency of preterm labour in these patients . Instructions: please extract entity words from the input sentence
[ "O", "O", "O", "B-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Participant_Condition", "B-Participant_Sex", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Participant_Sample-size", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Participant_Sample-size", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Pharmacological", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Control", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O" ]
Antibiotic elimination of group-B streptococci in urine in prevention of preterm labour . The presence of group-B streptococci in the urine of pregnant women seems to be associated with preterm labour . Urine samples from 4122 women at 27-31 weeks ' gestation were examined for bacteria . Group-B streptococci were found in the urine of 69 women . In a double-blind , controlled study these patients were given either penicillin ( 10 ( 6 ) IU three times daily for 6 days ; 37 patients ) or placebo ( 32 patients ) . The rates of primary rupture of the membranes ( 11 % v 53 % ; p less than 0.001 ) and preterm labour ( 5.4 % v 38 % ; p less than 0.002 ) were significantly lower in the penicillin group than in the placebo group . These results suggest that treatment and follow-up to prevent recolonisation in pregnant women with group-B streptococci in the urine may reduce the frequency of preterm labour in these patients .
[ "Antibiotic", "elimination", "of", "group", "-", "B", "streptococci", "in", "urine", "in", "prevention", "of", "preterm", "labour", ".", "The", "presence", "of", "group", "-", "B", "streptococci", "in", "the", "urine", "of", "pregnant", "women", "seems", "to", "be", "associated", "with", "preterm", "labour", ".", "Urine", "samples", "from", "4122", "women", "at", "27", "-", "31", "weeks", "'", "gestation", "were", "examined", "for", "bacteria", ".", "Group", "-", "B", "streptococci", "were", "found", "in", "the", "urine", "of", "69", "women", ".", "In", "a", "double", "-", "blind", ",", "controlled", "study", "these", "patients", "were", "given", "either", "penicillin", "(", "10", "(", "6", ")", "IU", "three", "times", "daily", "for", "6", "days", ";", "37", "patients", ")", "or", "placebo", "(", "32", "patients", ")", ".", "The", "rates", "of", "primary", "rupture", "of", "the", "membranes", "(", "11", "%", "v", "53", "%", ";", "p", "less", "than", "0.001", ")", "and", "preterm", "labour", "(", "5.4", "%", "v", "38", "%", ";", "p", "less", "than", "0.002", ")", "were", "significantly", "lower", "in", "the", "penicillin", "group", "than", "in", "the", "placebo", "group", ".", "These", "results", "suggest", "that", "treatment", "and", "follow", "-", "up", "to", "prevent", "recolonisation", "in", "pregnant", "women", "with", "group", "-", "B", "streptococci", "in", "the", "urine", "may", "reduce", "the", "frequency", "of", "preterm", "labour", "in", "these", "patients", "." ]
[ "Outcome_Physical", "Participant_Condition", "Intervention_Pharmacological", "Intervention_Control", "Participant_Sex", "Participant_Sample-size" ]
peptidase is a GENE-N
23345168_task0
Sentence: Blocking the proliferation of human tumor cell lines by peptidase inhibitors from Bauhinia seeds. Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: GENE-N
[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-GENE-N", "O", "O", "O", "O", "O" ]
Blocking the proliferation of human tumor cell lines by peptidase inhibitors from Bauhinia seeds.
[ "Blocking", "the", "proliferation", "of", "human", "tumor", "cell", "lines", "by", "peptidase", "inhibitors", "from", "Bauhinia", "seeds", "." ]
[ "GENE-N", "GENE-Y", "CHEMICAL" ]
peptidase is a GENE-N
23345168_task1
Sentence: Blocking the proliferation of human tumor cell lines by peptidase inhibitors from Bauhinia seeds. Instructions: please typing these entity words according to sentence: peptidase Options: GENE-N
[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-GENE-N", "O", "O", "O", "O", "O" ]
Blocking the proliferation of human tumor cell lines by peptidase inhibitors from Bauhinia seeds.
[ "Blocking", "the", "proliferation", "of", "human", "tumor", "cell", "lines", "by", "peptidase", "inhibitors", "from", "Bauhinia", "seeds", "." ]
[ "GENE-N", "GENE-Y", "CHEMICAL" ]
peptidase
23345168_task2
Sentence: Blocking the proliferation of human tumor cell lines by peptidase inhibitors from Bauhinia seeds. Instructions: please extract entity words from the input sentence
[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-GENE-N", "O", "O", "O", "O", "O" ]
Blocking the proliferation of human tumor cell lines by peptidase inhibitors from Bauhinia seeds.
[ "Blocking", "the", "proliferation", "of", "human", "tumor", "cell", "lines", "by", "peptidase", "inhibitors", "from", "Bauhinia", "seeds", "." ]
[ "GENE-N", "GENE-Y", "CHEMICAL" ]
Adhaesionen is an umlsterm, Hernien is an umlsterm, Duenndarms is an umlsterm
DerChirurg.00710466.ger.abstr_task0
Sentence: Zusammenfassung . Die haeufigsten Ursachen fuer einen mechanischen Duenndarmileus sind Folgen von intraabdominalen Adhaesionen und Incarcerationen in extraabdominalen Hernien . Ein Fall einer seltenen Hernierung des Duenndarms durch eine kongenitale Oeffnung im Ligamentum falciforme wird praesentiert . Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: umlsterm
[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]
Zusammenfassung . Die haeufigsten Ursachen fuer einen mechanischen Duenndarmileus sind Folgen von intraabdominalen Adhaesionen und Incarcerationen in extraabdominalen Hernien . Ein Fall einer seltenen Hernierung des Duenndarms durch eine kongenitale Oeffnung im Ligamentum falciforme wird praesentiert .
[ "Zusammenfassung", ".", "Die", "haeufigsten", "Ursachen", "fuer", "einen", "mechanischen", "Duenndarmileus", "sind", "Folgen", "von", "intraabdominalen", "Adhaesionen", "und", "Incarcerationen", "in", "extraabdominalen", "Hernien", ".", "Ein", "Fall", "einer", "seltenen", "Hernierung", "des", "Duenndarms", "durch", "eine", "kongenitale", "Oeffnung", "im", "Ligamentum", "falciforme", "wird", "praesentiert", "." ]
[ "umlsterm" ]
Adhaesionen is an umlsterm, Hernien is an umlsterm, Duenndarms is an umlsterm
DerChirurg.00710466.ger.abstr_task1
Sentence: Zusammenfassung . Die haeufigsten Ursachen fuer einen mechanischen Duenndarmileus sind Folgen von intraabdominalen Adhaesionen und Incarcerationen in extraabdominalen Hernien . Ein Fall einer seltenen Hernierung des Duenndarms durch eine kongenitale Oeffnung im Ligamentum falciforme wird praesentiert . Instructions: please typing these entity words according to sentence: Adhaesionen, Hernien, Duenndarms Options: umlsterm
[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]
Zusammenfassung . Die haeufigsten Ursachen fuer einen mechanischen Duenndarmileus sind Folgen von intraabdominalen Adhaesionen und Incarcerationen in extraabdominalen Hernien . Ein Fall einer seltenen Hernierung des Duenndarms durch eine kongenitale Oeffnung im Ligamentum falciforme wird praesentiert .
[ "Zusammenfassung", ".", "Die", "haeufigsten", "Ursachen", "fuer", "einen", "mechanischen", "Duenndarmileus", "sind", "Folgen", "von", "intraabdominalen", "Adhaesionen", "und", "Incarcerationen", "in", "extraabdominalen", "Hernien", ".", "Ein", "Fall", "einer", "seltenen", "Hernierung", "des", "Duenndarms", "durch", "eine", "kongenitale", "Oeffnung", "im", "Ligamentum", "falciforme", "wird", "praesentiert", "." ]
[ "umlsterm" ]
Adhaesionen, Hernien, Duenndarms
DerChirurg.00710466.ger.abstr_task2
Sentence: Zusammenfassung . Die haeufigsten Ursachen fuer einen mechanischen Duenndarmileus sind Folgen von intraabdominalen Adhaesionen und Incarcerationen in extraabdominalen Hernien . Ein Fall einer seltenen Hernierung des Duenndarms durch eine kongenitale Oeffnung im Ligamentum falciforme wird praesentiert . Instructions: please extract entity words from the input sentence
[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]
Zusammenfassung . Die haeufigsten Ursachen fuer einen mechanischen Duenndarmileus sind Folgen von intraabdominalen Adhaesionen und Incarcerationen in extraabdominalen Hernien . Ein Fall einer seltenen Hernierung des Duenndarms durch eine kongenitale Oeffnung im Ligamentum falciforme wird praesentiert .
[ "Zusammenfassung", ".", "Die", "haeufigsten", "Ursachen", "fuer", "einen", "mechanischen", "Duenndarmileus", "sind", "Folgen", "von", "intraabdominalen", "Adhaesionen", "und", "Incarcerationen", "in", "extraabdominalen", "Hernien", ".", "Ein", "Fall", "einer", "seltenen", "Hernierung", "des", "Duenndarms", "durch", "eine", "kongenitale", "Oeffnung", "im", "Ligamentum", "falciforme", "wird", "praesentiert", "." ]
[ "umlsterm" ]
IDUA is a Gene, Gly409 - ->Arg is a SNP, Tyr64 - ->Ter is a SNP, Gln310 - ->Ter is a SNP, Thr366 - ->Pro is a SNP, Thr366 - ->Pro is a SNP, Gly409 - ->Arg is a SNP, Tyr64 - ->Ter is a SNP, Gln310 - ->Ter is a SNP, IDUA is a Gene
372_task0
Sentence: Molecular analysis of Hurler syndrome in Druze and Muslim Arab patients in Israel: multiple allelic mutations of the IDUA gene in a small geographic area. The mutations underlying Hurler syndrome (mucopolysaccharidosis IH) in Druze and Muslim Israeli Arab patients have been characterized. Four alleles were identified, using a combination of (a) PCR amplification of reverse-transcribed RNA or genomic DNA segments, (b) cycle sequencing of PCR products, and (c) restriction-enzyme analysis. One allele has two amino acid substitutions, Gly409-->Arg in exon 9 and Ter-->Cys in exon 14. The other three alleles have mutations in exon 2 (Tyr64-->Ter), exon 7 (Gln310-->Ter), or exon 8 (Thr366-->Pro). Transfection of mutagenized cDNAs into Cos-1 cells showed that two missense mutations, Thr366-->Pro and Ter-->Cys, permitted the expression of only trace amounts of alpha-L-iduronidase activity, whereas Gly409-->Arg permitted the expression of 60% as much enzyme as did the normal cDNA. The nonsense mutations were associated with abnormalities of RNA processing: (1) both a very low level of mRNA and skipping of exon 2 for Tyr64-->Ter and (2) utilization of a cryptic splice site for Gln310-->Ter. In all instances, the probands were found homozygous, and the parents heterozygous, for the mutant alleles, as anticipated from the consanguinity in each family. The two-mutation allele was identified in a family from Gaza; the other three alleles were found in seven families, five of them Druze, residing in a very small area of northern Israel. Since such clustering suggests a classic founder effect, the presence of three mutant alleles of the IDUA gene was unexpected. Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: Gene, SNP
[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Gene", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-SNP", "I-SNP", "I-SNP", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-SNP", "I-SNP", "I-SNP", "O", "O", "O", "O", "O", "B-SNP", "I-SNP", "I-SNP", "O", "O", "O", "O", "O", "O", "B-SNP", "I-SNP", "I-SNP", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-SNP", "I-SNP", "I-SNP", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-SNP", "I-SNP", "I-SNP", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-SNP", "I-SNP", "I-SNP", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-SNP", "I-SNP", "I-SNP", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Gene", "O", "O", "O", "O", "O" ]
Molecular analysis of Hurler syndrome in Druze and Muslim Arab patients in Israel: multiple allelic mutations of the IDUA gene in a small geographic area. The mutations underlying Hurler syndrome (mucopolysaccharidosis IH) in Druze and Muslim Israeli Arab patients have been characterized. Four alleles were identified, using a combination of (a) PCR amplification of reverse-transcribed RNA or genomic DNA segments, (b) cycle sequencing of PCR products, and (c) restriction-enzyme analysis. One allele has two amino acid substitutions, Gly409-->Arg in exon 9 and Ter-->Cys in exon 14. The other three alleles have mutations in exon 2 (Tyr64-->Ter), exon 7 (Gln310-->Ter), or exon 8 (Thr366-->Pro). Transfection of mutagenized cDNAs into Cos-1 cells showed that two missense mutations, Thr366-->Pro and Ter-->Cys, permitted the expression of only trace amounts of alpha-L-iduronidase activity, whereas Gly409-->Arg permitted the expression of 60% as much enzyme as did the normal cDNA. The nonsense mutations were associated with abnormalities of RNA processing: (1) both a very low level of mRNA and skipping of exon 2 for Tyr64-->Ter and (2) utilization of a cryptic splice site for Gln310-->Ter. In all instances, the probands were found homozygous, and the parents heterozygous, for the mutant alleles, as anticipated from the consanguinity in each family. The two-mutation allele was identified in a family from Gaza; the other three alleles were found in seven families, five of them Druze, residing in a very small area of northern Israel. Since such clustering suggests a classic founder effect, the presence of three mutant alleles of the IDUA gene was unexpected.
[ "Molecular", "analysis", "of", "Hurler", "syndrome", "in", "Druze", "and", "Muslim", "Arab", "patients", "in", "Israel", ":", "multiple", "allelic", "mutations", "of", "the", "IDUA", "gene", "in", "a", "small", "geographic", "area", ".", "The", "mutations", "underlying", "Hurler", "syndrome", "(", "mucopolysaccharidosis", "IH", ")", "in", "Druze", "and", "Muslim", "Israeli", "Arab", "patients", "have", "been", "characterized", ".", "Four", "alleles", "were", "identified", ",", "using", "a", "combination", "of", "(", "a", ")", "PCR", "amplification", "of", "reverse", "-", "transcribed", "RNA", "or", "genomic", "DNA", "segments", ",", "(", "b", ")", "cycle", "sequencing", "of", "PCR", "products", ",", "and", "(", "c", ")", "restriction", "-", "enzyme", "analysis", ".", "One", "allele", "has", "two", "amino", "acid", "substitutions", ",", "Gly409", "-", "->Arg", "in", "exon", "9", "and", "Ter-->Cys", "in", "exon", "14", ".", "The", "other", "three", "alleles", "have", "mutations", "in", "exon", "2", "(", "Tyr64", "-", "->Ter", ")", ",", "exon", "7", "(", "Gln310", "-", "->Ter", ")", ",", "or", "exon", "8", "(", "Thr366", "-", "->Pro", ")", ".", "Transfection", "of", "mutagenized", "cDNAs", "into", "Cos-1", "cells", "showed", "that", "two", "missense", "mutations", ",", "Thr366", "-", "->Pro", "and", "Ter-->Cys", ",", "permitted", "the", "expression", "of", "only", "trace", "amounts", "of", "alpha", "-", "L", "-", "iduronidase", "activity", ",", "whereas", "Gly409", "-", "->Arg", "permitted", "the", "expression", "of", "60", "%", "as", "much", "enzyme", "as", "did", "the", "normal", "cDNA", ".", "The", "nonsense", "mutations", "were", "associated", "with", "abnormalities", "of", "RNA", "processing", ":", "(", "1", ")", "both", "a", "very", "low", "level", "of", "mRNA", "and", "skipping", "of", "exon", "2", "for", "Tyr64", "-", "->Ter", "and", "(", "2", ")", "utilization", "of", "a", "cryptic", "splice", "site", "for", "Gln310", "-", "->Ter", ".", "In", "all", "instances", ",", "the", "probands", "were", "found", "homozygous", ",", "and", "the", "parents", "heterozygous", ",", "for", "the", "mutant", "alleles", ",", "as", "anticipated", "from", "the", "consanguinity", "in", "each", "family", ".", "The", "two", "-", "mutation", "allele", "was", "identified", "in", "a", "family", "from", "Gaza", ";", "the", "other", "three", "alleles", "were", "found", "in", "seven", "families", ",", "five", "of", "them", "Druze", ",", "residing", "in", "a", "very", "small", "area", "of", "northern", "Israel", ".", "Since", "such", "clustering", "suggests", "a", "classic", "founder", "effect", ",", "the", "presence", "of", "three", "mutant", "alleles", "of", "the", "IDUA", "gene", "was", "unexpected", ".", "\n" ]
[ "SNP", "Gene" ]
IDUA is a Gene, Gly409 - ->Arg is a SNP, Tyr64 - ->Ter is a SNP, Gln310 - ->Ter is a SNP, Thr366 - ->Pro is a SNP, Thr366 - ->Pro is a SNP, Gly409 - ->Arg is a SNP, Tyr64 - ->Ter is a SNP, Gln310 - ->Ter is a SNP, IDUA is a Gene
372_task1
Sentence: Molecular analysis of Hurler syndrome in Druze and Muslim Arab patients in Israel: multiple allelic mutations of the IDUA gene in a small geographic area. The mutations underlying Hurler syndrome (mucopolysaccharidosis IH) in Druze and Muslim Israeli Arab patients have been characterized. Four alleles were identified, using a combination of (a) PCR amplification of reverse-transcribed RNA or genomic DNA segments, (b) cycle sequencing of PCR products, and (c) restriction-enzyme analysis. One allele has two amino acid substitutions, Gly409-->Arg in exon 9 and Ter-->Cys in exon 14. The other three alleles have mutations in exon 2 (Tyr64-->Ter), exon 7 (Gln310-->Ter), or exon 8 (Thr366-->Pro). Transfection of mutagenized cDNAs into Cos-1 cells showed that two missense mutations, Thr366-->Pro and Ter-->Cys, permitted the expression of only trace amounts of alpha-L-iduronidase activity, whereas Gly409-->Arg permitted the expression of 60% as much enzyme as did the normal cDNA. The nonsense mutations were associated with abnormalities of RNA processing: (1) both a very low level of mRNA and skipping of exon 2 for Tyr64-->Ter and (2) utilization of a cryptic splice site for Gln310-->Ter. In all instances, the probands were found homozygous, and the parents heterozygous, for the mutant alleles, as anticipated from the consanguinity in each family. The two-mutation allele was identified in a family from Gaza; the other three alleles were found in seven families, five of them Druze, residing in a very small area of northern Israel. Since such clustering suggests a classic founder effect, the presence of three mutant alleles of the IDUA gene was unexpected. Instructions: please typing these entity words according to sentence: IDUA, Gly409 - ->Arg, Tyr64 - ->Ter, Gln310 - ->Ter, Thr366 - ->Pro, Thr366 - ->Pro, Gly409 - ->Arg, Tyr64 - ->Ter, Gln310 - ->Ter, IDUA Options: Gene, SNP
[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Gene", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-SNP", "I-SNP", "I-SNP", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-SNP", "I-SNP", "I-SNP", "O", "O", "O", "O", "O", "B-SNP", "I-SNP", "I-SNP", "O", "O", "O", "O", "O", "O", "B-SNP", "I-SNP", "I-SNP", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-SNP", "I-SNP", "I-SNP", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-SNP", "I-SNP", "I-SNP", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-SNP", "I-SNP", "I-SNP", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-SNP", "I-SNP", "I-SNP", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Gene", "O", "O", "O", "O", "O" ]
Molecular analysis of Hurler syndrome in Druze and Muslim Arab patients in Israel: multiple allelic mutations of the IDUA gene in a small geographic area. The mutations underlying Hurler syndrome (mucopolysaccharidosis IH) in Druze and Muslim Israeli Arab patients have been characterized. Four alleles were identified, using a combination of (a) PCR amplification of reverse-transcribed RNA or genomic DNA segments, (b) cycle sequencing of PCR products, and (c) restriction-enzyme analysis. One allele has two amino acid substitutions, Gly409-->Arg in exon 9 and Ter-->Cys in exon 14. The other three alleles have mutations in exon 2 (Tyr64-->Ter), exon 7 (Gln310-->Ter), or exon 8 (Thr366-->Pro). Transfection of mutagenized cDNAs into Cos-1 cells showed that two missense mutations, Thr366-->Pro and Ter-->Cys, permitted the expression of only trace amounts of alpha-L-iduronidase activity, whereas Gly409-->Arg permitted the expression of 60% as much enzyme as did the normal cDNA. The nonsense mutations were associated with abnormalities of RNA processing: (1) both a very low level of mRNA and skipping of exon 2 for Tyr64-->Ter and (2) utilization of a cryptic splice site for Gln310-->Ter. In all instances, the probands were found homozygous, and the parents heterozygous, for the mutant alleles, as anticipated from the consanguinity in each family. The two-mutation allele was identified in a family from Gaza; the other three alleles were found in seven families, five of them Druze, residing in a very small area of northern Israel. Since such clustering suggests a classic founder effect, the presence of three mutant alleles of the IDUA gene was unexpected.
[ "Molecular", "analysis", "of", "Hurler", "syndrome", "in", "Druze", "and", "Muslim", "Arab", "patients", "in", "Israel", ":", "multiple", "allelic", "mutations", "of", "the", "IDUA", "gene", "in", "a", "small", "geographic", "area", ".", "The", "mutations", "underlying", "Hurler", "syndrome", "(", "mucopolysaccharidosis", "IH", ")", "in", "Druze", "and", "Muslim", "Israeli", "Arab", "patients", "have", "been", "characterized", ".", "Four", "alleles", "were", "identified", ",", "using", "a", "combination", "of", "(", "a", ")", "PCR", "amplification", "of", "reverse", "-", "transcribed", "RNA", "or", "genomic", "DNA", "segments", ",", "(", "b", ")", "cycle", "sequencing", "of", "PCR", "products", ",", "and", "(", "c", ")", "restriction", "-", "enzyme", "analysis", ".", "One", "allele", "has", "two", "amino", "acid", "substitutions", ",", "Gly409", "-", "->Arg", "in", "exon", "9", "and", "Ter-->Cys", "in", "exon", "14", ".", "The", "other", "three", "alleles", "have", "mutations", "in", "exon", "2", "(", "Tyr64", "-", "->Ter", ")", ",", "exon", "7", "(", "Gln310", "-", "->Ter", ")", ",", "or", "exon", "8", "(", "Thr366", "-", "->Pro", ")", ".", "Transfection", "of", "mutagenized", "cDNAs", "into", "Cos-1", "cells", "showed", "that", "two", "missense", "mutations", ",", "Thr366", "-", "->Pro", "and", "Ter-->Cys", ",", "permitted", "the", "expression", "of", "only", "trace", "amounts", "of", "alpha", "-", "L", "-", "iduronidase", "activity", ",", "whereas", "Gly409", "-", "->Arg", "permitted", "the", "expression", "of", "60", "%", "as", "much", "enzyme", "as", "did", "the", "normal", "cDNA", ".", "The", "nonsense", "mutations", "were", "associated", "with", "abnormalities", "of", "RNA", "processing", ":", "(", "1", ")", "both", "a", "very", "low", "level", "of", "mRNA", "and", "skipping", "of", "exon", "2", "for", "Tyr64", "-", "->Ter", "and", "(", "2", ")", "utilization", "of", "a", "cryptic", "splice", "site", "for", "Gln310", "-", "->Ter", ".", "In", "all", "instances", ",", "the", "probands", "were", "found", "homozygous", ",", "and", "the", "parents", "heterozygous", ",", "for", "the", "mutant", "alleles", ",", "as", "anticipated", "from", "the", "consanguinity", "in", "each", "family", ".", "The", "two", "-", "mutation", "allele", "was", "identified", "in", "a", "family", "from", "Gaza", ";", "the", "other", "three", "alleles", "were", "found", "in", "seven", "families", ",", "five", "of", "them", "Druze", ",", "residing", "in", "a", "very", "small", "area", "of", "northern", "Israel", ".", "Since", "such", "clustering", "suggests", "a", "classic", "founder", "effect", ",", "the", "presence", "of", "three", "mutant", "alleles", "of", "the", "IDUA", "gene", "was", "unexpected", ".", "\n" ]
[ "SNP", "Gene" ]
IDUA, Gly409 - ->Arg, Tyr64 - ->Ter, Gln310 - ->Ter, Thr366 - ->Pro, Thr366 - ->Pro, Gly409 - ->Arg, Tyr64 - ->Ter, Gln310 - ->Ter, IDUA
372_task2
Sentence: Molecular analysis of Hurler syndrome in Druze and Muslim Arab patients in Israel: multiple allelic mutations of the IDUA gene in a small geographic area. The mutations underlying Hurler syndrome (mucopolysaccharidosis IH) in Druze and Muslim Israeli Arab patients have been characterized. Four alleles were identified, using a combination of (a) PCR amplification of reverse-transcribed RNA or genomic DNA segments, (b) cycle sequencing of PCR products, and (c) restriction-enzyme analysis. One allele has two amino acid substitutions, Gly409-->Arg in exon 9 and Ter-->Cys in exon 14. The other three alleles have mutations in exon 2 (Tyr64-->Ter), exon 7 (Gln310-->Ter), or exon 8 (Thr366-->Pro). Transfection of mutagenized cDNAs into Cos-1 cells showed that two missense mutations, Thr366-->Pro and Ter-->Cys, permitted the expression of only trace amounts of alpha-L-iduronidase activity, whereas Gly409-->Arg permitted the expression of 60% as much enzyme as did the normal cDNA. The nonsense mutations were associated with abnormalities of RNA processing: (1) both a very low level of mRNA and skipping of exon 2 for Tyr64-->Ter and (2) utilization of a cryptic splice site for Gln310-->Ter. In all instances, the probands were found homozygous, and the parents heterozygous, for the mutant alleles, as anticipated from the consanguinity in each family. The two-mutation allele was identified in a family from Gaza; the other three alleles were found in seven families, five of them Druze, residing in a very small area of northern Israel. Since such clustering suggests a classic founder effect, the presence of three mutant alleles of the IDUA gene was unexpected. Instructions: please extract entity words from the input sentence
[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Gene", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-SNP", "I-SNP", "I-SNP", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-SNP", "I-SNP", "I-SNP", "O", "O", "O", "O", "O", "B-SNP", "I-SNP", "I-SNP", "O", "O", "O", "O", "O", "O", "B-SNP", "I-SNP", "I-SNP", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-SNP", "I-SNP", "I-SNP", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-SNP", "I-SNP", "I-SNP", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-SNP", "I-SNP", "I-SNP", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-SNP", "I-SNP", "I-SNP", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Gene", "O", "O", "O", "O", "O" ]
Molecular analysis of Hurler syndrome in Druze and Muslim Arab patients in Israel: multiple allelic mutations of the IDUA gene in a small geographic area. The mutations underlying Hurler syndrome (mucopolysaccharidosis IH) in Druze and Muslim Israeli Arab patients have been characterized. Four alleles were identified, using a combination of (a) PCR amplification of reverse-transcribed RNA or genomic DNA segments, (b) cycle sequencing of PCR products, and (c) restriction-enzyme analysis. One allele has two amino acid substitutions, Gly409-->Arg in exon 9 and Ter-->Cys in exon 14. The other three alleles have mutations in exon 2 (Tyr64-->Ter), exon 7 (Gln310-->Ter), or exon 8 (Thr366-->Pro). Transfection of mutagenized cDNAs into Cos-1 cells showed that two missense mutations, Thr366-->Pro and Ter-->Cys, permitted the expression of only trace amounts of alpha-L-iduronidase activity, whereas Gly409-->Arg permitted the expression of 60% as much enzyme as did the normal cDNA. The nonsense mutations were associated with abnormalities of RNA processing: (1) both a very low level of mRNA and skipping of exon 2 for Tyr64-->Ter and (2) utilization of a cryptic splice site for Gln310-->Ter. In all instances, the probands were found homozygous, and the parents heterozygous, for the mutant alleles, as anticipated from the consanguinity in each family. The two-mutation allele was identified in a family from Gaza; the other three alleles were found in seven families, five of them Druze, residing in a very small area of northern Israel. Since such clustering suggests a classic founder effect, the presence of three mutant alleles of the IDUA gene was unexpected.
[ "Molecular", "analysis", "of", "Hurler", "syndrome", "in", "Druze", "and", "Muslim", "Arab", "patients", "in", "Israel", ":", "multiple", "allelic", "mutations", "of", "the", "IDUA", "gene", "in", "a", "small", "geographic", "area", ".", "The", "mutations", "underlying", "Hurler", "syndrome", "(", "mucopolysaccharidosis", "IH", ")", "in", "Druze", "and", "Muslim", "Israeli", "Arab", "patients", "have", "been", "characterized", ".", "Four", "alleles", "were", "identified", ",", "using", "a", "combination", "of", "(", "a", ")", "PCR", "amplification", "of", "reverse", "-", "transcribed", "RNA", "or", "genomic", "DNA", "segments", ",", "(", "b", ")", "cycle", "sequencing", "of", "PCR", "products", ",", "and", "(", "c", ")", "restriction", "-", "enzyme", "analysis", ".", "One", "allele", "has", "two", "amino", "acid", "substitutions", ",", "Gly409", "-", "->Arg", "in", "exon", "9", "and", "Ter-->Cys", "in", "exon", "14", ".", "The", "other", "three", "alleles", "have", "mutations", "in", "exon", "2", "(", "Tyr64", "-", "->Ter", ")", ",", "exon", "7", "(", "Gln310", "-", "->Ter", ")", ",", "or", "exon", "8", "(", "Thr366", "-", "->Pro", ")", ".", "Transfection", "of", "mutagenized", "cDNAs", "into", "Cos-1", "cells", "showed", "that", "two", "missense", "mutations", ",", "Thr366", "-", "->Pro", "and", "Ter-->Cys", ",", "permitted", "the", "expression", "of", "only", "trace", "amounts", "of", "alpha", "-", "L", "-", "iduronidase", "activity", ",", "whereas", "Gly409", "-", "->Arg", "permitted", "the", "expression", "of", "60", "%", "as", "much", "enzyme", "as", "did", "the", "normal", "cDNA", ".", "The", "nonsense", "mutations", "were", "associated", "with", "abnormalities", "of", "RNA", "processing", ":", "(", "1", ")", "both", "a", "very", "low", "level", "of", "mRNA", "and", "skipping", "of", "exon", "2", "for", "Tyr64", "-", "->Ter", "and", "(", "2", ")", "utilization", "of", "a", "cryptic", "splice", "site", "for", "Gln310", "-", "->Ter", ".", "In", "all", "instances", ",", "the", "probands", "were", "found", "homozygous", ",", "and", "the", "parents", "heterozygous", ",", "for", "the", "mutant", "alleles", ",", "as", "anticipated", "from", "the", "consanguinity", "in", "each", "family", ".", "The", "two", "-", "mutation", "allele", "was", "identified", "in", "a", "family", "from", "Gaza", ";", "the", "other", "three", "alleles", "were", "found", "in", "seven", "families", ",", "five", "of", "them", "Druze", ",", "residing", "in", "a", "very", "small", "area", "of", "northern", "Israel", ".", "Since", "such", "clustering", "suggests", "a", "classic", "founder", "effect", ",", "the", "presence", "of", "three", "mutant", "alleles", "of", "the", "IDUA", "gene", "was", "unexpected", ".", "\n" ]
[ "SNP", "Gene" ]
4,5-diaryloxazole is a CHEMICAL
19952416_task0
Sentence: Design, synthesis, and in-vivo evaluation of 4,5-diaryloxazole as novel nonsteroidal anti-inflammatory drug. Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: CHEMICAL
[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-CHEMICAL", "O", "O", "O", "O", "O", "O", "O", "O" ]
Design, synthesis, and in-vivo evaluation of 4,5-diaryloxazole as novel nonsteroidal anti-inflammatory drug.
[ "Design", ",", "synthesis", ",", "and", "in", "-", "vivo", "evaluation", "of", "4,5-diaryloxazole", "as", "novel", "nonsteroidal", "anti", "-", "inflammatory", "drug", "." ]
[ "CHEMICAL", "GENE-Y" ]
4,5-diaryloxazole is a CHEMICAL
19952416_task1
Sentence: Design, synthesis, and in-vivo evaluation of 4,5-diaryloxazole as novel nonsteroidal anti-inflammatory drug. Instructions: please typing these entity words according to sentence: 4,5-diaryloxazole Options: CHEMICAL
[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-CHEMICAL", "O", "O", "O", "O", "O", "O", "O", "O" ]
Design, synthesis, and in-vivo evaluation of 4,5-diaryloxazole as novel nonsteroidal anti-inflammatory drug.
[ "Design", ",", "synthesis", ",", "and", "in", "-", "vivo", "evaluation", "of", "4,5-diaryloxazole", "as", "novel", "nonsteroidal", "anti", "-", "inflammatory", "drug", "." ]
[ "CHEMICAL", "GENE-Y" ]
4,5-diaryloxazole
19952416_task2
Sentence: Design, synthesis, and in-vivo evaluation of 4,5-diaryloxazole as novel nonsteroidal anti-inflammatory drug. Instructions: please extract entity words from the input sentence
[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-CHEMICAL", "O", "O", "O", "O", "O", "O", "O", "O" ]
Design, synthesis, and in-vivo evaluation of 4,5-diaryloxazole as novel nonsteroidal anti-inflammatory drug.
[ "Design", ",", "synthesis", ",", "and", "in", "-", "vivo", "evaluation", "of", "4,5-diaryloxazole", "as", "novel", "nonsteroidal", "anti", "-", "inflammatory", "drug", "." ]
[ "CHEMICAL", "GENE-Y" ]
Behandlung is an umlsterm, Thrombosen is an umlsterm, Kindes- is an umlsterm, Fallberichte is an umlsterm, Therapiedauer is an umlsterm, Thrombolysetherapie is an umlsterm, Becken- is an umlsterm, Beinvenenthrombose is an umlsterm, jugendlichen is an umlsterm, Beins is an umlsterm, Fibrinolytika is an umlsterm, Gewebeplasminogenaktivator is an umlsterm, Streptokinase is an umlsterm
MonatsschriftKinderheilkunde.91471106.ger.abstr_task0
Sentence: Ueber Thrombolysetherapien bei der Behandlung von Thrombosen im Kindes- und Jugendalter gibt es bereits viele Fallberichte , jedoch noch keine kontrollierten Studien ueber Dosierung und Therapiedauer des Thrombolytikums . Wir berichten ueber eine Thrombolysetherapie bei einer massiven Becken- und Beinvenenthrombose einer jugendlichen Patientin , bei der erstmals bei drohendem Verlust des betroffenen Beins 2 Fibrinolytika ( rekombinanter Gewebeplasminogenaktivator lokal und Streptokinase systemisch ) zeitgleich erfolgreich eingesetzt wurden . Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: umlsterm
[ "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O" ]
Ueber Thrombolysetherapien bei der Behandlung von Thrombosen im Kindes- und Jugendalter gibt es bereits viele Fallberichte , jedoch noch keine kontrollierten Studien ueber Dosierung und Therapiedauer des Thrombolytikums . Wir berichten ueber eine Thrombolysetherapie bei einer massiven Becken- und Beinvenenthrombose einer jugendlichen Patientin , bei der erstmals bei drohendem Verlust des betroffenen Beins 2 Fibrinolytika ( rekombinanter Gewebeplasminogenaktivator lokal und Streptokinase systemisch ) zeitgleich erfolgreich eingesetzt wurden .
[ "Ueber", "Thrombolysetherapien", "bei", "der", "Behandlung", "von", "Thrombosen", "im", "Kindes-", "und", "Jugendalter", "gibt", "es", "bereits", "viele", "Fallberichte", ",", "jedoch", "noch", "keine", "kontrollierten", "Studien", "ueber", "Dosierung", "und", "Therapiedauer", "des", "Thrombolytikums", ".", "Wir", "berichten", "ueber", "eine", "Thrombolysetherapie", "bei", "einer", "massiven", "Becken-", "und", "Beinvenenthrombose", "einer", "jugendlichen", "Patientin", ",", "bei", "der", "erstmals", "bei", "drohendem", "Verlust", "des", "betroffenen", "Beins", "2", "Fibrinolytika", "(", "rekombinanter", "Gewebeplasminogenaktivator", "lokal", "und", "Streptokinase", "systemisch", ")", "zeitgleich", "erfolgreich", "eingesetzt", "wurden", "." ]
[ "umlsterm" ]
Behandlung is an umlsterm, Thrombosen is an umlsterm, Kindes- is an umlsterm, Fallberichte is an umlsterm, Therapiedauer is an umlsterm, Thrombolysetherapie is an umlsterm, Becken- is an umlsterm, Beinvenenthrombose is an umlsterm, jugendlichen is an umlsterm, Beins is an umlsterm, Fibrinolytika is an umlsterm, Gewebeplasminogenaktivator is an umlsterm, Streptokinase is an umlsterm
MonatsschriftKinderheilkunde.91471106.ger.abstr_task1
Sentence: Ueber Thrombolysetherapien bei der Behandlung von Thrombosen im Kindes- und Jugendalter gibt es bereits viele Fallberichte , jedoch noch keine kontrollierten Studien ueber Dosierung und Therapiedauer des Thrombolytikums . Wir berichten ueber eine Thrombolysetherapie bei einer massiven Becken- und Beinvenenthrombose einer jugendlichen Patientin , bei der erstmals bei drohendem Verlust des betroffenen Beins 2 Fibrinolytika ( rekombinanter Gewebeplasminogenaktivator lokal und Streptokinase systemisch ) zeitgleich erfolgreich eingesetzt wurden . Instructions: please typing these entity words according to sentence: Behandlung, Thrombosen, Kindes-, Fallberichte, Therapiedauer, Thrombolysetherapie, Becken-, Beinvenenthrombose, jugendlichen, Beins, Fibrinolytika, Gewebeplasminogenaktivator, Streptokinase Options: umlsterm
[ "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O" ]
Ueber Thrombolysetherapien bei der Behandlung von Thrombosen im Kindes- und Jugendalter gibt es bereits viele Fallberichte , jedoch noch keine kontrollierten Studien ueber Dosierung und Therapiedauer des Thrombolytikums . Wir berichten ueber eine Thrombolysetherapie bei einer massiven Becken- und Beinvenenthrombose einer jugendlichen Patientin , bei der erstmals bei drohendem Verlust des betroffenen Beins 2 Fibrinolytika ( rekombinanter Gewebeplasminogenaktivator lokal und Streptokinase systemisch ) zeitgleich erfolgreich eingesetzt wurden .
[ "Ueber", "Thrombolysetherapien", "bei", "der", "Behandlung", "von", "Thrombosen", "im", "Kindes-", "und", "Jugendalter", "gibt", "es", "bereits", "viele", "Fallberichte", ",", "jedoch", "noch", "keine", "kontrollierten", "Studien", "ueber", "Dosierung", "und", "Therapiedauer", "des", "Thrombolytikums", ".", "Wir", "berichten", "ueber", "eine", "Thrombolysetherapie", "bei", "einer", "massiven", "Becken-", "und", "Beinvenenthrombose", "einer", "jugendlichen", "Patientin", ",", "bei", "der", "erstmals", "bei", "drohendem", "Verlust", "des", "betroffenen", "Beins", "2", "Fibrinolytika", "(", "rekombinanter", "Gewebeplasminogenaktivator", "lokal", "und", "Streptokinase", "systemisch", ")", "zeitgleich", "erfolgreich", "eingesetzt", "wurden", "." ]
[ "umlsterm" ]